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Global, regional, and national age-sex-specific mortality for 
282 causes of death in 195 countries and territories, 
1980–2017: a systematic analysis for the Global Burden of 
Disease Study 2017
GBD 2017 Causes of Death Collaborators*
Summary
Background Global development goals increasingly rely on country-specific estimates for benchmarking a nation’s 
progress. To meet this need, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 estimated 
global, regional, national, and, for selected locations, subnational cause-specific mortality beginning in the year 
1980. Here we report an update to that study, making use of newly available data and improved methods. GBD 2017 
provides a comprehensive assessment of cause-specific mortality for 282 causes in 195 countries and territories from 
1980 to 2017.
Methods The causes of death database is composed of vital registration (VR), verbal autopsy (VA), registry, survey, 
police, and surveillance data. GBD 2017 added ten VA studies, 127 country-years of VR data, 502 cancer-registry 
country-years, and an additional surveillance country-year. Expansions of the GBD cause of death hierarchy resulted 
in 18 additional causes estimated for GBD 2017. Newly available data led to subnational estimates for five additional 
countries—Ethiopia, Iran, New Zealand, Norway, and Russia. Deaths assigned International Classification of Diseases 
(ICD) codes for non-specific, implausible, or intermediate causes of death were reassigned to underlying causes by 
redistribution algorithms that were incorporated into uncertainty estimation. We used statistical modelling tools 
developed for GBD, including the Cause of Death Ensemble model (CODEm), to generate cause fractions and cause-
specific death rates for each location, year, age, and sex. Instead of using UN estimates as in previous versions, 
GBD 2017 independently estimated population size and fertility rate for all locations. Years of life lost (YLLs) were 
then calculated as the sum of each death multiplied by the standard life expectancy at each age. All rates reported here 
are age-standardised.
Findings At the broadest grouping of causes of death (Level 1), non-communicable diseases (NCDs) comprised the 
greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 
2017, while communicable, maternal, neonatal, and nutritional (CMNN) causes accounted for 18·6% (17·9–19·6), 
and injuries 8·0% (7·7–8·2). Total numbers of deaths from NCD causes increased from 2007 to 2017 by 22·7% 
(21·5–23·9), representing an additional 7·61 million (7·20–8·01) deaths estimated in 2017 versus 2007. The death 
rate from NCDs decreased globally by 7·9% (7·0–8·8). The number of deaths for CMNN causes decreased by 
22·2% (20·0–24·0) and the death rate by 31·8% (30·1–33·3). Total deaths from injuries increased by 2·3% 
(0·5–4·0) between 2007 and 2017, and the death rate from injuries decreased by 13·7% (12·2–15·1) to 
57·9 deaths (55·9–59·2) per 100 000 in 2017. Deaths from substance use disorders also increased, rising from 
284 000 deaths (268 000–289 000) globally in 2007 to 352 000 (334 000–363 000) in 2017. Between 2007 and 2017, 
total deaths from conflict and terrorism increased by 118·0% (88·8–148·6). A greater reduction in total deaths and 
death rates was observed for some CMNN causes among children younger than 5 years than for older adults, 
such as a 36·4% (32·2–40·6) reduction in deaths from lower respiratory infections for children younger than 
5 years compared with a 33·6% (31·2–36·1) increase in adults older than 70 years. Globally, the number of 
deaths was greater for men than for women at most ages in 2017, except at ages older than 85 years. Trends in 
global YLLs reflect an epidemiological transition, with decreases in total YLLs from enteric infections, respiratory 
infections and tuberculosis, and maternal and neonatal disorders between 1990 and 2017; these were generally 
greater in magnitude at the lowest levels of the Socio-demographic Index (SDI). At the same time, there 
were large increases in YLLs from neoplasms and cardiovascular diseases. YLL rates decreased across 
the five leading Level 2 causes in all SDI quintiles. The leading causes of YLLs in 1990—neonatal disorders, 
lower respiratory infections, and diarrhoeal diseases—were ranked second, fourth, and fifth, in 2017. Meanwhile, 
estimated YLLs increased for ischaemic heart disease (ranked first in 2017) and stroke (ranked third), even 
though YLL rates decreased. Population growth contributed to increased total deaths across the 20 leading 
Level 2 causes of mortality between 2007 and 2017. Decreases in the cause-specific mortality rate reduced the effect 
of population growth for all but three causes: substance use disorders, neurological disorders, and skin and 
subcutaneous diseases.
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Introduction
Systematic recording and analysis of causes of 
human death remains one of the most resilient successes 
for public health, beginning with routine and continuous 
reporting of deaths by physicians starting in the 
15th century.1 Today, hundreds of thousands of physicians 
evaluate and select the cause of death for millions of 
deaths annually, codifying the results according to the 
International Classification of Diseases (ICD) system.2 
These efforts form the basis of a global mortality 
reporting system that is widely relied upon to prioritise 
health system investments, track progress towards 
global development goals, and guide scientific research. 
Although there remains a need for wider adoption and 
improvement of these systems, continuous reporting of 
cause-specific mortality in many countries represents a 
success for global health.3
More mortality data are now becoming available 
because of broader adoption of vital registration 
systems and increased information-sharing made 
possible by digital communication. At the same time, 
efforts to correct, sort, analyse, and report this massive 
Research in context
Evidence before this study
Previously, the Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) 2016 provided estimates for 264 causes of 
death for 195 countries and territories, by age and sex, from 1980 
to 2016. GBD 2016 incorporated newly available data for many 
locations, expanded and refined the included causes of death, 
improved modelling techniques, and developed a star rating 
system for the quality of cause of death data. To better assess 
mortality among the oldest adults, terminal age categories for 
age 90–94 years and 95 years and older were added. Other 
organisations periodically produce estimates of cause‐specific 
mortality, including for a wide list of causes and across multiple 
age groups (WHO), for selected cancers (the International Agency 
for Research on Cancer), and for child deaths (the Maternal and 
Child Epidemiology Estimation [MCEE] group). GBD continues to 
provide the only peer‐reviewed annual estimates of cause‐specific 
mortality available for all locations over time.
Added value of this study
GBD 2017 includes estimates for 2017 and also updates the 
entire series from 1980 produced for GBD 2016. The list of 
included causes has been expanded and study methods have 
been improved in multiple ways. First, inclusion of an 
independent estimation of population and fertility developed 
for GBD 2017 substantially improved estimates in selected 
countries. Second, additional data were identified, including 
127 country‐years of vital registration and ten verbal autopsy 
studies. Third, new subnational assessments were developed 
for five countries in 2017: Ethiopia, Iran, New Zealand, Norway, 
and Russia. Fourth, a new stratum was developed for 
subnational‐level estimation in New Zealand to characterise 
populations by ethnicity as Māori or non‐Māori. Fifth, we 
revised adjustments made for misclassified deaths due to 
dementia, Parkinson’s disease, and atrial fibrillation. Finally, 
additional diseases are now estimated, including 
non‐rheumatic calcific aortic and degenerative mitral valve 
disease; subarachnoid haemorrhage; myelodysplastic, 
myeloproliferative, and other haemopoietic disorders; 
diabetes mellitus as type 1 and type 2 (previously combined); 
poisoning by carbon monoxide; liver cancer due to 
non‐alcoholic steatohepatitis; ectopic pregnancy; and invasive 
non‐typhoidal salmonella.
Implications of all the available evidence
Deaths due to communicable, maternal, neonatal, and 
nutritional causes continue to decline, while deaths from non‐
communicable diseases increase and injury deaths are stable. 
Declines in death rates of some non‐communicable diseases 
have slowed or ceased. GBD 2017 has increased its 
collaboration with governments, leading to additional data 
for subnational estimation. Engagement with GBD 
collaborators, policy makers, disease experts, and the public is 
guiding expansions of the cause list and resulting decreasing 
burden classified in residual “other” categories. 
Non‐communicable diseases remain the leading causes of 
death globally, and their burden is rising. GBD 2017 is 
motivated by the same goals as GBD 2016, including the belief 
that annual updates, reflecting improvements due to 
improved data availability, new causes estimated, and better 
methods to reduce bias and improve transparency in 
reporting, are contributing to the formulation and tracking of 
new evidence‐based health policy. We intend for GBD 2017 to 
serve as a global public good, freely available for policy makers 
and the public seeking to improve human health.
Interpretation Improvements in global health have been unevenly distributed among populations. Deaths due to 
injuries, substance use disorders, armed conflict and terrorism, neoplasms, and cardiovascular disease are expanding 
threats to global health. For causes of death such as lower respiratory and enteric infections, more rapid progress 
occurred for children than for the oldest adults, and there is continuing disparity in mortality rates by sex across age 
groups. Reductions in the death rate of some common diseases are themselves slowing or have ceased, primarily for 
NCDs, and the death rate for selected causes has increased in the past decade.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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amount of global data are evolving to keep pace with 
increasing demands for timely assessment of global, 
regional, and local mortality patterns. In addition to 
shifts in mortality patterns due to an ongoing 
epidemiological transition, rapid spikes in mortality 
due to specific causes are frequently observed and 
require recurrent updates to global estimates. Examples 
of mortality spikes include opioid-associated deaths in 
parts of the USA,4 suicide in eastern Europe in the 
1990s,5 and conflict-associated deaths in the eastern 
Mediterranean and North Africa region.6 Causes of 
death are now reported digitally in many locations, 
allowing health authorities to improve the quality and 
timeliness of mortality reporting.7,8 Global development 
goals increasingly rely on country-specific estimates for 
benchmarking a nation’s progress. Global commitments, 
such as the UN’s Sustainable Development Goals 
(SDGs),9 the Moscow Declaration to End Tuberculosis,10 
WHO’s First Global Conference on Air Pollution and 
Health11 in October, 2018, and the UN High-level 
Meetings on NCDs12 and tuberculosis,13 both in 
September, 2018, will require ongoing tracking of 
cause-specific mortality, including in locations where 
mortality surveillance data remain limited.
The following study represents an annual update to 
the Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD), an effort to produce consistent and com-
parable estimates of cause-specific mortality for all 
locations globally. GBD 2017 includes results by age and 
sex, for the years 1980 through to 2017, for 195 countries 
and territories. A cycle of continuous quality improve-
ment has led to substantial changes, including new data 
sources, new causes of death, and updated methods. 
For the first time, population estimates have been 
independently produced by GBD 2017,14 and subna-
tional estimates have been produced for Ethiopia, Iran, 
New Zealand, Norway, and Russia. The purpose of GBD 
2017 is to serve as a global public good, freely available 
for policy makers and the public seeking to improve 
human health.
Methods
Overview
GBD cause of death estimation incorporates methods to 
adjust for incomplete or missing vital registration (VR) 
and verbal autopsy (VA) data, general heterogeneity in 
data completeness and quality, and the redistribution 
of so-called garbage codes (insufficiently specific or 
implausible cause of death codes). A general description 
of these methods is provided in this section, with further 
detail presented in appendix 1. GBD 2017 complied with 
the Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER)15 statement (appendix 1 
section 1.3). Analyses were completed with Python 
version 2.7.14, Stata version 13.1, and R version 3.3.2. 
Statistical code used for GBD estimation is publicly 
available online.
Geographical units and time periods
The locations included in GBD 2017 have been arranged 
into a set of hierarchical categories composed of seven 
super-regions and a further nested set of 21 regions 
containing 195 countries and territories (appendix 1). 
Each year, GBD includes sub national analyses for a few 
new countries and continues to provide subnational 
estimates for countries that were added in previous cycles. 
Subnational estimation in GBD 2017 includes five new 
countries (Ethiopia, Iran, New Zealand, Norway, Russia) 
and countries previously estimated at subnational levels 
(GBD 2013: China, Mexico, and the UK [regional level]; 
GBD 2015: Brazil, India, Japan, Kenya, South Africa, 
Sweden, and the USA; GBD 2016: Indonesia and the UK 
[local government authority level]). All analyses are at the 
first level of administrative organisation within each 
country except for New Zealand (by Māori ethnicity), 
Sweden (by Stockholm and non-Stockholm), and the UK 
(by local government authorities). All subnational 
estimates for these countries were incorporated into 
model development and evaluation as part of GBD 2017. 
To meet data use requirements, in this publication we 
present all subnational estimates excluding those pending 
publication (Brazil, India, Japan, Kenya, Mexico, Sweden, 
the UK, and the USA); because of space constraints these 
selected subnational results are presented in appendix 2. 
Subnational estimates for countries with populations 
larger than 200 million (measured with our most recent 
year of published estimates) that have not yet been 
published elsewhere are presented wherever estimates 
are illustrated with maps but are not included in data 
tables.
The complete cause-specific estimation results include 
the years 1980 through to 2017, and are available for 
exploration by an online data visualisation tool. To better 
support current health policy assessment, we include a 
subset of analyses in the current study featuring the 
most recent interval, 2007–17. 
The GBD cause of death hierarchy
The GBD study attributes each death to a single 
underlying cause that began the series of events leading 
to death, in accordance with ICD principles. The GBD 
study organises causes of death in a hierarchical list 
containing four levels (appendix 1 section 7). At the 
highest level (Level 1), all disease burden is divided 
among three mutually exclus ive and collectively 
exhaustive categor ies: communicable, maternal, 
neonatal, and nutritional (CMNN) diseases; non-
communicable diseases (NCDs); and injuries. Level 2 
distinguishes these Level 1 categories into 21 cause 
groups, such as cardiovascular diseases; diarrhoeal 
diseases, lower respiratory infections (LRIs), and other 
common infectious diseases; or transport injuries. 
Level 3 disaggregates these causes further; in most 
cases this disaggregation represents the finest level of 
detail by cause, such as stroke, ischaemic heart disease, 
For the data visualisation tool 
see https://vizhub.health 
data.org/gbd‐compare/
See Online for appendix 1
For the statistical code see 
https://github.com/ihmeuw/
ihme‐modeling
See Online for appendix 2
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or road injuries. Where data are sufficiently available or 
specific policy relevance has been sought, selected 
causes are further disaggregated at Level 4, such as 
drug-susceptible tuberculosis, multidrug-resistant 
tubercu losis without extensive drug resistance, and 
extensively drug-resistant tuberculosis. For GBD 2017, 
the cause hierarchy was further refined to separately 
estimate causes with sub stantial policy interest or high 
levels of burden. Specific changes included separate 
estimation of non-rheumatic calcific aortic and degen-
erative mitral valve dis eases, and myelodysplastic, 
myeloproliferative, and other haemo poietic neoplasms, 
resulting in a reduction in the estim ates of some 
residual causes. Disaggregation of residual causes also 
allowed separate estimation of type 1 and type 2 diabetes, 
chronic kidney disease due to type 1 and type 2 diabetes, 
poisoning by carbon monox ide, liver cancer due to 
non-alcoholic steatohepatitis (NASH), subarachnoid 
haemorrhage, ectopic pregnancy, and invasive non-
typhoidal salmonella. Maternal and neonatal disorders, 
previously estimated as separate cause groupings at 
Level 2 of the hierarchy, were estimated for GBD 2017 
at Level 3 of the hierarchy, and then aggregated up to 
Level 2 to better capture the epidemiological connections 
and linked burden between them. The complete 
hierarchy of causes included in GBD 2017 and their 
corresponding ICD9 and ICD10 codes are described in 
appendix 1 (section 7).
Cause of death data
The GBD cause of death database consists of VR and VA 
data; survey and census data for injuries and maternal 
mortality; surveillance data for maternal mortality and 
child death; cancer registries; and police records for 
interpersonal violence and road injuries. Self-harm 
estimates incorporate VR data and are based on ICD 
categorisation as described in appendix 1 (section 7). In 
this iteration of GBD, ten new VA studies and 127 new 
country-years of VR data were added at the country 
level. 502 new cancer-registry country-years were 
added, as was one additional new surveillance country-
year. Data sources comprising the GBD cause of 
death database can be reviewed on the Global Health 
Data Exchange website. Multiple factors can influence 
changes between GBD studies in estimates for a given 
cause-location-year, including the quality of a country’s 
data system (as represented by the GBD star rating 
system) and the addition of more recent data. 
Figure 1 shows the relative stability of GBD estimates 
between study iterations. Variation between GBD 2016 
and GBD 2017 estimates was greater in countries with 
both low star ratings and no new VR data updates 
occurring between these iterations of the study. Changes 
to estimates can be seen even in high star rating 
locations because of changes in modelling strategy or 
model covariates even when no new VR data were 
available between cycles.
Data standardisation and processing
To standardise cause of death data, we used protocols 
to address the minor proportion of deaths that were 
assigned to age groups broader than the GBD five-year 
age groups or were not assigned an age or sex, and to 
address differences in ICD codes due to national 
variation or revision, as described in appendix 1 
(section 2). Garbage codes, deaths with non-specific 
codes (eg, unspecified stroke), deaths assigned to ICD 
codes that could not be underlying causes of death 
(eg, senility), or deaths assigned to intermediate but 
not underlying causes of death (eg, heart failure), were 
redistributed by age, sex, location, and year to the 
most likely causes of death. Methods used for this 
redistribution included regression models, redistri-
bution based on fixed proportions, pro portional 
reassignment, and fractional assignment of a death 
assigned to multiple causes, as developed by Naghavi 
and colleagues16 and detailed in appendix 1 (section 2.7). 
We excluded all data sources with more than 50% of 
deaths assigned to major garbage codes (those at 
Level 1 or Level 2 of the GBD hierarchy) in any location-
year to mitigate the potential for bias from these 
sources. The proportion of VR data assigned to major 
garbage code categories for each location-year is 
shown, with supporting detail, in appendix 1 (section 7). 
New to GBD 2017, the uncertainty around re-
distribution methods was also estimated. Additional 
details for this process are provided in appendix 1 
(section 2.7). Because mortality due to HIV/AIDS is 
sometimes coded to other causes of death such as 
tuberculosis, meningitis, or toxoplasmosis, we also 
corrected the cause of death assignment to HIV/AIDS 
for peak epidemic times. Tuberculosis deaths can be 
misclassified as pneumonia deaths in children in 
locations with a high tuberculosis burden. Methods to 
adjust for this potential mis classi fication are described 
in detail in appendix 1 (section 3.3).
Mortality rates from dementia and Parkinson’s disease 
reported in VR systems cannot be reconciled with 
observed trends in prevalence and excess mortality—a 
disparity that can be attributed to variation in death 
certification practices for these causes across countries 
and over time.17 For GBD 2017, we sought to address this 
known bias by using details from multiple cause of 
death data. For GBD 2017, multiple cause of death data 
were available to investigators only for the USA, where 
recent years show improved use of previously under-
utilised codes such as dementia. Statistical models of 
these USA data were used to reclassify deaths from 
other GBD causes and garbage codes to dementia and 
Parkinson’s disease according to the pattern of 
intermediate and immediate causes observed in the 
most recent years. Model results were applied to all 
countries. A similar reallocation pro cess was used for 
atrial fibrillation deaths misclassified as deaths due to 
heart failure or thromboembolic events. A detailed 
For the Global Health 
Data Exchange see 
http://ghdx.healthdata.org/
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description of these redistribution procedures and the 
manner in which they were applied to all countries is 
available in section 2 of appendix 1. This reallocation is 
illustrated in appendix 1 (section 7).
For the first time in GBD 2017, we separately estimated 
deaths from diabetes by type. Deaths due to diabetes can 
be reported in VR and VA data as type 1, type 2, or 
unspecified. Two data manipulation steps were necessary. 
First, we assumed all deaths reported in individuals 
younger than 15 years were type 1 regardless of the 
original code assignment. Second, we redistributed 
unspecified diabetes deaths on the basis of a regression 
in which the true proportions of type 1 and type 2 deaths 
by age-sex-location-year are a function of the proportion 
of unspecified deaths, age, the age-standardised pre-
valence of obesity, and an interaction term for age and 
obesity prevalence. These methods are described in detail 
in appendix 1 (section 3.3).
Figure 1: Effect of new VR data on Level 1 cause estimates from GBD 2016 to GBD 2017, based on national locations with varying quality of VR data, 2008–16  
The figure shows the degree of consistency between GBD 2016 and GBD 2017 estimates for Level 1 causes at the national level from 2008 to 2016. The diagonal line represents no change from 
GBD 2016 to GBD 2017. Each point represents one country‐year, with colours indicating the Level 1 cause grouping (communicable, maternal, neonatal, and nutritional diseases; non‐communicable 
diseases; and injuries). Panels indicate whether or not any new VR data between 2008 and 2016 were added for that location for GBD 2017, and whether or not a location has 4‐star or 5‐star VR 
quality. Points that are outside of the standard 95% prediction interval for a linear regression of 2017 values on 2016 values are annotated (if the same location‐cause had multiple points in a time 
series, only the furthest‐most point was annotated). The Spearman’s correlation coefficient is noted in the lower right‐hand corner of each panel. CSMR=cause‐specific mortality rate. GBD=Global 
Burden of Diseases, Injuries, and Risk Factors Study. VR=vital registration.
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Data completeness assessment
Completeness of VR data was assessed by location-year, 
and sources with less than 50% completeness were 
excluded. We multiplied the estimated all-cause mor tality 
for each age-sex-location-year by the cause fraction for the 
corresponding age-sex-location-year to adjust all included 
sources to 100% completeness. VA and VR data availability 
and completeness are shown for each location-year in 
appendix 1 (section 7). To further char acterise the quality 
of data available in each country, the GBD study rated 
each location-year from 1980 to 2017 on a level of 0 to 
5 stars according to methods previously described.18 
Ratings convey an overall measure of the reliability of 
cause of death estimates for each location-year but do not 
directly affect the estimation process.
Cause of death estimation with CODEm
The GBD Cause of Death Ensemble model (CODEm) 
systematically tested and combined results from 
different statistical models according to their out-of-
sample pre dictive validity. Results are incorporated into 
a weighted ensemble model as detailed in appendix 1 
(section 3.1) and below. For GBD 2017, CODEm was 
used to estimate 192 causes of death (appendix 1 
section 7). To predict the level for each cause of death, 
we used CODEm to systematically test a large number 
of functional forms and permutations of covariates.18 
Each resulting model that met the predetermined req-
uirements for regression coefficient significance and 
direction was fit on 70% of the data, holding out 30% for 
cross-validation (appendix 1 section 3.1). Out-of-sample 
pre dictive validity of these models was assessed by use 
of repeated cross-validation tests on the first 15% of the 
held-out data. Various ensemble models with different 
weighting parameters were created from the com-
bination of these models, with the highest weights 
assigned to models with the best out-of-sample pre-
diction error for trends and levels, as detailed in 
appendix 1 (section 7). Model performance of these 
ensembles was assessed against the root-mean squared 
error (RMSE) of the ensemble model predictions of the 
log of the age-specific death rates for a cause, assessed 
with the same 15% of the data. The ensemble model 
performing best was subsequently selected and 
assessed against the other 15% of the data withheld 
from the statistical model building. CODEm was run 
independently by sex for each cause of death. A separate 
model was run for countries with 4-star or greater 
VR systems to avert uncertainty inflation from more 
heterogeneous data. The distribution of RMSE relative 
to cause-specific mortality rates (CSMRs) at Level 2 of 
the GBD hierarchy shows that model performance was 
weakest for causes of death with comparatively low 
mortality rates (figure 2; appendix 2), while models for 
more common causes of death such as stroke, chronic 
obstructive pulmonary disease, and self-harm and 
interpersonal violence generally had low RMSE.
Cause of death estimation with alternative estimation 
strategies
Alternative estimation strategies were used to model a 
subset of causes of death with unique epidemiology, 
large changes in reporting over time, or particularly 
limited data availability, including HIV/AIDS, malaria, 
chronic kidney disease, cirrhosis, liver cancer, men-
ingitis, de mentia, and atrial fibrillation. Alternative 
strategies included prevalence-based models, incidence 
and case fatality models, and sub-cause proportion 
models as described in appendix 1 (section 7). Mortality-
incidence ratio models based on registry data were used 
to estimate mortality from 32 cancers (appendix 1 
section 3.3). Negative-binomial models were used for 
eight causes of death with typically low death counts 
or causes that typically have no deaths in countries 
with a high Socio-demographic Index (SDI), includ-
ing ascariasis, cystic echinococcosis, cysticer cosis, 
diphtheria, iodine deficiency, other intestinal infectious 
diseases, schistosomiasis, and varicella and herpes 
zoster virus. Once underlying cause of death estimates 
and accompanying uncertainty were generated, these 
models were combined with the cause of death 
correction procedure (CoDCorrect) to establish estimates 
consistent with all-cause mortality levels for each age-
sex-year location.
Estimation of fatal discontinuities
Fatal discontinuities are large changes in deaths due to 
unexpected spikes in injuries or epidemics—defined by 
GBD as more than one per million or more than 
Figure 2: Out-of-sample model performance for CODEm models and age-standardised cause-specific 
mortality rate by Level 1 causes
Model performance was defined by the root‐mean squared error of the ensemble model predictions of the log of 
the age‐specific death rates for a cause with 15% of the data held out from the statistical model building. The figure 
shows the association between the root‐mean squared error and the log of the CSMR, aggregated over 1980–2017. 
Each point represents one CODEm model specific for model‐specific age ranges and sex. Circles denote models run 
with all locations. Triangles denote models run on only data‐rich locations. Colours denote the Level 1 cause 
categories. Open circles and triangles denote models that were run with restricted age groups of less than 30 years. 
CODEm=Cause of Death Ensemble model. CSMR=cause‐specific mortality rate. 
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25 deaths—in a specific location-year. We classified 
fatal discontinuities as conflict and terrorism, major 
trans portation accidents, natural disasters, other forms 
of disaster such as large fires or the collapse of large 
buildings, or major outbreaks of infectious diseases. 
Data on fatal discontinuities came from VR data in the 
75 countries with a 4-star or 5-star data quality rat-
ing for the interval of 1980–2017. For the remaining 
120 countries with a rating of 3 stars or lower, we used 
alternative databases (appendix 1 section 7). Cholera 
and meningitis were estimated as fatal discontinuities to 
reduce the risk of underestimation for small-magnitude 
outbreaks caused by the smoothing of VR or VA data 
over time in CODEm. To address lags in reporting and 
publishing of data, we included news reports and other 
supplemental data sources when known gaps existed. 
Further detail about fatal discontinuity estimation is 
presented in appendix 1 (section 3.3).
Pathogen counterfactual analysis
Aetiology-specific mortality was estimated for LRIs and 
diarrhoeal diseases by use of a counterfactual approach 
that relates the frequency of each aetiology in a 
population and the association with that aetiology and 
either LRI or diarrhoea. LRI and diarrhoea were selected 
as initial candidates for this counterfactual analysis 
approach given the large disease burden they represent 
and the broad interest in interventions, mostly vaccine-
based, to reduce their burden.19 We attributed LRI 
deaths to four aetiologies: Haemophilus influenzae 
type B pneumonia, Streptococcus pneumoniae pneum-
ococcal pneumonia, influenza, and respiratory syncyt ial 
virus pneumonia. Diarrhoeal deaths were attribu-
ted to 13 aetiologies: adenovirus, Aeromonas spp, 
Campylobacter spp, Clostridium difficile, cryptospori-
diosis (Cryptosporidium spp), amoebiasis (Entamoeba 
histolytica), typical entero patho genic Escherichia coli, 
enterotoxigenic E coli, noro virus, rotavirus, non-
typhoidal Salmonella spp, shigellosis (Shigella spp), and 
cholera (Vibrio cholerae). The mortality attributable to 
each aetiology is the product of the attributable fraction 
and the mortality due to LRI or diarrhoea. The current 
counterfactual analysis is an extension of work begun in 
GBD 2010, based on the most common pathogens and 
available data. This method allows for less common 
aetiologies to be added in the future.
YLL computation
Years of life lost (YLLs) are a measure of premature death 
calculated as the sum of each death multiplied by the 
standard life expectancy at each age. The standard life 
expectancy was taken from the lowest observed risk of 
death for each five-year age group in all populations 
greater than 5 million. In 2017, GBD 2017 included a 
new demographic assessment of population, fertility, 
migration, and all-cause mortality.14 We used these 
components to generate single calendar-year and single 
age-year estimates of the population using transparent 
and replicable methods.14 This independent assessment 
of the population was subsequently used in the calcula-
tion of YLL rates and age-standardised mortality rates. 
Details of these calculations are available in appendix 1 
(section 4.3).
Decomposition of change in global deaths
Using methods adapted from demographic research 
from Das Gupta,20 we decomposed change in numbers of 
deaths by cause from 2007 to 2017, using three ex-
planatory components: as change occurring from growth 
in the total population; as shifts in population structure 
by age; or as changes in cause-specific mortality rates. 
We calculated the fraction of change in deaths by cause 
from each component using counter factual scenarios, 
changing the level of one factor from 2007 to 2017, with 
all other factors held constant. Since the effect depends 
on the order of entry of the factor, we calculated the 
average of all combinations of the three factors. Thus, the 
change in global deaths due to shifts in population age 
structure could be calculated by comparing the number 
of deaths in 2007 to the number of deaths in 2017, using 
the population age structure from 2017 and holding both 
population size and cause-specific mortality rates at 2007 
levels (appendix 1 section 7).
Uncertainty analysis
Uncertainty in our estimates was attributable to cause-
specific model specifications; varied availability of data by 
age, sex, location, or year; and variability of sample size 
within data sources. We quantified and propagated 
uncertainty into final estimates by calculating uncertainty 
intervals (UIs) for cause-specific estimation components 
based on 1000 draws from the posterior distribu tion 
of cause-specific mortality by age, sex, location, and 
year.21 95% UIs were calculated with the 2·5th and 
97·5th percentiles, and point estimates were calculated 
from the mean of the draws. Changes over time were 
considered statistically significant when the uncertainty 
interval of the percentage change over time did not cross 
zero.
Socio-demographic Index and epidemiological 
transition analysis
The SDI is a value between 0·0 and 1·0 calculated from 
the geometric mean of three rescaled components: total 
fertility rate under 25 years (TFRU25), lag-distributed 
income per capita (LDI), and average educational 
attainment in the population older than 15 years.22 
Because the total fertility rate—used in the calculation 
of SDI for GBD 2016—has a U-shaped association at 
the highest levels of development, for GBD 2017 we 
recomputed the SDI using TFRU25 only, an age range for 
which the association with development is clearest.14 We 
used a generalised additive model with a Loess smoother 
on SDI to estimate the association between SDI and each 
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
All causes 55 945·7 
(55 356·4 to 
56 516·7)
9·3% 
(8·2 to 10·2)*
737·7 
(729·9 to 745·4)
–14·2% 
(–15·0 to –13·5)*
1 646 249·6 
(1 622 870·6 to 
1 673 178·4)
–9·0% 
(–10·1 to –7·6)*
21 926·4 
(21 601·1 to 
22 314·9)
–22·2% 
(–23·2 to –21·0)*
Communicable, maternal, 
neonatal, and nutritional 
diseases
10 389·9 
(10 004·0 to 
10 975·9)
–22·2% 
(–24·0 to –20·0)*
143·8 
(138·4 to 151·6)
–31·8% 
(–33·3 to –30·1)*
578 416·6 
(558 815·0 to 
600 759·1)
–30·4% 
(–32·4 to –28·2)*
8280·6 
(8005·4 to 
8602·8)
–35·4% 
(–37·3 to –33·4)*
HIV/AIDS and sexually 
transmitted infections
1073·6 
(983·3 to 
1182·4)
–47·7% 
(–50·0 to –45·1)*
13·9 
(12·6 to 15·5)
–53·6% 
(–55·8 to –51·0)*
60 550·2 
(53 533·7 to 
69 156·3)
–47·3% 
(–50·2 to 
–44·0)*
806·4 
(703·1 to 
936·7)
–52·1% 
(–55·2 to –48·6)*
HIV/AIDS 954·5 
(907·3 to 
1009·7)
–50·3% 
(–52·1 to –48·3)*
12·1 
(11·5 to 12·9)
–56·5% 
(–58·0 to –54·7)*
50 497·1 
(47 658·0 to 
53 595·8)
–51·2% 
(–52·9 to –49·2)*
655·1 
(617·5 to 696·4)
–56·6% 
(–58·1 to –54·8)*
HIV/AIDS and 
drug‐susceptible 
tuberculosis co‐infection
194·6 
(137·7 to 253·0)
–55·4% 
(–58·4 to –51·6)*
2·5 
(1·8 to 3·2)
–61·1% 
(–63·7 to –57·7)*
10 664·8 
(7613·4 to 13 757·1)
–55·6% 
(–58·7 to –51·7)*
140·0 
(100·2 to 180·0)
–60·5% 
(–63·1 to –57·0)*
HIV/AIDS and multidrug‐
resistant tuberculosis 
without extensive drug 
resistance co‐infection
22·6 
(13·4 to 34·5)
–52·2% 
(–66·4 to –33·2)*
0·3 
(0·2 to 0·4)
–58·1% 
(–70·5 to –41·5)*
1247·8 
(746·6 to 1906·7)
–51·7% 
(–65·7 to –33·2)*
16·4 
(9·8 to 25·1)
–56·8% 
(–69·3 to –40·4)*
HIV/AIDS and extensively 
drug‐resistant tuberculosis 
co‐infection
1·2 
(0·8 to 1·8)
–8·3% 
(–26·8 to 14·7)
0·0 
(0·0 to 0·0)
–20·3% 
(–36·4 to –0·2)*
62·7 
(38·3 to 92·9)
–10·5% 
(–28·4 to 11·5)
0·8 
(0·5 to 1·2)
–21·0% 
(–36·7 to –1·4)*
HIV/AIDS resulting in other 
diseases
736·0 
(659·5 to 817·7)
–48·7% 
(–51·1 to –45·9)*
9·3 
(8·4 to 10·4)
–55·1% 
(–57·2 to –52·6)*
38 521·8 
(34 381·3 to 
43 095·5)
–49·8% 
(–52·3 to –46·9)*
497·9 
(444·2 to 558·4)
–55·4% 
(–57·6 to –52·8)*
Sexually transmitted 
infections excluding HIV
119·1 
(50·8 to 220·4)
–10·8% 
(–18·4 to –2·5)*
1·8 
(0·7 to 3·3)
–14·4% 
(–21·5 to –6·6)*
10 053·1 
(4057·0 to 
18 915·2)
–11·4% 
(–19·0 to –3·2)*
151·3 
(60·6 to 285·3)
–14·4% 
(–21·8 to –6·6)*
Syphilis 113·5 
(45·2 to 214·5)
–11·3% 
(–19·1 to –2·8)*
1·7 
(0·7 to 3·2)
–14·3% 
(–21·8 to –6·4)*
9836·1 
(3848·5 to 
18 676·4)
–11·5% 
(–19·3 to –3·1)*
148·6 
(58·0 to 282·3)
–14·3% 
(–21·8 to –6·2)*
Chlamydial infection 1·1 
(0·9 to 1·2)
2·5% 
(–4·5 to 11·3)
0·0 
(0·0 to 0·0)
–15·2% 
(–21·0 to –8·4)*
40·5 
(32·6 to 45·0)
–5·5% 
(–12·2 to 2·5)
0·5 
(0·4 to 0·6)
–17·9% 
(–23·7 to –11·0)*
Gonococcal infection 3·0 
(2·4 to 3·3)
3·7% 
(–3·4 to 12·5)
0·0 
(0·0 to 0·0)
–14·9% 
(–20·8 to –8·2)*
112·8 
(90·2 to 124·9)
–3·8% 
(–10·7 to 4·3)
1·4 
(1·1 to 1·6)
–17·4% 
(–23·5 to –10·7)*
Other sexually transmitted 
infections
1·5 
(1·2 to 1·7)
0·2% 
(–6·4 to 8·3)
0·0 
(0·0 to 0·0)
–15·9% 
(–21·6 to –9·5)*
63·6 
(51·0 to 70·7)
–6·2% 
(–12·7 to 1·1)
0·8 
(0·6 to 0·9)
–18·2% 
(–23·9 to –11·7)*
Respiratory infections and 
tuberculosis
3752·3 
(3629·4 to 
3889·3)
–8·0% 
(–10·3 to –5·5)*
50·5 
(48·8 to 52·3)
–24·5% 
(–26·4 to –22·6)*
148 233·5 
(141 335·1 to 
155 291·4)
–24·7% 
(–27·4 to –21·7)*
2056·0 
(1956·3 to 
2160·7)
–32·8% 
(–35·4 to –30·0)*
Tuberculosis 1183·7 
(1129·8 to 
1245·3)
–14·9% 
(–18·2 to –10·3)*
14·9 
(14·3 to 15·7)
–31·4% 
(–34·1 to –27·6)*
41 876·9 
(39 972·4 to 
44 120·5)
–21·2% 
(–24·4 to –17·4)*
533·4 
(509·1 to 562·6)
–33·3% 
(–35·9 to –30·0)*
Drug‐susceptible 
tuberculosis
1044·1 
(951·6 to 
1129·2)
–15·5% 
(–22·3 to –8·6)*
13·2 
(12·0 to 14·2)
–31·9% 
(–37·3 to –26·4)*
36 932·5 
(33 846·8 to 
39 919·1)
–21·9% 
(–27·8 to –16·0)*
470·7 
(431·3 to 508·4)
–33·8% 
(–38·7 to –29·0)*
Multidrug‐resistant 
tuberculosis without 
extensive drug resistance
126·9 
(70·1 to 202·2)
–11·6% 
(–47·4 to 38·1)
1·6 
(0·9 to 2·5)
–28·6% 
(–57·4 to 11·4)
4505·1 
(2582·5 to 6984·6)
–17·6% 
(–49·4 to 26·5)
57·2 
(33·0 to 88·4)
–30·2% 
(–56·9 to 6·6)
Extensively drug‐resistant 
tuberculosis
12·6 
(8·6 to 18·0)
14·0% 
(–18·7 to 58·7)
0·2 
(0·1 to 0·2)
–7·7% 
(–34·1 to 28·8)
439·2 
(306·2 to 616·5)
5·5% 
(–23·2 to 44·9)
5·5 
(3·8 to 7·7)
–11·1% 
(–35·2 to 22·1)
Lower respiratory infections 2558·6 
(2442·2 to 
2655·4)
–4·3% 
(–6·9 to –1·5)*
35·4 
(33·8 to 36·8)
–21·1% 
(–23·2 to –18·9)*
105 834·5 
(99 746·4 to 
111 767·8)
–25·9% 
(–29·2 to –22·2)*
1515·1 
(1424·8 to 
1602·2)
–32·6% 
(–35·7 to –29·2)*
Upper respiratory infections 9·1 
(6·1 to 12·4)
–30·5% 
(–41·0 to –14·5)*
0·1 
(0·1 to 0·2)
–42·1% 
(–49·6 to –29·9)*
477·3 
(247·3 to 730·5)
–33·2% 
(–44·1 to –12·9)*
6·9 
(3·5 to 10·6)
–38·6% 
(–48·3 to –19·4)*
Otitis media 0·9 
(0·7 to 1·5)
–41·4% 
(–51·6 to –28·4)*
0·0 
(0·0 to 0·0)
–50·4% 
(–58·8 to –39·9)*
44·8 
(31·2 to 72·1)
–49·4% 
(–59·9 to –35·5)*
0·6 
(0·4 to 1·0)
–54·5% 
(–64·1 to –41·8)*
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Enteric infections 1766·0 
(1398·0 to 
2386·0)
–17·2% 
(–24·6 to –8·2)*
24·4 
(19·5 to 32·4)
–29·9% 
(–34·9 to –23·1)*
84 625·5 
(73 770·6 to 
100 720·2)
–30·6% 
(–36·3 to –23·7)*
1208·6 
(1064·1 to 
1424·7)
–36·6% 
(–41·8 to –30·7)*
Diarrhoeal diseases 1569·6 
(1176·0 to 
2193·0)
–16·6% 
(–25·3 to –6·7)*
21·6 
(16·4 to 29·7)
–30·2% 
(–36·1 to –22·7)*
70 574·3 
(60 421·1 to 
86 165·2)
–32·0% 
(–38·6 to –23·9)*
1009·1 
(870·5 to 
1211·0)
–38·1% 
(–43·9 to –31·3)*
Typhoid and paratyphoid 135·9 
(76·9 to 218·9)
–22·3% 
(–27·3 to –18·1)*
1·9 
(1·1 to 3·0)
–27·8% 
(–32·8 to –23·9)*
9686·1 
(5484·9 to 
15 746·2)
–23·8% 
(–29·3 to –19·4)*
136·3 
(77·0 to 220·9)
–28·7% 
(–34·0 to –24·4)*
Typhoid fever 116·8 
(65·4 to 187·7)
–23·7% 
(–29·0 to –19·3)*
1·6 
(0·9 to 2·6)
–29·1% 
(–34·1 to –25·0)*
8331·7 
(4632·5 to 
13 419·2)
–25·3% 
(–31·0 to –20·8)*
117·3 
(65·5 to 188·5)
–30·1% 
(–35·6 to –25·7)*
Paratyphoid fever 19·1 
(8·7 to 37·3)
–12·7% 
(–20·1 to –4·2)*
0·3 
(0·1 to 0·5)
–18·9% 
(–26·1 to –10·8)*
1354·4 
(622·3 to 2620·2)
–13·2% 
(–21·3 to –3·8)*
19·0 
(8·8 to 36·6)
–18·6% 
(–26·5 to –9·7)*
Invasive non‐typhoidal 
salmonella
59·1 
(33·3 to 98·1)
–17·9% 
(–25·1 to –8·7)*
0·8 
(0·5 to 1·4)
–24·8% 
(–31·9 to –15·6)*
4260·8 
(2382·0 to 7378·6)
–17·2% 
(–25·7 to –6·8)*
61·6 
(34·7 to 107·6)
–22·6% 
(–30·7 to –12·5)*
Other intestinal infectious 
diseases
1·4 
(1·0 to 2·2)
–39·7% 
(–67·1 to 9·7)
0·0 
(0·0 to 0·0)
–44·7% 
(–70·1 to 2·3)
104·4 
(67·8 to 170·7)
–43·6% 
(–71·6 to 11·9)
1·5 
(1·0 to 2·5)
–46·9% 
(–73·7 to 6·3)
Neglected tropical diseases 
and malaria
720·1 
(530·7 to 
938·8)
–29·0% 
(–37·3 to –19·3)*
10·1 
(7·5 to 13·2)
–36·1% 
(–43·7 to –27·3)*
48 656·2 
(35 574·6 to 
64 934·2)
–33·7% 
(–42·4 to –23·7)*
699·9 
(508·0 to 
933·6)
–38·6% 
(–46·7 to –29·2)*
Malaria 619·8 
(440·1 to 839·5)
–30·8% 
(–39·4 to –20·8)*
8·7 
(6·1 to 11·9)
–37·3% 
(–45·4 to –27·9)*
43 546·6 
(29 966·3 to 
59 772·4)
–34·5% 
(–43·8 to –23·6)*
629·4 
(432·6 to 858·7)
–39·2% 
(–48·2 to –28·8)*
Chagas disease 7·9 
(7·5 to 8·6)
3·8% 
(–1·6 to 12·9)
0·1 
(0·1 to 0·1)
–21·1% 
(–25·2 to –14·3)*
174·9 
(166·1 to 193·5)
–4·2% 
(–9·0 to 4·8)
2·2 
(2·0 to 2·4)
–25·1% 
(–28·9 to –18·1)*
Leishmaniasis 7·5 
(0·0 to 34·5)
–64·8% 
(–96·8 to –44·5)*
0·1 
(0·0 to 0·5)
–67·8% 
(–97·5 to –50·3)*
509·8 
(0·3 to 2440·2)
–63·8% 
(–92·1 to –39·7)*
7·2 
(0·0 to 34·6)
–66·2% 
(–93·2 to –43·8)*
Visceral leishmaniasis 7·5 
(0·0 to 34·5)
–64·8% 
(–96·8 to –44·5)*
0·1 
(0·0 to 0·5)
–67·8% 
(–97·5 to –50·3)*
509·8 
(0·3 to 2440·2)
–63·8% 
(–92·1 to –39·7)*
7·2 
(0·0 to 34·6)
–66·2% 
(–93·2 to –43·8)*
African trypanosomiasis 1·4 
(0·3 to 4·9)
–80·7% 
(–95·6 to –27·8)*
0·0 
(0·0 to 0·1)
–82·8% 
(–96·0 to –34·3)*
77·6 
(15·0 to 283·6)
–80·8% 
(–95·6 to –27·2)*
1·0 
(0·2 to 3·8)
–82·3% 
(–96·0 to –33·6)*
Schistosomiasis 8·8 
(8·0 to 9·8)
–12·3% 
(–17·6 to –6·4)*
0·1 
(0·1 to 0·1)
–28·5% 
(–32·7 to –23·7)*
342·3 
(305·3 to 384·3)
–15·6% 
(–21·9 to –8·8)*
4·4 
(3·9 to 5·0)
–27·4% 
(–32·9 to –21·4)*
Cysticercosis 0·7 
(0·5 to 1·0)
–15·9% 
(–42·7 to 23·3)
0·0 
(0·0 to 0·0)
–27·3% 
(–50·5 to 5·3)
39·6 
(26·9 to 55·0)
–20·5% 
(–46·9 to 18·2)
0·5 
(0·4 to 0·7)
–28·9% 
(–52·5 to 4·8)
Cystic echinococcosis 1·2 
(0·9 to 1·5)
–30·0% 
(–52·1 to –1·3)*
0·0 
(0·0 to 0·0)
–41·9% 
(–59·8 to –19·0)*
52·0 
(38·1 to 68·0)
–38·8% 
(–56·8 to –12·9)*
0·7 
(0·5 to 0·9)
–46·4% 
(–62·0 to –24·1)*
Dengue 40·5 
(17·6 to 49·8)
65·5% 
(21·7 to 99·7)*
0·5 
(0·2 to 0·7)
40·7% 
(3·6 to 69·7)*
1902·9 
(716·6 to 2312·9)
32·0% 
(–1·8 to 61·2)
26·1 
(9·8 to 31·7)
18·2% 
(–12·0 to 45·0)
Yellow fever 4·8 
(1·0 to 13·8)
–16·6% 
(–28·7 to –2·0)*
0·1 
(0·0 to 0·2)
–23·3% 
(–34·4 to –9·6)*
313·9 
(67·2 to 900·2)
–16·0% 
(–28·9 to 0·0)
4·3 
(0·9 to 12·4)
–21·3% 
(–33·6 to –5·8)*
Rabies 11·7 
(9·3 to 14·7)
–48·1% 
(–58·8 to –37·3)*
0·2 
(0·1 to 0·2)
–54·8% 
(–63·8 to –45·0)*
633·7 
(504·4 to 836·4)
–51·5% 
(–61·3 to –38·9)*
8·6 
(6·8 to 11·5)
–56·2% 
(–65·1 to –44·3)*
Intestinal nematode 
infections
3·2 
(2·5 to 4·1)
–43·1% 
(–56·1 to –25·0)*
0·0 
(0·0 to 0·1)
–47·2% 
(–59·5 to –30·1)*
257·1 
(194·1 to 336·3)
–44·1% 
(–57·6 to –25·0)*
3·8 
(2·9 to 5·0)
–47·6% 
(–60·4 to –29·6)*
Ascariasis 3·2 
(2·5 to 4·1)
–43·1% 
(–56·1 to –25·0)*
0·0 
(0·0 to 0·1)
–47·2% 
(–59·5 to –30·1)*
257·1 
(194·1 to 336·3)
–44·1% 
(–57·6 to –25·0)*
3·8 
(2·9 to 5·0)
–47·6% 
(–60·4 to –29·6)*
Ebola virus disease 0·0 
(0·0 to 0·0)
–98·2% 
(–98·4 to –98·0)*
0·0 
(0·0 to 0·0)
–98·4% 
(–98·6 to –98·2)*
0·5 
(0·5 to 0·5)
–98·1% 
(–98·3 to –97·9)*
0·0 
(0·0 to 0·0)
–98·2% 
(–98·4 to –98·0)*
Zika virus disease 0·0 
(0·0 to 0·1)
·· 0·0 
(0·0 to 0·0)
·· 1·0 
(0·2 to 3·4)
·· 0·0 
(0·0 to 0·0)
··
Other neglected tropical 
diseases
12·6 
(8·0 to 36·3)
8·1% 
(–8·1 to 28·2)
0·2 
(0·1 to 0·5)
–3·7% 
(–18·3 to 13·9)
804·3 
(442·8 to 2696·6)
3·9% 
(–16·3 to 29·4)
11·6 
(6·3 to 39·6)
–3·5% 
(–22·2 to 20·7)
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Other infectious diseases 830·5 
(732·2 to 
947·8)
–25·9% 
(–32·4 to –18·8)*
11·6 
(10·1 to 13·3)
–33·8% 
(–39·3 to –27·4)*
53 008·6 
(44 786·0 to 
63 000·4)
–33·0% 
(–39·6 to –25·1)*
762·8 
(640·5 to 911·5)
–37·9% 
(–44·0 to –30·5)*
Meningitis 288·0 
(254·3 to 333·2)
–20·1% 
(–26·0 to –11·0)*
4·0 
(3·6 to 4·6)
–27·8% 
(–33·1 to –19·3)*
19 436·9 
(16 935·1 to 
22 335·8)
–25·2% 
(–31·5 to –15·7)*
280·5 
(243·6 to 323·2)
–30·2% 
(–36·3 to –21·4)*
Pneumococcal meningitis 42·1 
(36·6 to 49·4)
–13·4% 
(–20·6 to –2·3)*
0·6 
(0·5 to 0·7)
–22·4% 
(–28·9 to –12·4)*
2751·8 
(2325·8 to 3276·5)
–18·5% 
(–26·8 to –6·5)*
39·6 
(33·4 to 47·0)
–24·2% 
(–32·1 to –12·8)*
H influenzae type B 
meningitis
75·7 
(66·7 to 92·0)
–33·7% 
(–39·6 to –26·0)*
1·1 
(0·9 to 1·3)
–40·6% 
(–45·8 to –33·9)*
4907·3 
(4232·2 to 5813·6)
–40·4% 
(–46·1 to –33·0)*
70·5 
(60·6 to 83·9)
–44·7% 
(–50·1 to –37·7)*
Meningococcal infection 30·0 
(25·7 to 35·7)
–31·5% 
(–37·4 to –22·8)*
0·4 
(0·4 to 0·5)
–37·1% 
(–42·6 to –29·2)*
2180·3 
(1819·8 to 2614·5)
–34·9% 
(–41·4 to –26·4)*
31·9 
(26·5 to 38·4)
–38·8% 
(–45·0 to –30·5)*
Other meningitis 140·3 
(121·4 to 161·8)
–8·9% 
(–15·4 to 1·4)
2·0 
(1·7 to 2·3)
–17·3% 
(–23·4 to –7·5)*
9597·5 
(8195·6 to 
11 118·5)
–12·8% 
(–20·4 to –0·7)*
138·5 
(118·3 to 160·5)
–18·4% 
(–25·7 to –7·4)*
Encephalitis 92·4 
(83·1 to 107·9)
0·0% 
(–14·2 to 16·2)
1·2 
(1·1 to 1·4)
–14·3% 
(–26·5 to –0·9)*
4588·2 
(4059·5 to 5230·7)
–12·1% 
(–28·1 to 4·5)
64·1 
(56·6 to 72·4)
–20·1% 
(–35·0 to –5·0)*
Diphtheria 3·6 
(2·2 to 6·1)
–23·9% 
(–55·6 to 36·4)
0·1 
(0·0 to 0·1)
–28·6% 
(–58·8 to 29·2)
298·7 
(181·8 to 510·0)
–23·9% 
(–56·7 to 38·7)
4·4 
(2·7 to 7·6)
–28·3% 
(–59·5 to 31·4)
Whooping cough 91·8 
(45·9 to 163·2)
–23·3% 
(–54·8 to 35·6)
1·4 
(0·7 to 2·4)
–27·1% 
(–57·1 to 28·8)
7879·2 
(3938·1 to 
14 010·3)
–23·3% 
(–54·8 to 35·4)
117·9 
(58·9 to 209·6)
–27·1% 
(–57·0 to 28·8)
Tetanus 38·1 
(25·9 to 48·8)
–54·9% 
(–65·9 to –39·1)*
0·5 
(0·4 to 0·7)
–59·6% 
(–69·3 to –45·0)*
2447·7 
(1734·9 to 3199·0)
–59·3% 
(–69·9 to –43·5)*
35·1 
(25·0 to 46·3)
–62·1% 
(–72·1 to –47·0)*
Measles 95·3 
(34·5 to 205·2)
–57·0% 
(–61·9 to –51·9)*
1·4 
(0·5 to 3·1)
–59·3% 
(–64·0 to –54·4)*
8105·1 
(2935·7 to 
17 469·0)
–56·9% 
(–61·8 to –51·8)*
120·8 
(43·7 to 260·4)
–59·2% 
(–63·9 to –54·3)*
Varicella and herpes zoster 15·6 
(14·4 to 17·3)
–16·4% 
(–22·9 to –9·5)*
0·2 
(0·2 to 0·2)
–29·2% 
(–34·7 to –23·4)*
833·0 
(742·3 to 938·1)
–22·5% 
(–31·4 to –13·2)*
12·1 
(10·7 to 13·6)
–28·4% 
(–36·6 to –19·4)*
Acute hepatitis 126·4 
(94·5 to 143·7)
–9·8% 
(–15·5 to –2·3)*
1·6 
(1·2 to 1·9)
–24·5% 
(–29·2 to –18·4)*
5478·4 
(4040·3 to 6330·0)
–21·7% 
(–27·7 to –14·4)*
72·3 
(52·9 to 83·9)
–31·2% 
(–36·5 to –24·9)*
Acute hepatitis A 18·6 
(13·6 to 23·8)
–33·1% 
(–41·9 to –22·5)*
0·3 
(0·2 to 0·3)
–38·7% 
(–46·8 to –28·6)*
1286·7 
(935·2 to 1633·7)
–36·0% 
(–45·1 to –24·3)*
18·0 
(13·0 to 22·9)
–40·7% 
(–49·1 to –29·0)*
Acute hepatitis B 89·6 
(66·1 to 102·5)
–0·8% 
(–8·4 to 8·5)
1·1 
(0·8 to 1·3)
–19·6% 
(–25·4 to –12·4)*
3262·4 
(2367·8 to 3819·1)
–12·2% 
(–19·7 to –2·7)*
41·8 
(30·1 to 49·3)
–25·6% 
(–31·9 to –17·5)*
Acute hepatitis C 3·5 
(1·9 to 6·0)
–23·7% 
(–35·9 to –9·4)*
0·0 
(0·0 to 0·1)
–32·1% 
(–42·4 to –19·6)*
219·7 
(120·1 to 371·3)
–31·0% 
(–43·3 to –15·3)*
3·2 
(1·8 to 5·4)
–35·5% 
(–47·2 to –20·7)*
Acute hepatitis E 14·7 
(10·4 to 18·5)
–15·8% 
(–27·2 to –3·1)*
0·2 
(0·1 to 0·2)
–25·8% 
(–35·3 to –15·6)*
709·6 
(489·6 to 903·9)
–25·5% 
(–35·2 to –14·5)*
9·3 
(6·4 to 11·8)
–31·9% 
(–40·6 to –22·0)*
Other unspecified infectious 
diseases
79·3 
(59·9 to 85·1)
1·6% 
(–3·1 to 7·9)
1·1 
(0·8 to 1·2)
–13·4% 
(–17·5 to –8·1)*
3941·3 
(2831·7 to 4325·8)
–10·2% 
(–16·2 to –2·4)*
55·6 
(39·6 to 61·3)
–17·9% 
(–23·6 to –10·6)*
Maternal and neonatal 
disorders
1977·4 
(1890·1 to 
2060·6)
–24·1% 
(–26·9 to –21·0)*
29·5 
(28·2 to 30·8)
–26·6% 
(–29·3 to –23·5)*
167 684·6 
(160 060·7 to 
174 918·2)
–24·2% 
(–27·1 to –20·9)*
2518·2 
(2403·8 to 
2627·1)
–26·5% 
(–29·3 to –23·3)*
Maternal disorders 193·6 
(179·9 to 209·6)
–24·0% 
(–28·4 to –19·5)*
2·5 
(2·3 to 2·7)
–30·7% 
(–34·8 to –26·6)*
10 993·1 
(10 198·9 to 
11 928·5)
–25·3% 
(–29·7 to –20·9)*
140·9 
(130·8 to 153·0)
–31·5% 
(–35·5 to –27·5)*
Maternal haemorrhage 38·5 
(33·2 to 45·2)
–52·1% 
(–59·0 to –44·2)*
0·5 
(0·4 to 0·6)
–56·4% 
(–62·7 to –49·3)*
2173·8 
(1859·7 to 2552·5)
–53·0% 
(–60·1 to –45·0)*
27·8 
(23·8 to 32·7)
–57·1% 
(–63·6 to –49·7)*
Maternal sepsis and other 
pregnancy‐related 
infections
21·2 
(18·2 to 25·0)
–27·1% 
(–38·8 to –15·1)*
0·3 
(0·2 to 0·3)
–33·5% 
(–44·2 to –22·6)*
1198·0 
(1022·8 to 1420·8)
–28·9% 
(–41·1 to –16·2)*
15·4 
(13·1 to 18·3)
–34·5% 
(–45·4 to –22·5)*
Maternal hypertensive 
disorders
29·4 
(25·4 to 34·5)
–5·5% 
(–20·7 to 11·2)
0·4 
(0·3 to 0·4)
–13·0% 
(–27·3 to 2·6)
1729·6 
(1487·6 to 2033·2)
–6·6% 
(–22·1 to 10·2)
22·3 
(19·2 to 26·4)
–13·6% 
(–28·1 to 2·0)
Maternal obstructed labour 
and uterine rupture
13·0 
(10·2 to 16·8)
–17·7% 
(–35·9 to 2·9)
0·2 
(0·1 to 0·2)
–25·2% 
(–41·0 to –6·3)*
720·9 
(565·5 to 946·4)
–18·9% 
(–37·6 to 1·9)
9·2 
(7·2 to 12·1)
–25·8% 
(–42·9 to –6·9)*
(Table 1 continues on next page)
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All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
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change, 2007–17
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Maternal abortive outcome 17·4 
(14·7 to 20·8)
–7·0% 
(–22·3 to 10·1)
0·2 
(0·2 to 0·3)
–15·7% 
(–29·3 to –0·4)*
963·4 
(807·6 to 1161·1)
–8·9% 
(–24·2 to 8·7)
12·3 
(10·3 to 14·9)
–16·8% 
(–30·7 to –0·5)*
Ectopic pregnancy 10·2 
(7·1 to 15·2)
–11·6% 
(–41·4 to 27·9)
0·1 
(0·1 to 0·2)
–19·2% 
(–46·2 to 16·8)
590·6 
(409·0 to 881·4)
–13·3% 
(–43·8 to 26·9)
7·6 
(5·3 to 11·4)
–20·3% 
(–48·1 to 17·0)
Indirect maternal deaths 34·1 
(30·0 to 38·7)
–4·1% 
(–16·7 to 8·5)
0·4 
(0·4 to 0·5)
–12·5% 
(–24·0 to –1·0)*
1934·4 
(1694·2 to 2216·7)
–6·1% 
(–19·2 to 6·8)
24·8 
(21·7 to 28·5)
–13·9% 
(–25·8 to –2·3)*
Late maternal deaths 3·4 
(2·6 to 4·3)
–0·9% 
(–7·0 to 5·5)
0·0 
(0·0 to 0·1)
–9·5% 
(–14·7 to –4·0)*
194·7 
(152·2 to 251·4)
–2·0% 
(–8·2 to 4·1)
2·5 
(2·0 to 3·2)
–10·1% 
(–15·4 to –4·5)*
Maternal deaths 
aggravated by HIV/AIDS
1·6 
(1·0 to 2·1)
–23·9% 
(–31·0 to –16·0)*
0·0 
(0·0 to 0·0)
–32·1% 
(–38·4 to –25·2)*
84·4 
(53·0 to 113·8)
–26·7% 
(–33·6 to –19·2)*
1·1 
(0·7 to 1·4)
–34·2% 
(–40·6 to –27·5)*
Other maternal disorders 24·8 
(20·8 to 29·8)
–8·5% 
(–24·7 to 11·2)
0·3 
(0·3 to 0·4)
–16·5% 
(–31·2 to 1·5)
1403·1 
(1159·5 to 1690·3)
–9·8% 
(–26·7 to 10·8)
18·0 
(14·9 to 21·7)
–17·2% 
(–32·9 to 1·2)
Neonatal disorders 1783·8 
(1698·5 to 
1864·7)
–24·1% 
(–27·2 to –20·6)*
27·1 
(25·8 to 28·3)
–26·2% 
(–29·1 to –22·7)*
156 691·6 
(149 207·2 to 
163 802·2)
–24·1% 
(–27·2 to –20·6)*
2377·2 
(2263·7 to 
2485·1)
–26·2% 
(–29·1 to –22·7)*
Neonatal preterm birth 649·4 
(605·4 to 721·3)
–26·2% 
(–31·3 to –21·5)*
9·9 
(9·2 to 10·9)
–28·1% 
(–33·2 to –23·6)*
57 052·0 
(53 182·3 to 
63 367·1)
–26·2% 
(–31·3 to –21·5)*
865·6 
(806·9 to 961·5)
–28·1% 
(–33·2 to –23·6)*
Neonatal encephalopathy 
due to birth asphyxia and 
trauma
533·3 
(476·9 to 
580·3)
–24·5% 
(–30·2 to –18·0)*
8·1 
(7·2 to 8·8)
–26·5% 
(–32·0 to –20·2)*
46 845·9 
(41 894·1 to 
50 985·7)
–24·5% 
(–30·2 to –18·0)*
710·8 
(635·7 to 773·7)
–26·5% 
(–32·0 to –20·2)*
Neonatal sepsis and other 
neonatal infections
203·0 
(178·7 to 267·1)
–11·9% 
(–20·5 to –1·7)*
3·1 
(2·7 to 4·1)
–14·4% 
(–22·7 to –4·4)*
17 830·7 
(15 692·9 to 
23 459·0)
–11·9% 
(–20·5 to –1·7)*
270·4 
(238·0 to 355·8)
–14·4% 
(–22·7 to –4·4)*
Haemolytic disease and 
other neonatal jaundice
49·1 
(42·9 to 55·9)
–37·5% 
(–45·3 to –28·2)*
0·7 
(0·7 to 0·8)
–39·3% 
(–46·8 to –30·2)*
4309·1 
(3771·2 to 4914·0)
–37·5% 
(–45·3 to –28·2)*
65·4 
(57·2 to 74·5)
–39·3% 
(–46·8 to –30·2)*
Other neonatal disorders 349·0 
(294·9 to 382·3)
–23·6% 
(–29·8 to –15·5)*
5·3 
(4·5 to 5·8)
–25·7% 
(–31·7 to –17·8)*
30 654·0 
(25 899·7 to 
33 578·7)
–23·6% 
(–29·8 to –15·5)*
465·0 
(392·9 to 509·4)
–25·7% 
(–31·7 to –17·8)*
Nutritional deficiencies 270·0 
(249·3 to 
295·5)
–23·9% 
(–29·2 to –15·7)*
3·8 
(3·5 to 4·2)
–33·6% 
(–38·1 to –26·5)*
15 658·0 
(14 051·5 to 
17 506·6)
–34·7% 
(–40·5 to –26·1)*
228·7 
(204·9 to 
255·9)
–39·4% 
(–44·8 to –31·4)*
Protein‐energy malnutrition 231·8 
(212·4 to 254·2)
–26·1% 
(–31·7 to –17·9)*
3·3 
(3·0 to 3·7)
–34·6% 
(–39·4 to –27·5)*
14 405·4 
(12 873·5 to 
16 128·0)
–35·1% 
(–41·1 to –26·7)*
211·8 
(189·0 to 237·3)
–39·4% 
(–45·0 to –31·6)*
Other nutritional deficiencies 38·2 
(33·7 to 44·6)
–7·2% 
(–14·6 to 3·1)
0·5 
(0·4 to 0·6)
–25·8% 
(–31·7 to –17·5)*
1252·7 
(1087·5 to 1435·2)
–29·2% 
(–36·9 to –19·7)*
16·9 
(14·6 to 19·5)
–38·6% 
(–45·4 to –30·4)*
Non-communicable diseases 41 071·1 
(40 470·9 to 
41 548·9)
22·7% 
(21·5 to 23·9)*
536·1 
(528·4 to 542·2)
–7·9% 
(–8·8 to –7·0)*
872 601·8 
(859 538·6 to 
884 787·7)
13·6% 
(12·2 to 14·9)*
11 097·4 
(10 928·6 to 
11 253·8)
–9·6% 
(–10·7 to –8·6)*
Neoplasms 9556·2 
(9395·7 to 
9692·3)
25·4% 
(23·9 to 27·0)*
121·2 
(119·1 to 122·9)
–4·4% 
(–5·6 to –3·3)*
225 738·1 
(221 608·8 to 
229 322·4)
19·6% 
(17·8 to 21·4)*
2803·4 
(2751·5 to 
2848·8)
–5·6% 
(–7·0 to –4·1)*
Lip and oral cavity cancer 193·7 
(184·7 to 201·6)
35·6% 
(29·5 to 40·8)*
2·4 
(2·3 to 2·5)
4·0% 
(–0·6 to 8·0)
5090·6 
(4819·5 to 5328·3)
30·5% 
(23·8 to 36·4)*
62·2 
(58·9 to 65·1)
3·0% 
(–2·3 to 7·6)
Nasopharynx cancer 69·5 
(66·9 to 72·3)
24·4% 
(20·0 to 28·8)*
0·9 
(0·8 to 0·9)
–3·0% 
(–6·4 to 0·4)
2034·5 
(1954·7 to 2117·4)
18·3% 
(13·9 to 23·1)*
24·8 
(23·8 to 25·8)
–5·0% 
(–8·5 to –1·3)*
Other pharynx cancer 117·4 
(102·1 to 124·5)
40·4% 
(29·7 to 48·4)*
1·4 
(1·3 to 1·5)
7·9% 
(–0·3 to 14·0)
3204·2 
(2766·3 to 3405·1)
36·0% 
(25·4 to 44·2)*
38·9 
(33·5 to 41·3)
6·5% 
(–1·7 to 12·8)
Oesophageal cancer 436·0 
(425·0 to 447·6)
13·0% 
(9·9 to 16·3)*
5·5 
(5·3 to 5·6)
–14·5% 
(–16·9 to –12·0)*
9647·5 
(9410·7 to 9903·5)
8·9% 
(5·8 to 12·2)*
118·3 
(115·4 to 121·4)
–16·2% 
(–18·6 to –13·7)*
Stomach cancer 865·0 
(848·3 to 884·7)
9·4% 
(7·1 to 12·1)*
11·0 
(10·8 to 11·2)
–17·1% 
(–18·8 to –15·1)*
18 782·0 
(18 409·7 to 
19 207·7)
4·8% 
(2·4 to 7·4)*
231·6 
(227·0 to 236·8)
–18·6% 
(–20·5 to –16·6)*
Colon and rectum cancer 896·0 
(876·3 to 915·7)
27·8% 
(24·0 to 31·3)*
11·5 
(11·3 to 11·8)
–4·3% 
(–7·1 to –1·8)*
18 106·7 
(17 678·0 to 
18 525·0)
23·8% 
(19·2 to 27·6)*
224·7 
(219·4 to 229·9)
–4·5% 
(–8·0 to –1·7)*
(Table 1 continues on next page)
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Liver cancer 819·4 
(789·7 to 855·5)
27·0% 
(23·0 to 32·9)*
10·2 
(9·8 to 10·7)
–2·5% 
(–5·6 to 2·0)
20 536·2 
(19 678·7 to 
21 551·9)
21·2% 
(17·0 to 27·4)*
250·7 
(240·4 to 263·0)
–4·6% 
(–8·0 to 0·1)
Liver cancer due to 
hepatitis B
325·4 
(304·6 to 
348·2)
20·3% 
(15·3 to 28·2)*
4·0 
(3·7 to 4·3)
–6·2% 
(–10·0 to 0·1)
9449·0 
(8837·3 to 
10 138·6)
14·7% 
(9·7 to 21·9)*
114·6 
(107·3 to 123·0)
–8·4% 
(–12·2 to –2·6)*
Liver cancer due to 
hepatitis C
234·3 
(219·4 to 250·6)
30·4% 
(26·7 to 35·0)*
3·0 
(2·8 to 3·2)
–2·1% 
(–4·9 to 1·4)
4898·4 
(4554·0 to 5259·3)
26·9% 
(23·3 to 31·6)*
60·3 
(56·2 to 64·7)
–3·0% 
(–5·8 to 0·5)
Liver cancer due to alcohol 
use
129·3 
(114·5 to 147·3)
31·7% 
(26·8 to 37·3)*
1·6 
(1·4 to 1·8)
0·6% 
(–3·0 to 4·8)
3040·7 
(2647·6 to 3549·8)
27·8% 
(22·4 to 33·9)*
37·2 
(32·5 to 43·3)
–0·6% 
(–4·5 to 3·9)
Liver cancer due to NASH 66·9 
(59·6 to 74·5)
42·3% 
(38·0 to 47·6)*
0·8 
(0·8 to 0·9)
7·6% 
(4·4 to 11·7)*
1443·8 
(1288·9 to 1605·9)
37·3% 
(32·7 to 42·8)*
17·8 
(15·9 to 19·7)
6·3% 
(2·9 to 10·5)*
Liver cancer due to other 
causes
63·5 
(57·4 to 70·6)
28·2% 
(23·6 to 34·3)*
0·8 
(0·7 to 0·9)
–0·9% 
(–4·2 to 3·6)
1704·2 
(1528·4 to 1903·8)
21·1% 
(16·0 to 27·4)*
20·9 
(18·8 to 23·3)
–3·5% 
(–7·2 to 1·4)
Gallbladder and biliary tract 
cancer
174·0 
(154·2 to 184·9)
25·0% 
(21·5 to 28·7)*
2·2 
(2·0 to 2·4)
–6·7% 
(–9·4 to –4·0)*
3434·0 
(3009·7 to 3660·0)
21·8% 
(17·8 to 26·3)*
42·6 
(37·3 to 45·4)
–6·8% 
(–9·9 to –3·5)*
Pancreatic cancer 441·1 
(432·8 to 449·0)
39·9% 
(36·7 to 42·6)*
5·6 
(5·5 to 5·7)
4·8% 
(2·5 to 6·8)*
8988·1 
(8806·6 to 9162·9)
35·8% 
(32·5 to 38·6)*
111·1 
(108·9 to 113·2)
4·0% 
(1·5 to 6·1)*
Larynx cancer 126·5 
(123·4 to 129·9)
21·1% 
(17·8 to 24·4)*
1·6 
(1·5 to 1·6)
–7·7% 
(–10·1 to –5·2)*
3170·0 
(3089·7 to 3260·3)
17·3% 
(13·9 to 20·9)*
38·5 
(37·6 to 39·6)
–9·1% 
(–11·7 to –6·4)*
Tracheal, bronchus, and lung 
cancer
1883·1 
(1844·2 to 
1922·8)
29·6% 
(26·5 to 32·5)*
23·7 
(23·3 to 24·2)
–2·0% 
(–4·3 to 0·1)
40 391·6 
(39 506·7 to 
41 285·6)
24·8% 
(21·7 to 27·6)*
496·4 
(485·5 to 507·2)
–4·1% 
(–6·5 to –2·0)*
Malignant skin melanoma 61·7 
(47·9 to 70·3)
23·6% 
(19·0 to 26·9)*
0·8 
(0·6 to 0·9)
–5·1% 
(–8·5 to –2·5)*
1513·2 
(1220·7 to 1774·4)
16·1% 
(12·7 to 20·0)*
18·7 
(15·1 to 21·9)
–7·2% 
(–9·8 to –3·8)*
Non‐melanoma skin cancer 65·1 
(63·1 to 66·5)
38·6% 
(34·9 to 41·2)*
0·8 
(0·8 to 0·9)
2·7% 
(0·0 to 4·5)*
1239·1 
(1200·2 to 1266·6)
30·0% 
(26·2 to 32·7)*
15·5 
(15·0 to 15·8)
0·5% 
(–2·3 to 2·6)
Non‐melanoma skin cancer 
(squamous‐cell carcinoma)
65·1 
(63·1 to 66·5)
38·6% 
(34·9 to 41·2)*
0·8 
(0·8 to 0·9)
2·7% 
(0·0 to 4·5)*
1239·1 
(1200·2 to 1266·6)
30·0% 
(26·2 to 32·7)*
15·5 
(15·0 to 15·8)
0·5% 
(–2·3 to 2·6)
Breast cancer 611·6 
(589·2 to 640·7)
27·0% 
(21·3 to 31·2)*
7·6 
(7·4 to 8·0)
–2·6% 
(–6·9 to 0·4)
16 400·7 
(15 737·0 to 
17 320·2)
23·9% 
(17·3 to 28·7)*
200·2 
(192·1 to 211·4)
–1·7% 
(–6·8 to 2·1)
Cervical cancer 259·7 
(241·1 to 269·2)
18·8% 
(12·9 to 22·8)*
3·2 
(3·0 to 3·3)
–7·2% 
(–11·7 to –4·0)*
7773·5 
(7227·4 to 8087·8)
15·1% 
(9·4 to 19·1)*
94·6 
(88·1 to 98·5)
–7·2% 
(–11·8 to –3·9)*
Uterine cancer 85·2 
(83·2 to 87·4)
18·8% 
(15·8 to 22·5)*
1·1 
(1·0 to 1·1)
–10·4% 
(–12·5 to –7·7)*
1930·0 
(1879·9 to 1983·0)
14·8% 
(11·6 to 19·0)*
23·7 
(23·1 to 24·3)
–11·2% 
(–13·7 to –8·0)*
Ovarian cancer 176·0 
(171·4 to 181·2)
30·3% 
(26·8 to 33·7)*
2·2 
(2·1 to 2·3)
–1·0% 
(–3·6 to 1·6)
4496·9 
(4370·7 to 4642·1)
29·1% 
(24·8 to 33·1)*
54·9 
(53·4 to 56·7)
1·1% 
(–2·2 to 4·2)
Prostate cancer 415·9 
(357·3 to 489·5)
32·5% 
(29·3 to 38·4)*
5·5 
(4·7 to 6·5)
–2·5% 
(–4·9 to 1·9)
6214·5 
(5324·2 to 7293·0)
28·3% 
(24·9 to 34·5)*
79·3 
(68·1 to 93·0)
–3·6% 
(–6·2 to 1·2)
Testicular cancer 7·7 
(7·4 to 8·0)
6·1% 
(2·3 to 10·9)*
0·1 
(0·1 to 0·1)
–9·4% 
(–12·6 to –5·2)*
338·7 
(323·8 to 357·4)
0·9% 
(–3·3 to 6·3)
4·3 
(4·1 to 4·5)
–10·8% 
(–14·5 to –6·1)*
Kidney cancer 138·5 
(128·7 to 142·5)
30·1% 
(26·2 to 34·1)*
1·8 
(1·6 to 1·8)
–1·3% 
(–4·3 to 1·7)
3143·3 
(2952·2 to 3234·1)
23·1% 
(18·5 to 27·3)*
39·4 
(37·0 to 40·5)
–3·3% 
(–6·9 to 0·0)
Bladder cancer 196·5 
(191·5 to 205·8)
27·8% 
(25·1 to 30·4)*
2·6 
(2·5 to 2·7)
–5·4% 
(–7·3 to –3·4)*
3350·1 
(3257·4 to 3511·6)
22·6% 
(19·9 to 25·3)*
42·2 
(41·0 to 44·1)
–6·9% 
(–8·9 to –4·8)*
Brain and nervous system 
cancer
247·1 
(213·0 to 265·0)
29·2% 
(23·2 to 33·4)*
3·1 
(2·7 to 3·3)
3·8% 
(–1·0 to 7·0)
8577·8 
(7527·0 to 9359·3)
18·4% 
(11·9 to 24·6)*
109·8 
(96·1 to 120·0)
0·0% 
(–5·6 to 5·3)
Thyroid cancer 41·2 
(39·9 to 44·1)
28·9% 
(24·3 to 33·3)*
0·5 
(0·5 to 0·6)
–1·2% 
(–4·5 to 2·0)
1001·2 
(963·6 to 1074·0)
22·1% 
(16·7 to 28·0)*
12·4 
(12·0 to 13·4)
–2·3% 
(–6·6 to 2·4)
Mesothelioma 29·9 
(29·1 to 30·6)
26·9% 
(20·1 to 32·6)*
0·4 
(0·4 to 0·4)
–3·4% 
(–8·4 to 0·7)
655·7 
(635·2 to 677·0)
21·0% 
(13·8 to 27·3)*
8·1 
(7·9 to 8·4)
–5·4% 
(–10·8 to –0·8)*
Hodgkin lymphoma 32·6 
(27·6 to 38·1)
0·2% 
(–3·5 to 3·6)
0·4 
(0·4 to 0·5)
–16·8% 
(–19·8 to –14·0)*
1327·6 
(1110·1 to 1567·7)
–5·2% 
(–8·6 to –1·8)*
17·1 
(14·3 to 20·2)
–17·1% 
(–20·1 to –13·9)*
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Non‐Hodgkin lymphoma 248·6 
(243·5 to 253·1)
29·4% 
(25·5 to 32·4)*
3·2 
(3·1 to 3·2)
0·1% 
(–2·7 to 2·4)
6828·8 
(6611·8 to 7020·0)
22·1% 
(15·6 to 26·9)*
86·8 
(84·0 to 89·5)
0·2% 
(–5·2 to 4·3)
Multiple myeloma 107·1 
(98·5 to 118·9)
32·7% 
(28·4 to 36·4)*
1·4 
(1·3 to 1·5)
–0·4% 
(–3·5 to 2·4)
2234·7 
(2091·4 to 2493·2)
30·4% 
(25·6 to 34·4)*
27·7 
(25·9 to 30·8)
0·3% 
(–3·3 to 3·4)
Leukaemia 347·6 
(317·3 to 364·9)
12·8% 
(9·5 to 15·6)*
4·5 
(4·1 to 4·7)
–9·6% 
(–12·2 to –7·4)*
11 712·0 
(10 531·4 to 
12 523·3)
2·3% 
(–3·7 to 6·2)
153·4 
(137·9 to 164·5)
–12·0% 
(–17·3 to –8·5)*
Acute lymphoid leukaemia 52·2 
(46·0 to 56·7)
14·1% 
(2·6 to 23·2)*
0·7 
(0·6 to 0·7)
–1·5% 
(–11·6 to 6·2)
2661·7 
(2341·7 to 2941·1)
5·3% 
(–8·6 to 15·4)
36·1 
(31·7 to 40·0)
–4·7% 
(–17·6 to 4·7)
Chronic lymphoid 
leukaemia
35·2 
(33·5 to 36·9)
21·4% 
(17·7 to 25·0)*
0·5 
(0·4 to 0·5)
–10·3% 
(–13·0 to –7·6)*
634·1 
(595·7 to 674·2)
18·3% 
(14·2 to 22·4)*
8·0 
(7·5 to 8·5)
–9·2% 
(–12·3 to –6·1)*
Acute myeloid leukaemia 99·9 
(91·3 to 104·6)
24·6% 
(17·1 to 29·8)*
1·3 
(1·2 to 1·3)
–1·0% 
(–6·6 to 3·0)
3192·6 
(2868·8 to 3405·6)
16·2% 
(4·4 to 24·6)*
41·3 
(37·0 to 44·1)
–1·4% 
(–11·3 to 5·8)
Chronic myeloid leukaemia 24·1 
(22·2 to 26·1)
3·3% 
(0·4 to 6·4)*
0·3 
(0·3 to 0·3)
–19·9% 
(–22·2 to –17·6)*
643·3 
(583·4 to 699·1)
–1·7% 
(–5·2 to 1·5)
8·0 
(7·3 to 8·7)
–19·7% 
(–22·4 to –17·1)*
Other leukaemia 136·2 
(121·0 to 146·8)
4·9% 
(0·9 to 9·7)*
1·8 
(1·6 to 1·9)
–15·6% 
(–18·7 to –12·1)*
4580·2 
(3955·1 to 5013·3)
–8·1% 
(–14·6 to –1·8)*
60·0 
(51·9 to 65·7)
–20·8% 
(–26·5 to –15·4)*
Other malignant cancers 359·5 
(331·4 to 370·8)
26·8% 
(23·3 to 29·5)*
4·6 
(4·2 to 4·8)
0·1% 
(–2·6 to 2·2)
11 189·0 
(10 386·5 to 
11 664·8)
18·4% 
(12·8 to 22·8)*
144·4 
(133·8 to 150·9)
–0·3% 
(–5·1 to 3·5)
Other neoplasms 102·9 
(80·2 to 122·4)
42·0% 
(35·6 to 51·7)*
1·3 
(1·0 to 1·6)
7·4% 
(2·1 to 15·8)*
2425·8 
(2024·4 to 2932·1)
32·9% 
(25·9 to 42·7)*
31·1 
(25·9 to 37·4)
7·9% 
(2·0 to 16·5)*
Myelodysplastic, 
myeloproliferative, and 
other haemopoietic 
neoplasms
98·8 
(76·7 to 118·1)
42·6% 
(36·2 to 52·2)*
1·3 
(1·0 to 1·5)
7·1% 
(1·8 to 15·3)*
2189·1 
(1820·8 to 2665·5)
33·9% 
(26·6 to 43·3)*
27·9 
(23·2 to 33·8)
7·2% 
(1·2 to 15·6)*
Other benign and in‐situ 
neoplasms
4·1 
(3·2 to 4·8)
29·6% 
(17·2 to 44·5)*
0·1 
(0·0 to 0·1)
15·5% 
(4·1 to 29·2)*
236·8 
(186·4 to 277·7)
25·0% 
(12·7 to 38·6)*
3·2 
(2·5 to 3·7)
14·3% 
(3·0 to 27·0)*
Cardiovascular diseases 17 790·9 
(17 527·1 to 
18 042·7)
21·1% 
(19·7 to 22·6)*
233·1 
(229·7 to 236·4)
–10·3% 
(–11·4 to –9·3)*
330 172·6 
(324 899·3 to 
335 159·9)
14·7% 
(13·3 to 16·2)*
4148·0 
(4082·0 to 
4210·8)
–11·3% 
(–12·4 to –10·1)*
Rheumatic heart disease 285·5 
(266·2 to 303·3)
1·3% 
(–3·9 to 6·0)
3·7 
(3·4 to 3·9)
–21·3% 
(–25·2 to –17·8)*
7492·6 
(6926·7 to 8046·7)
–10·2% 
(–15·4 to –6·2)*
94·5 
(87·5 to 101·4)
–25·9% 
(–30·0 to –22·7)*
Ischaemic heart disease 8930·4 
(8790·7 to 
9138·7)
22·3% 
(20·6 to 23·8)*
116·9 
(115·1 to 119·7)
–9·7% 
(–11·0 to –8·7)*
164 983·4 
(162 168·9 to 
168 584·2)
17·3% 
(15·4 to 19·0)*
2065·9 
(2030·6 to 
2111·7)
–9·8% 
(–11·2 to –8·5)*
Stroke 6167·3 
(6044·3 to 
6327·6)
16·6% 
(14·7 to 18·6)*
80·5 
(78·9 to 82·6)
–13·6% 
(–15·0 to –12·1)*
113 355·9 
(110 957·8 to 
116 180·6)
12·1% 
(9·9 to 14·1)*
1422·2 
(1392·0 to 
1457·7)
–13·8% 
(–15·5 to –12·3)*
Ischaemic stroke 2747·4 
(2657·1 to 
2857·6)
21·2% 
(19·0 to 23·3)*
36·6 
(35·5 to 38·0)
–11·8% 
(–13·4 to –10·3)*
40 834·1 
(39 133·3 to 
43 140·9)
16·9% 
(14·3 to 19·3)*
521·8 
(500·5 to 550·2)
–12·0% 
(–13·9 to –10·3)*
Intracerebral haemorrhage 2974·9 
(2880·8 to 
3072·8)
12·5% 
(9·6 to 15·1)*
38·2 
(37·0 to 39·4)
–15·7% 
(–17·8 to –13·8)*
61 562·6 
(59 598·2 to 
63 531·4)
9·3% 
(6·5 to 11·8)*
764·1 
(739·7 to 788·4)
–15·4% 
(–17·6 to –13·5)*
Subarachnoid 
haemorrhage
445·0 
(417·2 to 492·3)
18·4% 
(13·4 to 24·6)*
5·7 
(5·3 to 6·3)
–9·4% 
(–13·1 to –4·9)*
10 959·3 
(10 294·3 to 
12 264·1)
10·7% 
(6·8 to 16·5)*
136·4 
(128·2 to 152·5)
–11·4% 
(–14·5 to –7·0)*
Hypertensive heart disease 925·7 
(681·4 to 
994·9)
46·6% 
(26·3 to 59·3)*
12·3 
(9·0 to 13·2)
7·5% 
(–7·3 to 16·3)
15 135·2 
(11 349·8 to 
16 311·7)
35·7% 
(19·1 to 47·9)*
191·5 
(143·3 to 206·2)
3·8% 
(–8·8 to 12·9)
Non‐rheumatic valvular heart 
disease
144·9 
(121·8 to 150·4)
31·8% 
(27·7 to 34·7)*
2·0 
(1·6 to 2·0)
–5·3% 
(–7·9 to –3·2)*
2168·4 
(1980·3 to 2322·7)
21·8% 
(18·6 to 25·0)*
27·9 
(25·4 to 29·6)
–6·2% 
(–8·5 to –3·8)*
Non‐rheumatic calcific 
aortic valve disease
102·7 
(82·7 to 108·0)
40·0% 
(33·0 to 44·9)*
1·4 
(1·1 to 1·5)
–1·0% 
(–5·6 to 2·2)
1345·1 
(1185·5 to 1432·5)
30·4% 
(25·1 to 35·3)*
17·5 
(15·3 to 18·6)
–1·7% 
(–5·3 to 1·6)
(Table 1 continues on next page)
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Non‐rheumatic 
degenerative mitral valve 
disease
35·7 
(30·5 to 42·5)
16·4% 
(11·0 to 23·4)*
0·5 
(0·4 to 0·6)
–14·0% 
(–18·1 to –8·6)*
683·6 
(592·6 to 787·0)
10·3% 
(4·9 to 16·2)*
8·7 
(7·5 to 10·0)
–13·0% 
(–16·9 to –8·3)*
Other non‐rheumatic valve 
diseases
6·4 
(4·9 to 8·7)
9·7% 
(–4·1 to 42·2)
0·1 
(0·1 to 0·1)
–17·8% 
(–28·5 to 8·0)
139·7 
(105·8 to 187·5)
8·1% 
(–2·4 to 27·6)
1·8 
(1·4 to 2·4)
–12·4% 
(–21·3 to 4·7)
Cardiomyopathy and 
myocarditis
368·5 
(341·9 to 386·9)
8·1% 
(3·8 to 18·2)*
4·8 
(4·5 to 5·0)
–16·6% 
(–19·8 to –9·4)*
9623·3 
(8867·5 to 
10 208·8)
–5·1% 
(–9·6 to 5·5)
122·4 
(113·0 to 129·7)
–21·5% 
(–25·1 to –13·0)*
Myocarditis 46·5 
(39·7 to 51·8)
14·4% 
(5·6 to 29·7)*
0·6 
(0·5 to 0·7)
–13·3% 
(–20·4 to –0·1)*
1259·3 
(1100·1 to 1415·5)
–0·3% 
(–6·9 to 7·6)
16·6 
(14·5 to 18·5)
–15·2% 
(–21·1 to –7·7)*
Alcoholic cardiomyopathy 88·9 
(80·9 to 96·3)
–25·3% 
(–29·5 to –8·3)*
1·1 
(1·0 to 1·2)
–40·5% 
(–43·7 to –27·6)*
2849·2 
(2599·0 to 3073·1)
–30·7% 
(–34·7 to –12·1)*
34·7 
(31·7 to 37·5)
–43·2% 
(–46·5 to –28·2)*
Other cardiomyopathy 233·2 
(213·7 to 248·3)
28·5% 
(24·5 to 32·4)*
3·1 
(2·8 to 3·3)
–3·6% 
(–6·7 to –0·7)*
5514·8 
(4946·7 to 5992·9)
15·7% 
(10·9 to 19·9)*
71·1 
(64·0 to 77·0)
–5·4% 
(–9·3 to –2·0)*
Atrial fibrillation and flutter 287·2 
(276·4 to 304·8)
47·8% 
(45·4 to 50·6)*
4·0 
(3·9 to 4·2)
2·6% 
(0·9 to 4·6)*
3054·5 
(2923·0 to 3235·4)
40·5% 
(37·9 to 43·4)*
40·6 
(38·9 to 43·1)
2·2% 
(0·3 to 4·2)*
Aortic aneurysm 167·2 
(159·8 to 174·1)
23·7% 
(19·9 to 27·6)*
2·2 
(2·1 to 2·3)
–8·5% 
(–11·2 to –5·8)*
3039·9 
(2877·2 to 3186·4)
19·0% 
(14·5 to 23·6)*
38·2 
(36·2 to 40·0)
–8·5% 
(–11·9 to –5·1)*
Peripheral vascular disease 70·2 
(43·2 to 123·3)
55·7% 
(31·0 to 74·2)*
1·0 
(0·6 to 1·7)
10·5% 
(–6·8 to 24·1)
916·9 
(576·9 to 1540·0)
48·3% 
(25·0 to 65·6)*
11·8 
(7·4 to 20·0)
9·7% 
(–7·5 to 22·6)
Endocarditis 83·4 
(74·3 to 94·3)
32·2% 
(25·2 to 36·8)*
1·1 
(1·0 to 1·2)
1·0% 
(–4·0 to 5·0)
2174·5 
(2033·2 to 2373·0)
16·9% 
(8·9 to 22·2)*
28·3 
(26·4 to 30·9)
–2·3% 
(–8·8 to 2·1)
Other cardiovascular and 
circulatory diseases
360·7 
(338·1 to 392·9)
21·9% 
(17·9 to 24·8)*
4·7 
(4·4 to 5·1)
–7·9% 
(–10·9 to –5·9)*
8228·0 
(7681·4 to 9061·9)
12·6% 
(9·5 to 15·7)*
104·7 
(97·8 to 115·2)
–9·4% 
(–12·0 to –7·1)*
Chronic respiratory diseases 3914·2 
(3790·6 to 
4044·8)
15·8% 
(12·7 to 19·3)*
51·4 
(49·7 to 53·1)
–14·2% 
(–16·5 to –11·5)*
68 004·9 
(65 869·4 to 
70 592·2)
9·7% 
(7·0 to 13·2)*
861·9 
(835·4 to 
895·0)
–15·7% 
(–17·7 to –13·0)*
Chronic obstructive 
pulmonary disease
3197·8 
(3029·0 to 
3358·9)
17·5% 
(13·3 to 21·1)*
42·2 
(40·0 to 44·2)
–13·6% 
(–16·5 to –11·0)*
50 990·0 
(47 678·7 to 
54 146·9)
13·2% 
(8·8 to 16·9)*
647·3 
(605·9 to 
686·4)
–14·3% 
(–17·5 to –11·6)*
Pneumoconiosis 21·6 
(20·5 to 22·7)
10·7% 
(5·1 to 16·6)*
0·3 
(0·3 to 0·3)
–16·7% 
(–20·8 to –12·4)*
426·9 
(403·6 to 452·9)
7·9% 
(1·8 to 14·6)*
5·3 
(5·0 to 5·6)
–16·4% 
(–21·1 to –11·3)*
Silicosis 11·3 
(10·4 to 12·5)
12·0% 
(1·2 to 22·8)*
0·1 
(0·1 to 0·2)
–15·5% 
(–23·6 to –7·4)*
235·7 
(210·3 to 258·2)
11·8% 
(–0·7 to 23·6)
2·9 
(2·6 to 3·2)
–13·4% 
(–23·1 to –4·3)*
Asbestosis 3·4 
(2·3 to 3·9)
23·3% 
(15·1 to 33·9)*
0·0 
(0·0 to 0·1)
–8·3% 
(–14·1 to –0·4)*
54·6 
(38·6 to 65·6)
15·6% 
(7·4 to 28·5)*
0·7 
(0·5 to 0·8)
–11·4% 
(–17·5 to –1·3)*
Coal worker 
pneumoconiosis
3·2 
(2·9 to 4·0)
–2·2% 
(–12·0 to 11·7)
0·0 
(0·0 to 0·1)
–26·6% 
(–33·8 to –16·7)*
58·9 
(52·2 to 76·4)
–6·4% 
(–16·3 to 8·3)
0·7 
(0·7 to 1·0)
–27·9% 
(–35·4 to –16·9)*
Other pneumoconiosis 3·6 
(3·1 to 4·5)
8·9% 
(0·0 to 25·4)*
0·0 
(0·0 to 0·1)
–17·5% 
(–24·1 to –5·0)*
77·6 
(66·1 to 96·4)
4·2% 
(–3·8 to 19·5)
1·0 
(0·8 to 1·2)
–18·3% 
(–24·7 to –5·9)*
Asthma 495·1 
(338·2 to 641·2)
–0·7% 
(–6·2 to 8·1)
6·3 
(4·3 to 8·2)
–23·9% 
(–28·1 to –17·2)*
12 139·9 
(8538·5 to 
15 576·3)
–7·5% 
(–11·4 to –1·6)*
152·8 
(108·3 to 195·8)
–25·8% 
(–28·9 to –20·4)*
Interstitial lung disease and 
pulmonary sarcoidosis
147·6 
(114·9 to 181·3)
49·8% 
(39·0 to 58·6)*
1·9 
(1·5 to 2·4)
11·4% 
(4·0 to 17·9)*
2716·7 
(2156·9 to 3371·3)
43·0% 
(32·1 to 53·4)*
34·2 
(27·1 to 42·4)
10·4% 
(2·3 to 18·6)*
Other chronic respiratory 
diseases
52·1 
(45·9 to 59·6)
21·3% 
(14·1 to 34·2)*
0·7 
(0·6 to 0·8)
–3·2% 
(–8·7 to 6·7)
1731·4 
(1504·5 to 1998·9)
10·8% 
(3·2 to 24·3)*
22·1 
(19·3 to 25·5)
–6·3% 
(–12·6 to 5·3)
Digestive diseases 2377·7 
(2295·1 to 
2518·0)
15·3% 
(12·1 to 19·7)*
30·3 
(29·2 to 32·1)
–10·7% 
(–13·1 to –7·3)*
65 348·4 
(62 343·9 to 
69 371·3)
7·5% 
(4·2 to 11·9)*
819·8 
(781·7 to 
869·7)
–12·2% 
(–14·9 to –8·5)*
Cirrhosis and other chronic 
liver diseases
1322·9 
(1268·2 to 
1449·1)
15·0% 
(8·7 to 21·5)*
16·5 
(15·8 to 18·1)
–9·7% 
(–14·7 to –4·6)*
39 652·4 
(37 985·2 to 
43 624·9)
8·9% 
(3·4 to 14·4)*
488·9 
(468·0 to 537·5)
–11·3% 
(–15·8 to –6·9)*
Cirrhosis and other chronic 
liver diseases due to 
hepatitis B
384·0 
(349·1 to 441·7)
8·6% 
(1·1 to 17·3)*
4·8 
(4·3 to 5·5)
–14·3% 
(–20·2 to –7·3)*
11 721·5 
(10 648·0 to 
13 431·7)
3·4% 
(–3·3 to 10·7)
144·1 
(130·8 to 165·3)
–15·5% 
(–20·9 to –9·5)*
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Cirrhosis and other chronic 
liver diseases due to 
hepatitis C
342·2 
(312·6 to 381·1)
17·4% 
(11·3 to 23·0)*
4·2 
(3·9 to 4·7)
–8·4% 
(–13·0 to –3·9)*
9980·1 
(9074·7 to 
11 116·9)
12·2% 
(6·8 to 17·3)*
121·9 
(111·0 to 135·8)
–9·6% 
(–13·9 to –5·5)*
Cirrhosis and other chronic 
liver diseases due to alcohol 
use
332·3 
(303·0 to 373·3)
16·9% 
(11·2 to 23·7)*
4·1 
(3·7 to 4·6)
–8·8% 
(–13·2 to –3·4)*
9785·4 
(8919·3 to 
10 962·1)
12·3% 
(7·1 to 18·3)*
119·0 
(108·6 to 133·5)
–10·0% 
(–14·2 to –5·2)*
Cirrhosis due to NASH 118·0 
(108·6 to 128·6)
27·6% 
(21·2 to 33·3)*
1·5 
(1·3 to 1·6)
–1·4% 
(–6·3 to 3·1)
3285·5 
(3011·9 to 3586·8)
22·2% 
(16·6 to 27·2)*
40·0 
(36·6 to 43·6)
–3·0% 
(–7·4 to 1·0)
Cirrhosis and other chronic 
liver diseases due to other 
causes
146·4 
(130·9 to 164·6)
14·2% 
(8·2 to 20·2)*
1·9 
(1·7 to 2·1)
–8·6% 
(–13·4 to –3·8)*
4880·0 
(4392·5 to 5457·1)
2·1% 
(–4·3 to 10·7)
63·9 
(57·5 to 71·4)
–12·0% 
(–17·5 to –4·5)*
Upper digestive system 
diseases
292·1 
(279·7 to 312·3)
2·9% 
(–1·3 to 8·6)
3·8 
(3·6 to 4·0)
–21·6% 
(–24·8 to –17·3)*
6789·9 
(6413·1 to 7259·0)
–4·5% 
(–9·5 to 1·8)
85·2 
(80·4 to 91·2)
–23·3% 
(–27·3 to –18·4)*
Peptic ulcer disease 240·3 
(229·4 to 258·8)
0·6% 
(–3·6 to 5·6)
3·1 
(3·0 to 3·3)
–23·5% 
(–26·6 to –19·7)*
5513·3 
(5202·4 to 5947·8)
–6·8% 
(–11·4 to –1·5)*
69·1 
(65·1 to 74·7)
–25·4% 
(–29·0 to –21·0)*
Gastritis and duodenitis 51·8 
(43·0 to 56·9)
15·5% 
(7·5 to 28·9)*
0·7 
(0·6 to 0·7)
–11·7% 
(–17·6 to –2·2)*
1276·6 
(1047·1 to 1419·7)
6·8% 
(–3·1 to 22·4)
16·1 
(13·2 to 17·9)
–13·2% 
(–21·1 to –1·3)*
Appendicitis 43·9 
(40·2 to 47·5)
1·8% 
(–4·0 to 9·6)
0·6 
(0·5 to 0·6)
–17·0% 
(–21·5 to –10·7)*
1633·2 
(1473·2 to 1772·7)
–8·7% 
(–16·7 to 0·6)
21·4 
(19·3 to 23·3)
–20·1% 
(–27·2 to –12·1)*
Paralytic ileus and intestinal 
obstruction
240·5 
(198·7 to 261·6)
21·1% 
(14·4 to 29·0)*
3·2 
(2·7 to 3·5)
–5·8% 
(–11·0 to 0·3)
7245·9 
(5866·8 to 7980·6)
6·5% 
(–3·1 to 15·5)
97·0 
(78·9 to 106·8)
–8·7% 
(–16·8 to –0·8)*
Inguinal, femoral, and 
abdominal hernia
44·2 
(38·6 to 50·0)
21·7% 
(16·2 to 28·4)*
0·6 
(0·5 to 0·7)
–8·9% 
(–12·9 to –4·2)*
914·3 
(792·8 to 1021·9)
12·1% 
(4·5 to 20·4)*
11·7 
(10·1 to 13·1)
–10·6% 
(–16·5 to –3·9)*
Inflammatory bowel disease 38·6 
(31·6 to 41·2)
20·4% 
(11·5 to 27·2)*
0·5 
(0·4 to 0·5)
–10·5% 
(–16·0 to –5·9)*
829·7 
(711·4 to 900·7)
10·3% 
(–2·7 to 19·5)
10·7 
(9·1 to 11·7)
–11·3% 
(–20·7 to –4·5)*
Vascular intestinal disorders 96·1 
(89·0 to 100·8)
22·6% 
(17·0 to 28·1)*
1·3 
(1·2 to 1·3)
–10·2% 
(–14·2 to –6·2)*
1570·1 
(1433·3 to 1667·3)
17·6% 
(10·7 to 24·8)*
20·0 
(18·3 to 21·3)
–10·0% 
(–15·3 to –5·0)*
Gallbladder and biliary 
diseases
110·5 
(105·5 to 116·6)
28·8% 
(25·3 to 33·8)*
1·5 
(1·4 to 1·6)
–5·0% 
(–7·5 to –1·7)*
1983·2 
(1863·2 to 2092·0)
18·5% 
(13·4 to 25·3)*
25·4 
(23·8 to 26·8)
–6·9% 
(–10·9 to –1·8)*
Pancreatitis 101·6 
(89·5 to 108·3)
20·6% 
(16·4 to 25·7)*
1·3 
(1·1 to 1·4)
–5·7% 
(–9·0 to –1·7)*
2890·0 
(2537·1 to 3102·9)
13·8% 
(8·7 to 19·5)*
35·8 
(31·4 to 38·4)
–6·8% 
(–10·9 to –2·1)*
Other digestive diseases 87·3 
(81·9 to 93·3)
25·4% 
(18·1 to 32·3)*
1·2 
(1·1 to 1·2)
–7·1% 
(–12·1 to –2·4)*
1839·7 
(1663·9 to 2038·5)
16·4% 
(5·8 to 27·4)*
23·7 
(21·5 to 26·3)
–6·5% 
(–14·9 to 1·8)
Neurological disorders 3094·2 
(3039·6 to 
3142·6)
42·1% 
(40·2 to 43·9)*
43·1 
(42·3 to 43·7)
0·1% 
(–1·2 to 1·3)
38 004·5 
(37 134·8 to 
39 174·6)
26·2% 
(23·9 to 30·2)*
507·6 
(496·1 to 
523·4)
–3·1% 
(–4·8 to –0·1)*
Alzheimer’s disease and other 
dementias
2514·6 
(2470·5 to 
2550·3)
46·2% 
(43·9 to 48·0)*
35·4 
(34·8 to 35·9)
0·6% 
(–0·9 to 1·8)
23 951·1 
(23 523·6 to 
24 326·8)
38·6% 
(35·7 to 40·9)*
323·7 
(317·9 to 328·7)
–0·3% 
(–2·3 to 1·2)
Parkinson’s disease 340·6 
(324·4 to 355·1)
38·3% 
(33·3 to 41·4)*
4·6 
(4·4 to 4·8)
0·8% 
(–2·8 to 3·0)
4361·2 
(4182·8 to 4578·7)
33·8% 
(28·5 to 37·0)*
56·9 
(54·5 to 59·8)
0·3% 
(–3·6 to 2·6)
Epilepsy 130·2 
(117·0 to 150·8)
3·8% 
(–1·6 to 15·7)
1·7 
(1·5 to 2·0)
–10·7% 
(–15·4 to –0·5)*
6232·1 
(5709·8 to 7289·7)
–5·5% 
(–11·6 to 8·3)
82·6 
(75·5 to 96·6)
–14·9% 
(–20·6 to –2·1)*
Multiple sclerosis 20·7 
(17·7 to 22·2)
22·4% 
(8·0 to 27·8)*
0·3 
(0·2 to 0·3)
–3·9% 
(–14·5 to 0·4)
628·2 
(563·0 to 682·4)
17·1% 
(4·1 to 24·5)*
7·7 
(6·9 to 8·3)
–5·5% 
(–15·1 to 0·6)
Motor neuron disease 34·1 
(32·8 to 37·1)
32·7% 
(28·0 to 37·0)*
0·4 
(0·4 to 0·5)
1·2% 
(–2·4 to 4·5)
828·1 
(796·7 to 917·1)
27·2% 
(22·6 to 31·3)*
10·3 
(9·9 to 11·4)
0·1% 
(–3·5 to 3·3)
Other neurological disorders 53·9 
(51·6 to 59·0)
25·4% 
(17·8 to 32·3)*
0·7 
(0·7 to 0·8)
2·0% 
(–3·9 to 6·8)
2003·8 
(1856·8 to 2269·5)
11·4% 
(3·6 to 21·1)*
26·5 
(24·3 to 30·1)
–2·8% 
(–9·3 to 5·1)
Mental disorders 0·3 
(0·3 to 0·4)
19·9% 
(10·0 to 29·2)*
0·0 
(0·0 to 0·0)
7·5% 
(–1·4 to 15·9)
17·5 
(15·9 to 19·2)
18·5% 
(8·8 to 27·5)*
0·2 
(0·2 to 0·2)
7·2% 
(–1·6 to 15·3)
Eating disorders 0·3 
(0·3 to 0·4)
19·9% 
(10·0 to 29·2)*
0·0 
(0·0 to 0·0)
7·5% 
(–1·4 to 15·9)
17·5 
(15·9 to 19·2)
18·5% 
(8·8 to 27·5)*
0·2 
(0·2 to 0·2)
7·2% 
(–1·6 to 15·3)
Anorexia nervosa 0·2 
(0·2 to 0·3)
17·6% 
(7·0 to 27·6)*
0·0 
(0·0 to 0·0)
5·5% 
(–4·1 to 14·4)
12·7 
(10·9 to 14·1)
15·9% 
(5·6 to 25·6)*
0·2 
(0·1 to 0·2)
5·0% 
(–4·4 to 13·7)
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Bulimia nervosa 0·1 
(0·1 to 0·1)
26·4% 
(12·9 to 40·5)*
0·0 
(0·0 to 0·0)
13·5% 
(1·0 to 26·2)*
4·8 
(4·0 to 6·7)
25·9% 
(12·0 to 40·0)*
0·1 
(0·1 to 0·1)
13·6% 
(1·1 to 26·3)*
Substance use disorders 351·5 
(334·1 to 362·7)
23·8% 
(20·2 to 27·3)*
4·3 
(4·1 to 4·5)
2·0% 
(–1·0 to 5·0)
13 597·6 
(12 979·5 to 
14 033·3)
18·8% 
(15·3 to 22·4)*
168·0 
(160·4 to 
173·3)
0·8% 
(–2·2 to 3·9)
Alcohol use disorders 184·9 
(166·7 to 193·0)
2·7% 
(–2·2 to 7·7)
2·3 
(2·0 to 2·4)
–16·5% 
(–20·4 to –12·4)*
6750·4 
(6113·2 to 7082·7)
–2·1% 
(–7·2 to 3·3)
82·4 
(74·7 to 86·5)
–18·4% 
(–22·7 to –13·9)*
Drug use disorders 166·6 
(163·4 to 170·3)
60·2% 
(56·9 to 63·6)*
2·1 
(2·0 to 2·1)
34·1% 
(31·4 to 36·9)*
6847·2 
(6704·5 to 7004·4)
50·4% 
(47·0 to 54·0)*
85·5 
(83·7 to 87·5)
30·5% 
(27·6 to 33·5)*
Opioid use disorders 109·5 
(105·7 to 113·6)
77·0% 
(68·8 to 88·5)*
1·4 
(1·3 to 1·4)
49·4% 
(42·5 to 59·2)*
4641·2 
(4480·6 to 4818·9)
65·0% 
(57·3 to 75·0)*
58·0 
(56·1 to 60·3)
43·9% 
(37·1 to 52·6)*
Cocaine use disorders 7·3 
(6·6 to 8·1)
42·2% 
(30·1 to 58·3)*
0·1 
(0·1 to 0·1)
19·6% 
(9·2 to 33·0)*
311·5 
(281·5 to 344·1)
35·6% 
(24·0 to 51·2)*
3·9 
(3·5 to 4·3)
16·7% 
(6·5 to 30·0)*
Amphetamine use 
disorders
4·5 
(3·3 to 5·0)
27·2% 
(0·8 to 41·0)*
0·1 
(0·0 to 0·1)
8·7% 
(–14·0 to 20·7)
206·9 
(151·6 to 227·8)
21·0% 
(–3·6 to 34·4)
2·6 
(1·9 to 2·8)
5·6% 
(–15·5 to 17·4)
Other drug use disorders 45·3 
(42·9 to 48·2)
35·2% 
(22·8 to 46·1)*
0·6 
(0·5 to 0·6)
11·3% 
(1·2 to 19·9)*
1687·6 
(1589·4 to 1805·9)
25·9% 
(14·0 to 37·3)*
21·0 
(19·8 to 22·5)
8·2% 
(–2·0 to 17·8)
Diabetes and kidney 
diseases
2611·2 
(2557·8 to 
2667·2)
34·2% 
(32·0 to 36·2)*
33·6 
(32·9 to 34·3)
1·3% 
(–0·3 to 2·7)
58 116·9 
(56 801·5 to 
59 525·7)
25·1% 
(23·0 to 27·2)*
726·4 
(710·0 to 744·4)
–1·1% 
(–2·8 to 0·6)
Diabetes mellitus 1369·8 
(1340·3 to 
1401·9)
34·7% 
(32·2 to 37·3)*
17·5 
(17·1 to 17·9)
1·2% 
(–0·7 to 3·1)
29 300·2 
(28 711·5 to 
29 950·1)
29·9% 
(27·2 to 32·4)*
363·1 
(355·7 to 371·2)
0·7% 
(–1·4 to 2·6)
Type 1 diabetes mellitus 345·5 
(319·3 to 371·1)
15·1% 
(10·5 to 19·0)*
4·3 
(4·0 to 4·7)
–11·0% 
(–14·6 to –7·8)*
9477·3 
(8944·6 to 
10 079·9)
11·1% 
(7·2 to 14·3)*
117·3 
(110·8 to 124·6)
–10·6% 
(–13·9 to –7·9)*
Type 2 diabetes mellitus 1024·3 
(985·5 to 
1066·8)
43·0% 
(40·4 to 45·8)*
13·2 
(12·7 to 13·7)
5·9% 
(4·1 to 8·0)*
19 822·9 
(19 013·8 to 
20 687·8)
41·3% 
(38·3 to 44·4)*
245·8 
(235·8 to 256·5)
7·1% 
(5·0 to 9·4)*
Chronic kidney disease 1230·2 
(1195·1 to 
1258·8)
33·7% 
(30·5 to 36·1)*
15·9 
(15·5 to 16·3)
1·5% 
(–0·9 to 3·2)
28 508·5 
(27 610·2 to 
29 314·0)
21·0% 
(18·2 to 23·5)*
359·4 
(348·2 to 369·6)
–2·5% 
(–4·7 to –0·6)*
Chronic kidney disease due 
to type 1 diabetes mellitus
77·3 
(62·4 to 95·2)
23·2% 
(19·0 to 27·4)*
0·9 
(0·8 to 1·2)
–1·2% 
(–4·0 to 1·2)
2622·0 
(2121·7 to 3205·5)
17·8% 
(13·6 to 22·3)*
31·9 
(25·9 to 38·9)
–2·9% 
(–5·6 to –0·3)*
Chronic kidney disease due 
to type 2 diabetes mellitus
349·0 
(306·8 to 395·9)
40·5% 
(36·4 to 43·6)*
4·5 
(4·0 to 5·1)
4·2% 
(1·4 to 6·2)*
6671·9 
(5825·5 to 7625·9)
35·4% 
(31·0 to 38·7)*
82·8 
(72·4 to 94·5)
2·9% 
(–0·2 to 5·2)
Chronic kidney disease due 
to hypertension
347·4 
(304·6 to 391·5)
41·4% 
(37·4 to 44·2)*
4·6 
(4·0 to 5·2)
3·2% 
(0·4 to 5·2)*
5954·8 
(5175·1 to 6741·9)
33·4% 
(29·3 to 36·5)*
75·2 
(65·4 to 84·9)
2·3% 
(–0·7 to 4·5)
Chronic kidney disease due 
to glomerulonephritis
189·7 
(165·2 to 217·3)
25·5% 
(22·1 to 28·8)*
2·4 
(2·1 to 2·8)
–1·3% 
(–3·2 to 0·7)
5554·9 
(4929·1 to 6250·8)
12·7% 
(9·6 to 16·1)*
70·6 
(62·8 to 79·4)
–5·5% 
(–7·5 to –3·3)*
Chronic kidney disease due 
to other and unspecified 
causes
266·8 
(232·8 to 304·0)
25·9% 
(22·4 to 29·4)*
3·4 
(3·0 to 3·9)
–1·4% 
(–3·7 to 0·6)
7704·8 
(6794·9 to 8614·8)
10·0% 
(6·8 to 13·4)*
98·9 
(87·4 to 110·0)
–7·7% 
(–9·9 to –5·4)*
Acute glomerulonephritis 11·2 
(10·5 to 12·1)
14·7% 
(8·7 to 22·3)*
0·1 
(0·1 to 0·2)
–9·5% 
(–14·5 to –3·5)*
308·2 
(282·4 to 336·8)
–5·5% 
(–10·4 to 2·2)
3·9 
(3·6 to 4·3)
–20·9% 
(–25·1 to –15·1)*
Skin and subcutaneous 
diseases
100·3 
(65·3 to 131·7)
42·3% 
(34·9 to 52·0)*
1·3 
(0·9 to 1·7)
8·1% 
(2·7 to 16·5)*
2517·9 
(1703·3 to 3283·8)
26·1% 
(18·6 to 35·7)*
33·1 
(22·4 to 43·2)
5·0% 
(–1·2 to 13·8)
Bacterial skin diseases 76·0 
(48·7 to 95·6)
45·5% 
(36·8 to 54·9)*
1·0 
(0·6 to 1·3)
12·7% 
(6·0 to 20·7)*
2096·6 
(1378·0 to 2691·9)
26·4% 
(18·0 to 36·9)*
27·6 
(18·2 to 35·6)
6·4% 
(–0·6 to 15·9)
Cellulitis 18·9 
(10·3 to 26·0)
57·0% 
(45·8 to 67·1)*
0·2 
(0·1 to 0·3)
19·6% 
(9·8 to 28·2)*
480·1 
(264·6 to 640·2)
38·3% 
(30·8 to 50·4)*
6·2 
(3·4 to 8·3)
13·7% 
(7·3 to 23·9)*
Pyoderma 57·1 
(35·8 to 70·8)
42·1% 
(32·4 to 52·4)*
0·8 
(0·5 to 0·9)
10·5% 
(3·2 to 19·0)*
1616·4 
(1051·6 to 2136·7)
23·3% 
(14·3 to 35·0)*
21·5 
(14·1 to 28·8)
4·5% 
(–3·2 to 15·0)
Decubitus ulcer 20·3 
(13·2 to 30·6)
32·4% 
(22·9 to 51·0)*
0·3 
(0·2 to 0·4)
–5·1% 
(–12·2 to 9·2)
321·7 
(211·2 to 471·5)
26·2% 
(17·9 to 42·5)*
4·2 
(2·7 to 6·1)
–2·3% 
(–8·8 to 11·5)
(Table 1 continues on next page)
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All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
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change, 2007–17
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change, 2007–17
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change, 2007–17
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change, 2007–17
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Other skin and subcutaneous 
diseases
3·9 
(2·6 to 7·2)
35·8% 
(26·6 to 49·6)*
0·1 
(0·0 to 0·1)
3·3% 
(–3·5 to 14·4)
99·6 
(69·4 to 165·8)
19·1% 
(10·8 to 34·1)*
1·3 
(0·9 to 2·2)
0·7% 
(–6·1 to 13·1)
Musculoskeletal disorders 121·3 
(105·6 to 126·2)
30·9% 
(25·1 to 35·1)*
1·6 
(1·4 to 1·6)
–0·1% 
(–4·4 to 3·2)
2842·7 
(2440·7 to 2953·1)
19·6% 
(13·7 to 23·2)*
35·9 
(30·8 to 37·3)
–2·5% 
(–7·1 to 0·4)
Rheumatoid arthritis 47·3 
(39·0 to 51·2)
25·8% 
(16·2 to 31·9)*
0·6 
(0·5 to 0·7)
–5·9% 
(–12·9 to –1·2)*
866·0 
(707·8 to 941·4)
17·9% 
(8·6 to 23·3)*
10·9 
(8·9 to 11·8)
–9·1% 
(–16·1 to –5·0)*
Other musculoskeletal 
disorders
74·0 
(66·1 to 78·7)
34·4% 
(30·2 to 38·8)*
1·0 
(0·9 to 1·0)
3·9% 
(0·9 to 7·5)*
1976·6 
(1730·3 to 2089·1)
20·3% 
(15·6 to 24·0)*
25·0 
(21·9 to 26·4)
0·8% 
(–3·0 to 3·8)
Other non-communicable 
diseases
1153·3 
(1101·8 to 
1208·3)
0·8% 
(–3·9 to 4·0)
16·3 
(15·5 to 17·1)
–11·2% 
(–15·3 to –8·5)*
68 240·8 
(64 835·4 to 
72 452·1)
–10·6% 
(–15·8 to –6·9)*
993·0 
(941·3 to 
1054·3)
–16·4% 
(–21·3 to –12·8)*
Congenital anomalies 584·9 
(556·3 to 618·3)
–14·3% 
(–21·1 to –10·1)*
8·7 
(8·2 to 9·2)
–18·2% 
(–24·7 to –14·1)*
48 860·4 
(46 405·7 to 
51 687·3)
–15·3% 
(–22·0 to –11·0)*
729·4 
(692·5 to 771·7)
–18·8% 
(–25·2 to –14·6)*
Neural tube defects 61·7 
(46·7 to 83·7)
–13·1% 
(–24·5 to –1·0)*
0·9 
(0·7 to 1·3)
–16·5% 
(–27·6 to –4·8)*
5317·5 
(4017·1 to 7217·5)
–13·4% 
(–24·8 to –1·4)*
80·0 
(60·4 to 108·6)
–16·7% 
(–27·7 to –5·0)*
Congenital heart anomalies 261·2 
(216·6 to 308·2)
–17·9% 
(–24·6 to –9·8)*
3·9 
(3·2 to 4·6)
–21·8% 
(–28·1 to –14·1)*
21 634·4 
(17 770·6 to 
25 604·8)
–18·9% 
(–25·5 to –10·8)*
321·7 
(263·6 to 381·4)
–22·4% 
(–28·7 to –14·6)*
Orofacial clefts 3·8 
(1·5 to 8·8)
–40·0% 
(–54·5 to –22·5)*
0·1 
(0·0 to 0·1)
–41·9% 
(–55·9 to –25·1)*
331·3 
(130·1 to 770·5)
–40·0% 
(–54·5 to –22·7)*
5·0 
(2·0 to 11·7)
–41·9% 
(–56·0 to –25·2)*
Down syndrome 26·1 
(21·3 to 35·1)
3·1% 
(–7·4 to 17·4)
0·4 
(0·3 to 0·5)
–5·2% 
(–14·2 to 7·0)
1906·1 
(1481·7 to 2707·9)
–1·4% 
(–11·5 to 13·9)
27·7 
(21·3 to 39·8)
–7·3% 
(–16·7 to 7·1)
Other chromosomal 
abnormalities
17·9 
(12·0 to 26·3)
4·6% 
(–6·3 to 18·2)
0·3 
(0·2 to 0·4)
0·3% 
(–10·1 to 13·2)
1507·9 
(1012·2 to 2233·3)
3·9% 
(–6·9 to 17·4)
22·6 
(15·1 to 33·5)
0·0% 
(–10·4 to 13·0)
Congenital musculoskeletal 
and limb anomalies
11·0 
(8·6 to 14·0)
–8·7% 
(–17·3 to 0·0)
0·2 
(0·1 to 0·2)
–12·8% 
(–20·9 to –4·5)*
912·2 
(708·9 to 1172·9)
–9·8% 
(–18·2 to –1·0)*
13·6 
(10·6 to 17·5)
–13·3% 
(–21·5 to –4·9)*
Urogenital congenital 
anomalies
14·1 
(10·3 to 16·9)
–2·5% 
(–11·8 to 9·2)
0·2 
(0·1 to 0·2)
–8·5% 
(–17·1 to 2·1)
1105·8 
(781·3 to 1347·8)
–5·5% 
(–14·6 to 6·3)
16·4 
(11·5 to 20·0)
–9·7% 
(–18·3 to 1·3)
Digestive congenital 
anomalies
50·8 
(37·7 to 71·8)
–16·2% 
(–27·1 to –6·4)*
0·8 
(0·6 to 1·1)
–19·3% 
(–29·8 to –9·8)*
4398·7 
(3253·9 to 6229·0)
–16·5% 
(–27·3 to –6·7)*
66·3 
(49·0 to 93·9)
–19·4% 
(–29·9 to –9·9)*
Other congenital 
anomalies
138·3 
(102·3 to 175·6)
–12·4% 
(–20·1 to –0·5)*
2·1 
(1·5 to 2·6)
–15·9% 
(–23·3 to –4·5)*
11 746·6 
(8613·3 to 
14 951·0)
–13·0% 
(–20·7 to –1·1)*
176·1 
(128·8 to 224·2)
–16·3% 
(–23·7 to –4·8)*
Urinary diseases and male 
infertility
271·2 
(263·9 to 282·2)
39·6% 
(34·9 to 43·4)*
3·6 
(3·5 to 3·7)
5·7% 
(2·2 to 8·5)*
6255·2 
(6044·8 to 6542·1)
20·8% 
(15·5 to 24·9)*
81·1 
(78·3 to 84·8)
–0·7% 
(–5·1 to 2·7)
Urinary tract infections 206·4 
(197·9 to 223·2)
48·3% 
(42·9 to 53·5)*
2·7 
(2·6 to 3·0)
10·9% 
(7·2 to 14·5)*
4522·3 
(4285·2 to 5016·3)
31·4% 
(24·4 to 38·8)*
58·4 
(55·2 to 65·0)
7·2% 
(1·7 to 13·0)*
Urolithiasis 12·3 
(10·5 to 15·7)
30·4% 
(19·0 to 49·4)*
0·2 
(0·1 to 0·2)
–1·2% 
(–9·7 to 12·9)
255·1 
(216·0 to 323·5)
19·6% 
(9·7 to 36·9)*
3·2 
(2·7 to 4·0)
–5·9% 
(–13·6 to 7·7)
Other urinary diseases 52·5 
(42·3 to 58·0)
15·0% 
(8·0 to 25·5)*
0·7 
(0·6 to 0·8)
–9·9% 
(–15·3 to –2·2)*
1477·8 
(1172·2 to 1660·2)
–3·0% 
(–9·6 to 6·4)
19·4 
(15·4 to 21·9)
–18·2% 
(–23·3 to –10·6)*
Gynaecological diseases 8·2 
(7·4 to 8·7)
19·1% 
(5·1 to 30·0)*
0·1 
(0·1 to 0·1)
–2·6% 
(–13·6 to 6·0)
292·9 
(272·6 to 318·7)
9·2% 
(–2·8 to 20·6)
3·7 
(3·4 to 4·0)
–6·0% 
(–15·4 to 3·6)
Uterine fibroids 2·4 
(1·6 to 3·0)
33·3% 
(6·7 to 54·6)*
0·0 
(0·0 to 0·0)
8·1% 
(–14·9 to 24·7)
74·2 
(52·7 to 95·5)
13·0% 
(–4·2 to 31·6)
0·9 
(0·6 to 1·2)
–4·8% 
(–20·0 to 10·5)
Polycystic ovarian 
syndrome
0·0 
(0·0 to 0·0)
12·9% 
(–12·8 to 50·4)
0·0 
(0·0 to 0·0)
1·0% 
(–22·5 to 34·8)
0·7 
(0·1 to 1·5)
10·1% 
(–15·8 to 51·2)
0·0 
(0·0 to 0·0)
–0·1% 
(–24·3 to 37·2)
Endometriosis 0·2 
(0·1 to 0·2)
11·8% 
(–12·4 to 45·5)
0·0 
(0·0 to 0·0)
–3·2% 
(–23·8 to 25·5)
7·7 
(3·2 to 12·0)
10·4% 
(–12·9 to 41·7)
0·1 
(0·0 to 0·1)
–3·2% 
(–23·2 to 24·3)
Genital prolapse 0·6 
(0·3 to 0·9)
0·6% 
(–15·4 to 16·1)
0·0 
(0·0 to 0·0)
–24·1% 
(–36·0 to –13·0)*
14·5 
(6·8 to 20·1)
–4·4% 
(–18·4 to 10·4)
0·2 
(0·1 to 0·2)
–24·0% 
(–35·2 to –11·9)*
Other gynaecological 
diseases
5·0 
(4·1 to 5·6)
16·0% 
(4·1 to 27·9)*
0·1 
(0·1 to 0·1)
–3·6% 
(–12·2 to 5·9)
195·8 
(163·0 to 228·9)
8·9% 
(–2·9 to 20·6)
2·5 
(2·1 to 2·9)
–4·8% 
(–14·2 to 5·1)
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Haemoglobinopathies and 
haemolytic anaemias
104·6 
(82·0 to 132·2)
5·8% 
(–1·4 to 13·4)
1·4 
(1·1 to 1·8)
–11·3% 
(–17·6 to –4·8)*
4831·6 
(3643·1 to 6268·9)
–1·8% 
(–13·1 to 9·4)
66·6 
(50·0 to 86·2)
–11·1% 
(–21·6 to –0·5)*
Thalassaemias 7·2 
(6·0 to 8·4)
–23·7% 
(–32·6 to –12·7)*
0·1 
(0·1 to 0·1)
–27·9% 
(–36·5 to –17·2)*
564·7 
(474·8 to 667·6)
–24·6% 
(–33·9 to –13·2)*
8·2 
(6·9 to 9·7)
–28·6% 
(–37·6 to –17·6)*
Sickle cell disorders 38·4 
(24·0 to 54·8)
3·7% 
(–11·6 to 17·7)
0·5 
(0·3 to 0·8)
–3·1% 
(–17·6 to 10·3)
2796·4 
(1747·3 to 3913·6)
2·1% 
(–13·7 to 17·3)
39·7 
(24·8 to 55·3)
–3·9% 
(–19·1 to 11·0)
G6PD deficiency 16·7 
(12·1 to 22·5)
11·8% 
(4·7 to 19·6)*
0·2 
(0·2 to 0·3)
–7·1% 
(–12·1 to –1·0)*
692·6 
(522·0 to 896·1)
4·4% 
(–2·5 to 12·3)
8·8 
(6·7 to 11·4)
–9·6% 
(–15·0 to –3·3)*
Other 
haemoglobinopathies and 
haemolytic anaemias
42·2 
(35·1 to 49·2)
13·0% 
(9·3 to 16·5)*
0·6 
(0·5 to 0·6)
–16·1% 
(–18·7 to –13·4)*
777·8 
(634·5 to 917·2)
1·3% 
(–2·2 to 4·8)
9·9 
(8·1 to 11·7)
–19·9% 
(–22·3 to –17·4)*
Endocrine, metabolic, blood, 
and immune disorders
144·5 
(115·1 to 152·3)
28·2% 
(19·7 to 33·3)*
1·9 
(1·5 to 2·0)
0·8% 
(–5·0 to 4·4)
4506·4 
(3762·3 to 4919·9)
10·4% 
(2·7 to 16·9)*
59·7 
(50·0 to 65·5)
–5·5% 
(–11·2 to –0·2)*
Sudden infant death 
syndrome
40·0 
(18·0 to 77·0)
–17·3% 
(–28·6 to –1·4)*
0·6 
(0·3 to 1·2)
–20·2% 
(–31·2 to –4·9)*
3494·3 
(1570·1 to 6734·0)
–17·3% 
(–28·6 to –1·4)*
52·7 
(23·7 to 101·5)
–20·2% 
(–31·2 to –4·9)*
Injuries 4484·7 
(4332·0 to 
4585·6)
2·3% 
(0·5 to 4·0)*
57·9 
(55·9 to 59·2)
–13·7% 
(–15·1 to –12·2)*
195 231·1 
(188 807·7 to 
199 825·5)
–6·4% 
(–7·8 to –4·8)*
2548·3 
(2461·9 to 
2609·6)
–16·9% 
(–18·2 to –15·3)*
Transport injuries 1335·0 
(1289·1 to 
1369·5)
–3·1% 
(–6·0 to –0·6)*
17·0 
(16·4 to 17·4)
–17·0% 
(–19·5 to –14·9)*
61 937·8 
(60 031·2 to 
63 736·5)
–9·6% 
(–11·8 to –7·3)*
800·5 
(775·9 to 
823·3)
–19·5% 
(–21·4 to –17·5)*
Road injuries 1243·1 
(1191·9 to 
1276·9)
–3·2% 
(–6·3 to –0·5)*
15·8 
(15·2 to 16·3)
–17·1% 
(–19·7 to –14·9)*
57 638·4 
(55 500·8 to 
59 369·2)
–9·7% 
(–12·0 to –7·3)*
745·0 
(718·1 to 767·4)
–19·6% 
(–21·6 to –17·5)*
Pedestrian road injuries 486·2 
(459·7 to 535·0)
–6·4% 
(–11·7 to –2·1)*
6·2 
(5·9 to 6·8)
–21·4% 
(–25·5 to –17·9)*
20 850·8 
(19 596·0 to 
23 164·4)
–14·8% 
(–18·7 to –11·0)*
270·4 
(253·9 to 300·8)
–25·1% 
(–28·3 to –21·9)*
Cyclist road injuries 68·9 
(59·2 to 76·2)
9·1% 
(1·8 to 16·4)*
0·9 
(0·7 to 1·0)
–8·8% 
(–14·8 to –2·5)*
2853·5 
(2471·6 to 3209·0)
1·0% 
(–5·7 to 8·3)
36·3 
(31·5 to 41·0)
–11·8% 
(–17·8 to –5·3)*
Motorcyclist road injuries 225·7 
(196·1 to 238·6)
–0·6% 
(–8·9 to 5·2)
2·9 
(2·5 to 3·0)
–12·4% 
(–19·5 to –7·3)*
11 416·3 
(9969·6 to 
12 098·0)
–5·7% 
(–12·5 to –0·5)*
146·2 
(127·5 to 154·9)
–14·8% 
(–20·7 to –10·1)*
Motor vehicle road injuries 451·1 
(423·4 to 472·9)
–2·5% 
(–6·2 to 1·3)
5·8 
(5·4 to 6·0)
–15·6% 
(–18·6 to –12·2)*
22 004·1 
(20 639·8 to 
23 130·9)
–7·8% 
(–10·4 to –3·0)*
285·3 
(267·6 to 299·7)
–17·2% 
(–19·6 to –12·8)*
Other road injuries 11·2 
(9·9 to 12·8)
–5·5% 
(–11·0 to 16·1)
0·1 
(0·1 to 0·2)
–19·4% 
(–24·1 to –1·3)*
513·8 
(454·1 to 583·4)
–11·7% 
(–17·3 to 10·6)
6·7 
(5·9 to 7·6)
–21·4% 
(–26·5 to –1·7)*
Other transport injuries 91·9 
(84·5 to 107·2)
–1·5% 
(–6·2 to 3·7)
1·2 
(1·1 to 1·4)
–15·5% 
(–19·5 to –10·9)*
4299·4 
(3919·6 to 5048·3)
–7·8% 
(–12·6 to –2·4)*
55·4 
(50·5 to 65·0)
–17·9% 
(–22·2 to –13·2)*
Unintentional injuries 1804·9 
(1695·7 to 
1872·0)
2·9% 
(0·5 to 6·0)*
23·8 
(22·4 to 24·7)
–15·3% 
(–17·3 to –12·8)*
69 430·5 
(64 685·1 to 
72 366·8)
–12·8% 
(–15·0 to –9·6)*
928·8 
(865·6 to 
969·3)
–23·0% 
(–25·0 to 
–20·0)*
Falls 695·8 
(644·9 to 741·7)
27·4% 
(21·2 to 35·6)*
9·2 
(8·5 to 9·8)
–2·8% 
(–7·4 to 3·4)
16 688·1 
(15 101·9 to 
17 636·8)
10·1% 
(4·8 to 17·2)*
216·6 
(196·4 to 228·6)
–8·4% 
(–12·7 to –2·5)*
Drowning 295·2 
(284·5 to 306·2)
–17·2% 
(–19·8 to –14·1)*
4·0 
(3·8 to 4·1)
–27·3% 
(–29·6 to –24·5)*
16 563·3 
(15 784·2 to 
17 350·0)
–26·1% 
(–29·0 to –22·4)*
228·3 
(217·2 to 239·7)
–32·8% 
(–35·5 to –29·3)*
Fire  heat  and hot substances 120·6 
(101·6 to 129·4)
–7·9% 
(–10·9 to –1·2)*
1·6 
(1·3 to 1·7)
–22·9% 
(–25·4 to –17·3)*
5286·3 
(4308·9 to 5836·4)
–16·5% 
(–21·0 to –7·3)*
71·0 
(57·8 to 78·6)
–25·5% 
(–29·6 to –17·1)*
Poisonings 72·4 
(52·7 to 79·4)
–6·8% 
(–16·1 to 2·9)
0·9 
(0·7 to 1·0)
–20·8% 
(–28·4 to –12·5)*
3321·7 
(2454·1 to 3669·2)
–14·6% 
(–22·7 to –3·8)*
44·1 
(32·7 to 48·8)
–23·9% 
(–31·0 to –14·1)*
Poisoning by carbon 
monoxide
35·5 
(25·7 to 38·8)
–12·5% 
(–22·4 to –5·0)*
0·5 
(0·3 to 0·5)
–26·6% 
(–34·8 to –20·3)*
1462·4 
(1073·0 to 1613·6)
–19·1% 
(–27·2 to –11·8)*
18·9 
(13·8 to 20·9)
–29·0% 
(–36·2 to –22·4)*
Poisoning by other means 36·9 
(26·8 to 41·0)
–0·5% 
(–10·1 to 11·9)
0·5 
(0·4 to 0·5)
–14·4% 
(–22·4 to –3·9)*
1859·3 
(1385·8 to 2072·9)
–10·7% 
(–19·6 to 3·3)
25·2 
(19·0 to 28·1)
–19·6% 
(–27·7 to –6·8)*
(Table 1 continues on next page)
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All-age deaths (thousands) Age-standardised death rate 
(per 100 000)
All-age YLLs (thousands) Age-standardised YLL rate 
(per 100 000)
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
2017 Percentage 
change, 2007–17
(Continued from previous page)
Exposure to mechanical 
forces
136·5 
(117·6 to 143·2)
–6·7% 
(–9·8 to –3·7)*
1·8 
(1·5 to 1·8)
–20·3% 
(–22·9 to –17·8)*
6385·5 
(5500·4 to 6710·8)
–13·8% 
(–16·6 to –10·8)*
84·0 
(72·3 to 88·3)
–23·0% 
(–25·5 to –20·3)*
Unintentional firearm 
injuries
22·6 
(21·1 to 25·8)
–2·9% 
(–7·5 to 2·8)
0·3 
(0·3 to 0·3)
–16·4% 
(–20·3 to –11·5)*
1094·5 
(1013·5 to 1275·4)
–7·4% 
(–12·2 to –1·3)*
14·4 
(13·3 to 16·9)
–16·5% 
(–20·9 to –11·1)*
Other exposure to 
mechanical forces
113·9 
(94·7 to 120·8)
–7·4% 
(–10·6 to –4·1)*
1·5 
(1·2 to 1·6)
–21·0% 
(–23·7 to –18·3)*
5291·0 
(4401·1 to 5626·1)
–15·0% 
(–18·0 to –11·7)*
69·6 
(57·8 to 74·0)
–24·3% 
(–26·9 to –21·2)*
Adverse effects of medical 
treatment
121·6 
(103·6 to 137·6)
16·6% 
(12·0 to 20·9)*
1·6 
(1·4 to 1·8)
–6·2% 
(–10·0 to –2·5)*
4363·9 
(3619·9 to 5234·0)
4·0% 
(–1·2 to 11·0)
58·1 
(48·0 to 70·7)
–9·5% 
(–13·9 to –3·6)*
Animal contact 81·1 
(44·9 to 94·0)
–1·4% 
(–6·8 to 6·2)
1·1 
(0·6 to 1·2)
–16·0% 
(–20·5 to –9·6)*
3911·9 
(2167·6 to 4585·6)
–9·5% 
(–15·8 to 0·2)
52·4 
(29·0 to 61·8)
–19·2% 
(–25·2 to –10·2)*
Venomous animal contact 70·9 
(37·0 to 83·8)
–1·3% 
(–7·5 to 6·2)
0·9 
(0·5 to 1·1)
–16·0% 
(–21·0 to –9·7)*
3407·7 
(1758·4 to 4087·5)
–9·7% 
(–16·4 to –0·7)*
45·5 
(23·4 to 54·9)
–19·4% 
(–25·8 to –11·3)*
Non‐venomous animal 
contact
10·1 
(7·1 to 14·4)
–1·6% 
(–15·3 to 10·2)
0·1 
(0·1 to 0·2)
–16·1% 
(–27·4 to –6·2)*
504·2 
(335·8 to 750·1)
–7·9% 
(–26·1 to 6·5)
6·9 
(4·5 to 10·3)
–17·2% 
(–33·6 to –4·3)*
Foreign body 124·1 
(119·3 to 130·0)
1·7% 
(–1·9 to 4·8)
1·7 
(1·6 to 1·8)
–14·1% 
(–17·0 to –11·6)*
5907·0 
(5566·3 to 6301·2)
–12·4% 
(–16·4 to –8·3)*
83·3 
(78·3 to 88·9)
–20·1% 
(–23·8 to –16·3)*
Pulmonary aspiration and 
foreign body in airway
115·7 
(111·4 to 121·3)
1·9% 
(–1·9 to 5·0)
1·6 
(1·5 to 1·7)
–13·9% 
(–17·0 to –11·4)*
5526·1 
(5212·6 to 5910·0)
–12·2% 
(–16·6 to –8·0)*
78·1 
(73·5 to 83·7)
–19·9% 
(–23·8 to –16·0)*
Foreign body in other body 
part
8·4 
(7·5 to 10·3)
–0·5% 
(–6·9 to 7·1)
0·1 
(0·1 to 0·1)
–15·8% 
(–20·8 to –10·0)*
381·0 
(326·2 to 474·4)
–14·4% 
(–21·1 to –6·2)*
5·2 
(4·4 to 6·5)
–23·3% 
(–29·2 to –16·1)*
Environmental heat and cold 
exposure
53·3 
(36·8 to 59·2)
–13·2% 
(–22·4 to –8·4)*
0·7 
(0·5 to 0·8)
–29·4% 
(–37·1 to –25·4)*
1845·6 
(1246·6 to 2066·2)
–21·4% 
(–28·8 to –17·5)*
23·7 
(15·8 to 26·7)
–32·7% 
(–39·5 to –29·1)*
Exposure to forces of nature 9·6 
(8·7 to 11·0)
–38·0% 
(–43·9 to –28·9)*
0·1 
(0·1 to 0·1)
–45·8% 
(–50·8 to –37·9)*
477·6 
(438·4 to 544·3)
–45·0% 
(–49·4 to –37·3)*
6·3 
(5·8 to 7·2)
–50·2% 
(–54·2 to –43·2)*
Other unintentional injuries 94·7 
(91·9 to 98·3)
–14·5% 
(–16·7 to –12·1)*
1·2 
(1·2 to 1·3)
–25·8% 
(–27·6 to –23·8)*
4679·6 
(4519·4 to 4888·2)
–20·7% 
(–22·9 to –18·1)*
60·9 
(58·8 to 63·7)
–28·9% 
(–30·9 to –26·6)*
Self-harm and interpersonal 
violence
1344·8 
(1283·1 to 
1380·4)
7·3% 
(4·6 to 9·7)*
17·1 
(16·3 to 17·5)
–7·6% 
(–9·9 to –5·5)*
63 862·9 
(61 029·9 to 
65 755·7)
5·4% 
(2·8 to 7·7)*
819·0 
(782·2 to 
843·4)
–5·7% 
(–7·9 to –3·7)*
Self‐harm 793·8 
(743·5 to 819·7)
1·1% 
(–2·6 to 3·7)
10·0 
(9·4 to 10·3)
–14·8% 
(–18·0 to –12·6)*
33 577·2 
(31 449·3 to 
34 719·1)
–3·4% 
(–7·0 to –0·9)*
423·6 
(396·9 to 438·2)
–15·1% 
(–18·4 to –12·9)*
Self‐harm by firearm 63·8 
(54·6 to 78·6)
6·8% 
(2·3 to 10·8)*
0·8 
(0·7 to 1·0)
–10·3% 
(–13·9 to –7·2)*
2653·6 
(2241·9 to 3288·1)
0·9% 
(–3·5 to 5·5)
33·5 
(28·2 to 41·6)
–11·5% 
(–15·2 to –7·6)*
Self‐harm by other 
specified means
730·0 
(678·5 to 754·9)
0·6% 
(–3·2 to 3·4)
9·2 
(8·5 to 9·5)
–15·2% 
(–18·4 to –12·8)*
30 923·6 
(28 832·4 to 
32 098·2)
–3·7% 
(–7·5 to –1·1)*
390·1 
(363·6 to 405·1)
–15·4% 
(–18·8 to –13·1)*
Interpersonal violence 405·3 
(365·2 to 431·7)
0·5% 
(–2·0 to 3·2)
5·2 
(4·7 to 5·5)
–11·1% 
(–13·3 to –8·7)*
21 439·8 
(19 275·8 to 
22 799·8)
–1·6% 
(–4·4 to 1·3)
276·8 
(248·4 to 294·2)
–10·9% 
(–13·4 to –8·2)*
Assault by firearm 174·4 
(147·9 to 188·9)
7·5% 
(4·3 to 10·8)*
2·2 
(1·9 to 2·4)
–3·6% 
(–6·5 to –0·5)*
9541·2 
(8106·2 to 
10 291·7)
5·4% 
(2·1 to 9·0)*
122·9 
(104·3 to 132·4)
–3·7% 
(–6·7 to –0·4)*
Assault by sharp object 91·4 
(74·4 to 111·2)
–11·5% 
(–15·3 to –6·0)*
1·2 
(0·9 to 1·4)
–22·3% 
(–25·6 to –17·6)*
4634·5 
(3747·0 to 5648·9)
–13·9% 
(–17·6 to –8·5)*
59·2 
(47·8 to 72·1)
–22·6% 
(–25·9 to –17·8)*
Assault by other means 139·5 
(123·6 to 164·4)
1·3% 
(–3·4 to 5·6)
1·8 
(1·6 to 2·1)
–11·5% 
(–15·4 to –7·6)*
7264·1 
(6400·8 to 8583·0)
–1·3% 
(–5·4 to 3·6)
94·7 
(83·3 to 111·5)
–11·2% 
(–14·9 to –6·8)*
Conflict and terrorism 129·7 
(118·1 to 143·2)
118·0% 
(88·8 to 148·6)*
1·7 
(1·6 to 1·9)
98·4% 
(72·4 to 126·1)*
7966·6 
(7244·5 to 8855·9)
113·5% 
(84·5 to 146·8)*
107·3 
(97·6 to 119·1)
97·9% 
(71·0 to 128·8)*
Executions and police conflict 16·0 
(15·7 to 16·3)
203·9% 
(186·9 to 220·9)*
0·2 
(0·2 to 0·2)
172·4% 
(156·8 to 187·6)*
879·3 
(862·3 to 898·1)
202·1% 
(184·8 to 219·8)*
11·4 
(11·2 to 11·7)
176·4% 
(160·5 to 192·9)*
Data in parentheses are 95% uncertainty intervals. G6PD=glucose‐6‐phosphate dehydrogenase. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. H influenzae=Haemophilus influenzae. 
NASH=non‐alcoholic steatohepatitis. YLL=years of life lost. *Percentage changes that are statistically significant.
Table 1: Global death and YLL numbers, age-standardised rates per 100 000, and percentage change between 2007 and 2017 for both sexes combined for all GBD causes and Levels 1 
through 4 of the cause hierarchy
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age-sex-cause death rate using GBD estimates from all 
national locations across all years from 1980 to 2017 
(appendix 1 section 7). Expected cause-specific death rates 
were scaled to the expected all-cause death rate to ensure 
internal consistency. We then computed the number of 
YLLs and deaths expected for each age-sex-location-year 
based on SDI alone and compared these estimates to 
observed rates. Additional details of the development and 
calculation of SDI for GBD 2017 are described in 
appendix 1 (section 5).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all the data in the study 
and had final responsibility for the decision to submit 
for publication.
Results
Global causes of death
Mortality estimates by cause for the years 1990, 2007, and 
2017 are available by age and sex through the GBD results 
tool and for each year in the GBD estimation period 
1980–2017 through the online data visualisation tool. All 
reported rates are age-standardised.
In 2017, at the broadest level of cause of death 
classification in the GBD cause list (Level 1), CMNN 
causes accounted for 18·6% (95% UI 17·9–19·6) of 
total deaths or 10·4 million (10·0–11·0) deaths in 2017, 
while non-communicable causes (NCDs) accounted for 
73·4% (72·5–74·1) or 41·1 million (40·5–41·5) deaths, 
and injuries accounted for 8·0% (7·7–8·2) of deaths or 
4·48 million (4·33–4·59) deaths (table 1). Of the 
1·65 billion (1·62–1·67) global YLLs in 2017, 35·1% 
(34·2–36·2) were from CMNN causes, 53·0% (52·2–53·8) 
were from NCDs, and the remaining 11·9% (11·5–12·1) 
were from injuries. Both the number of deaths and death 
rates from CMNN causes decreased from 2007 to 2017, by 
22·2% (20·0–24·0) in terms of total deaths and by 31·8% 
(30·1–33·3) in terms of mortality rate. Decreases in the 
number and rate of YLLs from CMNN causes were 
similar in magnitude (30·4% [28·2–32·4] decrease in 
YLLs; 35·4% [33·4–37·3] decrease in YLL rate) over the 
same time period. By contrast, total deaths from NCD 
causes increased between 2007 and 2017 by 22·7% 
(21·5–23·9) and total YLLs from NCD causes increased 
by 13·6% (12·2–14·9), repre senting an additional 7·61 
million (7·20–8·01) deaths and 105 million (94·3–114·0) 
YLLs estimated in 2017. Rates of both deaths and YLLs 
from NCD causes decreased over the same time period, 
by 7·9% (7·0–8·8) to 536·1 deaths (528·4–542·2) per 
100 000, with a 9·6% (8·6–10·7) decrease in the YLL rate 
to 11 100 YLLs (10 900–11 300) per 100 000 in 2017. Total 
deaths from injuries varied little between 2007 and 2017, 
with an increase of 2·3% (0·5–4·0) to 4·48 million 
(4·33–4·59) deaths, while death rates from injury 
decreased by 13·7% (12·2–15·1) to 57·9 deaths 
(55·9–59·2) per 100 000 in 2017. Decreases in the number 
of YLLs (by 6·4% [4·8–7·8] to 195 million [189–200] YLLs 
in 2017) and YLL rate (by 16·9% [15·3–18·2] to 
2550 [2460–2610] YLLs per 100 000 in 2017) for injuries 
were estimated during the same period.
Communicable, maternal, neonatal, and nutritional diseases
The overall decrease in communicable causes of death 
included reductions in some of the largest contributors to 
global mortality, including HIV/AIDS, tuberculosis, 
diarrhoeal diseases, and malaria (table 1). The peak in 
HIV/AIDS mortality occurred in 2006 with 1·95 million 
deaths (95% UI 1·87–2·04) and a rate of 28·8 deaths 
(27·7–30·1) per 100 000, but between 2007 and 2017, total 
mortality from HIV/AIDS decreased from 1·92 million 
(1·84–2·00) deaths to 0·954 million (0·907–1·01) deaths 
with a commensurate decrease (56·5% [54·7–58·0]) in the 
mortality rate from 27·9 deaths (26·8–29·1) per 100 000 in 
2007 to 12·1 deaths (11·5–12·9) per 100 000 in 2017. 
Although tuberculosis caused an estimated 1·18 million 
(1·13–1·25) deaths in 2017, this was nonetheless a decrease 
of 14·9% (10·3–18·2) from levels in 2007, when 
tuberculosis caused 1·39 million (1·34–1·46) deaths. Drug-
susceptible tuberculosis deaths were the largest component 
of tuberculosis deaths in 2017 (88·2% [81·4–93·3]) and 
decreased the most since 2007 (15·5% [8·6–22·3]) in 
comparison with other tuberculosis sub-causes. All 
HIV/AIDS and tuberculosis co-infections also decreased, 
with declines occurring for deaths from HIV/AIDS and 
drug-resistant tuberculosis co-infection (8·3% [–26·8 to 
14·7]), HIV/AIDS and multidrug-resistant tuber cu losis co-
infection (52·2% [33·2–66·4]), and HIV/AIDS and drug-
susceptible tuberculosis co-infection (55·4% [51·6–58·4]). 
The total number of deaths from diarrhoeal diseases 
decreased by 16·6% (6·7–25·3) between 2007 and 2017, 
from 1·88 million (1·53–2·47) deaths in 2007 to 
1·57 million (1·18–2·19) deaths in 2017. There was a 
parallel decrease in the death rate (30·2% [22·7–36·1]) 
from diarrhoeal diseases, from 31·0 deaths (25·0–40·9) 
per 100 000 in 2007 to 21·6 deaths (16·4–29·7) per 100 000 
in 2017. There were 620 000 deaths (440 000–840 000) from 
malaria in 2017, a decrease of 30·8% (20·8–39·4) from 
2007 when 896 000 deaths (664 000–1 180 000) were 
estimated. Deaths due to measles decreased by 57·0% 
(51·9–61·9) from 222 000 deaths (82 300–457 000) in 2007 
to 95 300 (34 500–205 000) in 2017. Invasive non-typhoidal 
salmonella deaths were estimated to have decreased from 
71 900 deaths (42 200–116 000) in 2007 to 59 100 deaths 
(33 300–98 100) in 2017. A notable exception to the estimated 
improvements for communicable diseases occurred for 
dengue, where deaths increased by 65·5% (21·7–99·7) 
from 24 500 (11 500–29 600) in 2007 to 40 500 (17 600–49 800) 
in 2017, with a similar increase in mortality rate (40·7% 
[3·6–69·7], from 0·4 deaths [0·2–0·5] per 100 000 in 2007 
to 0·5 deaths [0·2–0·7] per 100 000 in 2017).
At Level 2 of the GBD cause hierarchy, there were 
1·98 million (95% UI 1·89–2·06) deaths from maternal 
For the online results tool see 
http://ghdx.healthdata.org/gbd‐
results‐tool
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and neonatal disorders globally in 2017, and 90·2% 
(89·4–90·9) of these deaths were from neonatal 
disorders (table 1). Deaths from neonatal disorders 
decreased by 24·1% (20·6–27·2), from 2·35 million 
(2·27–2·44) deaths in 2007 to 1·78 million (1·70–1·86) in 
2017. A 26·2% (22·7–29·1) decrease in death rates for 
neonatal disorders was also estimated, from 36·7 deaths 
(35·3–38·0) per 100 000 in 2007 to 27·1 (25·8–28·3) per 
100 000 in 2017. Deaths from maternal disorders 
decreased by 24·0% (19·5–28·4), from 255 000 deaths 
(241 000–268 000) in 2007 to 194 000 deaths 
(180 000–210 000) in 2017. The mortality rate for 
maternal disorders decreased by 30·7% (26·6–34·8), 
from 3·6 deaths (3·4–3·8) per 100 000 in 2007 to 2·5 
(2·3–2·7) per 100 000 in 2017.
There were 270 000 deaths (95% UI 249 000–295 000) 
from nutritional deficiencies in 2017, representing 
2·60% (2·37–2·86) of all deaths from CMNN causes in 
that year (table 1). Decreases in death rates from 
nutritional deficiencies followed a trajectory similar to 
that of maternal and neonatal disorders, with mortality 
rates from nutritional deficiencies decreasing by 33·6% 
(26·5–38·1), from 5·8 deaths (5·4–6·2) per 100 000 in 
2007 to 3·8 (3·5–4·2) per 100 000 in 2017.
Non-communicable diseases
At Level 2 of the GBD hierarchy, the largest numbers of 
deaths from NCDs were estimated for cardiovascular 
diseases (17·8 million [95% UI 17·5–18·0] deaths), 
followed by neoplasms (9·56 million [9·40–9·69] deaths) 
and chronic respiratory diseases (3·91 million [3·79–4·04] 
deaths; table 1). Overall, deaths from NCDs increased 
globally, from 33·5 million (33·1–33·8) in 2007 to 
41·1 million (40·5–41·5) in 2017, while the death rate 
decreased (from 582·1 deaths [575·1–587·8] per 100 000 
in 2007 to 536·1 deaths [528·4–542·2] per 100 000 in 
2017). Total deaths from NCDs decreased significantly for 
only two Level 3 causes: sudden infant death syndrome 
(17·3% [1·4–28·6]) and congenital anomalies (14·3% 
[10·1–21·1]). During the past decade the estimated 
number of deaths from neurological disorders increased 
by 42·1% (40·2–43·9), from 2·18 million (2·14–2·20) 
deaths in 2007 to 3·09 million (3·04–3·14) deaths in 
2017; although the death rate increased, this change was 
not significant (0·1% [–1·2 to 1·3], from 43·0 deaths 
[42·3–43·4] per 100 000 in 2007 to 43·1 deaths [42·3–43·7] 
per 100 000 in 2017). Among neurological disorders, the 
greatest increase between 2007 and 2017 occurred for 
deaths from Alzheimer’s disease and other dementias 
(an increase of 46·2% [43·9–48·0], from 1·72 million 
[1·70–1·74] deaths in 2007 to 2·51 million [2·47–2·55] in 
2017; and from 35·2 deaths [34·7–35·5] per 100 000 in 
2007 to 35·4 [34·8–35·9] per 100 000 in 2017). 
At a global level, total deaths from cardiovascular diseases 
increased by 21·1% (95% UI 19·7–22·6) between 2007 and 
2017 but death rates decreased from 259·9 deaths 
(257·1–263·7) per 100 000 in 2007 to 233·1 (229·7–236·4) 
per 100 000 in 2017 (table 1). In combination, ischaemic 
heart disease and stroke—at Level 3 of the cause hier-
archy—accounted for 84·9% (84·3–86·3) of cardio vascular 
disease deaths in 2017. Deaths from both these causes 
increased between 2007 and 2017, from 7·30 million 
(7·22–7·46) deaths to 8·93 million (8·79–9·14) deaths for 
ischaemic heart disease, and from 5·29 million (5·22–5·40) 
deaths to 6·17 million (6·04–6·33) deaths for stroke. The 
largest decline in mortality rates among cardiovascular 
diseases during the same decade occurred for rheumatic 
heart disease, which decreased by 21·3% (17·8–25·2) 
between 2007 and 2017, from 4·7 deaths (4·4–5·0) per 
100 000 to 3·7 deaths (3·4–3·9) per 100 000.
Neoplasms contributed to 23·3% (95% UI 23·0–23·5) of 
deaths from NCDs in 2017, with tracheal, bronchus, and 
lung cancer leading to the most deaths (1·88 million 
[1·84–1·92]), followed by colon and rectum cancer (896 000 
[876 000–916 000]; table 1). Newly estimated for GBD 2017, 
liver cancer due to NASH caused 66 900 deaths 
(59 600–74 500) in 2017, representing an increase of 42·3% 
(38·0–47·6) from 2007. Globally, deaths from cancers 
increased by 25·4% (23·9–27·0) between 2007 and 2017, 
from 7·62 million (7·51–7·70) deaths in 2007 to 
9·56 million (9·40–9·69) deaths in 2017. The largest 
increases occurred for other neoplasms, which includes 
myelodysplastic, myeloproliferative, and other haemo-
poietic neoplasms, benign and in-situ intestinal, cervical, 
and uterine neoplasms, and other benign and in-situ 
neoplasms (increase of 42·0% [35·6–51·7] to 103 000 deaths 
[80 200–122 000]), other pharynx cancer (increase of 40·4% 
[29·7–48·4] to 117 000 deaths [102 000–124 000]), and 
pancreatic cancer (increase of 39·9% [36·7–42·6] to 
441 000 deaths [433 000–449 000]). Mortality rates for most 
types of cancer decreased in the decade 2007–17; the largest 
statistically significant decreases occurred for stomach 
cancer (decrease of 17·1% [15·1–18·8] to 11·0 deaths 
[10·8–11·2] per 100 000), Hodgkin lymphoma (decrease of 
16·8% [14·0–19·8] to 0·4 deaths [0·4–0·5] per 100 000), 
and oesophageal cancer (decrease of 14·5% [12·0–16·9] to 
5·5 deaths [5·3–5·6] per 100 000).
Several non-communicable causes were separately 
estimated for the first time in GBD 2017. Among these, 
diabetes mellitus resulted in 1·37 million (95% UI 
1·34–1·40) deaths in 2017, of which 25·2% (23·0–27·3) 
were from type 1 diabetes (table 1). Total deaths from 
type 1 diabetes increased from 2007 to 2017 by 15·1% 
(10·5–19·0) and those from type 2 diabetes by 43·0% 
(40·4–45·8). During this time period, the mortality rate 
decreased by 11·0% (7·8–14·6) for type 1 diabetes and 
increased by 5·9% (4·1–8·0) for type 2 diabetes. Deaths 
from diabetes-related chronic kidney disease also 
increased over the past decade, rising from 62 800 deaths 
(51 100–76 200) in 2007 to 77 300 deaths (62 400–95 200) 
in 2017 for chronic kidney disease due to type 1 diabetes 
and from 248 000 deaths (219 000–282 000) in 2007 to 
349 000 (307 000–396 000) in 2017 for chronic kidney 
disease due to type 2 diabetes. Among other newly 
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estimated causes, subarachnoid haemorrhage was 
estimated to have caused 445 000 deaths (417 000–492 000) 
in 2017, representing 0·8% (0·7–0·9) of global deaths 
and 2·5% (2·3–2·8) of cardiovascular disease deaths in 
2017; deaths from non-rheumatic valvular heart disease 
(145 000 [122 000–150 000]) represented 0·3% (0·2–0·3) 
of global deaths and 0·8% (0·7–0·9) of cardiovascular 
disease deaths in 2017. Deaths from substance use 
disorders increased between 2007 and 2017, rising 
from 284 000 deaths (268 000–289 000) to 352 000 deaths 
(334 000–363 000) globally; although not statistically 
significant, the death rate for these disorders increased 
by 2·0% (–1·0 to 5·0) during this period, rising from 
4·3 deaths (4·0 to 4·3) per 100 000 to 4·3 (4·1 to 4·5) per 
100 000 (table 1). The great est number of deaths from 
drug use disorders were due to opioid use disorders, 
which resulted in 110 000 deaths (106 000–114 000) 
globally in 2017, comprising 65·7% (63·8–67·4) of global 
deaths from drug use disorders.
Injuries
At Level 3 of the cause hierarchy, most injury deaths 
were from road injuries, which caused 1·24 million 
(95% UI 1·19–1·28) deaths in 2017, representing 27·7% 
(26·7–28·9) of all injury deaths in that year (table 1). 
794 000 deaths (744 000–820 000) in 2017 were from self-
harm, followed by 696 000 deaths (645 000–742 000) from 
falls, 405 000  deaths (365 000–432 000) from interpersonal 
violence, and 295 000 deaths (285 000–306 000) from 
drowning. Mortality rates in 2017 were highest among 
injury causes of death at Level 3 of the GBD hierarchy for 
road injuries (15·8 deaths [15·2–16·3] per 100 000), self-
harm (10·0 deaths [9·4–10·3] per 100 000), and falls 
(9·2 deaths [8·5–9·8] per 100 000). Overall, from 2007 to 
2017, there were 20·1 million (18·7–20·8) deaths from 
unintentional injuries, 15·1 million (14·8–15·4) deaths 
from transport injuries, and 14·4 million (13·7–14·7) 
deaths from self-harm and interpersonal violence. 
Poisoning by carbon monoxide, estimated for the first 
time for GBD 2017, caused 35 500 deaths (25 700–38 800) 
in 2017.
Since 1980, sudden changes in the expected number of 
deaths—described as fatal discontinuities in the GBD 
study—were found in several countries (figure 3). To 
emphasise the magnitude of these events, we describe 
total deaths rather than rates in this report. Figure 3 
combines total deaths across disparate types of fatal 
discontinuity; appendix 2 separates these deaths by 
Caribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
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Figure 3: All-age deaths due to fatal discontinuities (violence, disasters, famine, and disease outbreak),  for both sexes combined, 1980–2017
We have chosen to show this map in counts to capture the wide range of discontinuity‐related deaths ranging from motor vehicle accidents with a smaller number of deaths to natural disasters and 
conflicts with a larger number of deaths. Deaths are coded to the location of residence for the deceased. Maps by each subtype—violence, disasters, famine, and disease outbreak—are provided in 
appendix 2. ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor‐Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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All-age deaths 
(thousands)
Under-5 deaths 
(thousands)
Deaths at age 
5–14 years (thousands)
Deaths at age 
15–49 years (thousands)
Deaths at age 
50–69 years (thousands)
Deaths at age ≥70 years 
(thousands)
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
All causes 55 945·7 
(55 356·4 to 
56 516·7)
9·3% 
(8·2 to 
10·2)*
5391·6 
(5195·4 to 
5612·9)
–31·4% 
(–33·8 to 
–28·7)*
731·7 
(720·0 to 
744·1)
–21·9% 
(–23·2 to 
–20·5)*
7614·0 
(7496·5 
to 7741·4)
–11·2% 
(–12·3 to 
–9·9)*
14 998·6 
(14 827·9 
to 
15 170·8)
22·7% 
(21·2 to 
24·0)*
27 209·8 
(26 976·2 
to 
27 441·9)
25·9% 
(24·7 to 
26·9)*
Communicable, 
maternal, neonatal, 
and nutritional 
diseases
10 389·9 
(10 004·0 
to 10 975·9)
–22·2% 
(–24·0 to 
–20·0)*
4366·5 
(4193·1 to 
4563·3)
–33·6% 
(–36·3 to 
–30·8)*
352·2 
(330·8 to 
380·6)
–29·4% 
(–31·7 to 
–27·0)*
1896·8 
(1813·8 to 
1992·6)
–33·2% 
(–34·8 to 
–31·5)*
1463·3 
(1377·8 to 
1606·9)
–1·8% 
(–4·2 to 
1·3)
2311·0 
(2113·6 to 
2616·4)
18·4% 
(15·0 to 
22·7)*
HIV/AIDS and 
sexually 
transmitted 
infection
1073·6 s 
(983·3 to 
1182·4)
–47·7% 
(–50·0 to 
–45·1)*
187·8 
(117·0 to 
286·3)
–47·9% 
(–58·3 to 
–38·4)*
46·2 
(43·1 to 
49·3)
–12·9% 
(–17·6 to 
–7·9)*
679·6 
(633·3 to 
727·6)
–50·1% 
(–52·1 to 
–47·9)*
144·8 
(135·6 to 
156·1)
–42·2% 
(–45·6 to 
–38·4)*
15·2 
(14·0 to 
16·6)
–46·3% 
(–50·4 to 
–41·3)*
HIV/AIDS 954·5 
(907·3 to 
1009·7)
–50·3% 
(–52·1 to 
–48·3)*
77·5 
(69·0 to 
86·8)
–67·1% 
(–70·3 to 
–63·4)*
44·8 
(42·0 to 
47·7)
–13·0% 
(–17·9 to 
–7·9)*
676·1 
(629·7 to 
724·5)
–50·2% 
(–52·3 to 
–48·0)*
142·6 
(133·3 to 
153·7)
–42·7% 
(–46·0 to 
–38·8)*
13·5 
(12·3 to 
14·9)
–49·8% 
(–54·0 to 
–44·6)*
HIV/AIDS 
resulting in other 
diseases
736·0 
(659·5 to 
817·7)
–48·7% 
(–51·1 to 
–45·9)*
54·6 
(46·0 to 
64·9)
–64·5% 
(–68·8 to 
–59·2)*
30·1 
(26·3 to 
35·0)
–11·3% 
(–17·4 to 
–4·4)*
531·1 
(470·1 to 
596·1)
–49·8% 
(–52·6 to 
–46·9)*
109·5 
(97·1 to 
124·8)
–35·9% 
(–40·3 to 
–30·2)*
10·7 
(9·3 to 
12·3)
–38·0% 
(–43·7 to 
–30·3)*
Respiratory 
infections and 
tuberculosis
3752·3 
(3629·4 to 
3889·3)
–8·0% 
(–10·3 to 
–5·5)*
870·5 
(803·3 to 
941·4)
–36·7% 
(–40·6 to 
–32·4)*
58·1 
(52·1 to 
64·1)
–27·4% 
(–31·5 to 
–23·3)*
543·2 
(520·8 to 
570·8)
–18·2% 
(–20·7 to 
–15·2)*
836·8 
(805·0 to 
868·5)
7·8% 
(4·5 to 
12·0)*
1443·7 
(1392·6 to 
1503·7)
21·9% 
(19·4 to 
24·7)*
Tuberculosis 1183·7 
(1129·8 to 
1245·3)
–14·9% 
(–18·2 to 
–10·3)*
57·4 
(51·3 to 
63·6)
–39·8% 
(–44·5 to 
–34·2)*
13·7 
(12·2 to 
15·5)
–38·4% 
(–42·7 to 
–33·8)*
371·7 
(353·1 to 
392·2)
–23·4% 
(–26·5 to 
–19·8)*
429·7 
(410·6 to 
452·7)
–5·2% 
(–9·6 to 
0·9)
311·2 
(294·2 to 
330·7)
–6·9% 
(–11·2 to 
–0·4)*
Drug‐susceptible 
tuberculosis
1044·1 
(951·6 to 
1129·2)
–15·5% 
(–22·3 to 
–8·6)*
51·4 
(45·3 to 
57·6)
–40·5% 
(–46·0 to 
–34·1)*
12·2 
(10·7 to 
13·9)
–39·0% 
(–44·2 to 
–33·5)*
326·5 
(297·0 to 
353·9)
–23·8% 
(–29·9 to 
–18·1)*
377·7 
(342·6 to 
409·5)
–6·0% 
(–14·3 to 
2·4)
276·4 
(251·1 to 
300·9)
–7·6% 
(–15·6 to 
0·8)
Lower respiratory 
infections
2558·6 
(2442·2 to 
2655·4)
–4·3% 
(–6·9 to 
–1·5)*
808·9 
(747·3 to 
873·6)
–36·4% 
(–40·6 to 
–32·2)*
43·9 
(38·9 to 
48·7)
–23·0% 
(–27·5 to 
–18·5)*
170·5 
(157·0 to 
182·6)
–4·0% 
(–6·3 to 
–1·5)*
405·8 
(366·8 to 
422·6)
26·5% 
(23·2 to 
29·7)*
1129·4 
(1078·5 to 
1180·4)
33·6% 
(31·2 to 
36·1)*
Enteric infections 1766·0 
(1398·0 to 
2386·0)
–17·2% 
(–24·6 to 
–8·2)*
589·4 
(528·3 to 
653·6)
–39·1% 
(–46·1 to 
–31·0)*
111·9 
(83·6 to 
151·3)
–27·9% 
(–32·7 to 
–21·7)*
187·1 
(135·4 to 
278·7)
–14·4% 
(–20·0 to 
–5·5)*
249·3 
(158·0 to 
413·5)
2·8% 
(–5·3 to 
16·8)
628·3 
(395·4 to 
975·5)
14·8% 
(4·3 to 
30·7)*
Diarrhoeal diseases 1569·6 
(1176·0 to 
2193·0)
–16·6% 
(–25·3 to 
–6·7)*
533·8 
(477·2 to 
593·1)
–40·6% 
(–47·8 to 
–32·2)*
44·5 
(27·5 to 
73·1)
–27·2% 
(–36·6 to 
–14·1)*
128·2 
(77·2 to 
216·2)
–14·1% 
(–21·6 to 
–1·9)*
239·1 
(145·9 to 
404·4)
3·5% 
(–4·7 to 
18·0)
624·0 
(390·4 to 
972·3)
15·0% 
(4·5 to 
31·1)*
Neglected tropical 
diseases and 
malaria
720·1 
(530·7 to 
938·8)
–29·0% 
(–37·3 to 
–19·3)*
375·9 
(250·3 to 
527·8)
–39·2% 
(–50·3 to 
–27·4)*
66·1 
(49·5 to 
87·7)
–32·3% 
(–41·8 to 
–23·5)*
135·6 
(98·0 to 
186·4)
–13·9% 
(–26·4 to 
–4·2)*
91·9 
(66·5 to 
126·7)
–1·3% 
(–11·2 to 
8·0)
50·6 
(38·5 to 
68·2)
4·6% 
(–7·2 to 
18·0)
Malaria 619·8 
(440·1 to 
839·5)
–30·8% 
(–39·4 to 
–20·8)*
354·3 
(226·3 to 
508·1)
–39·8% 
(–51·4 to 
–27·2)*
54·3 
(38·9 to 
75·3)
–30·7% 
(–39·4 to 
–21·7)*
109·0 
(72·2 to 
161·0)
–9·5% 
(–17·1 to 
–1·1)*
71·2 
(46·5 to 
107·2)
–3·3% 
(–12·6 to 
6·2)
31·0 
(20·8 to 
46·4)
–10·8% 
(–19·4 to 
–2·0)*
Other infectious 
diseases
830·5 
(732·2 to 
947·8)
–25·9% 
(–32·4 to 
–18·8)*
414·0 
(331·4 to 
515·2)
–38·1% 
(–45·4 to 
–28·9)*
60·6 
(51·0 to 
74·0)
–38·8% 
(–45·2 to 
–31·7)*
143·3 
(127·1 to 
157·6)
–14·7% 
(–18·0 to 
–10·0)*
110·5 
(102·4 to 
121·6)
10·8% 
(6·3 to 
17·4)*
102·1 
(94·1 to 
110·9)
19·6% 
(14·7 to 
24·5)*
Meningitis 288·0 
(254·3 to 
333·2)
–20·1% 
(–26·0 to 
–11·0)*
153·1 
(127·7 to 
179·4)
–30·0% 
(–38·2 to 
–19·2)*
23·4 
(19·1 to 
29·9)
–25·2% 
(–30·6 to 
–12·8)*
54·7 
(46·2 to 
69·3)
–9·5% 
(–13·6 to 
–1·6)*
31·8 
(28·7 to 
44·2)
12·3% 
(6·0 to 
20·0)*
25·1 
(22·5 to 
35·7)
13·8% 
(6·3 to 
21·0)*
Maternal and 
neonatal disorders
1977·4 
(1890·1 to 
2060·6)
–24·1% 
(–26·9 to 
–21·0)*
1783·8 
(1698·5 to 
1864·7)
–24·1% 
(–27·2 to 
–20·6)*
0·8 
(0·7 to 
0·9)
–18·5% 
(–28·5 to 
–4·9)*
191·1 
(177·5 to 
206·9)
–24·2% 
(–28·6 to 
–19·6)*
1·8 
(1·6 to 
2·0)
2·1% 
(–7·6 to 
14·1)
·· ··
Neonatal disorders 1783·8 
(1698·5 to 
1864·7)
–24·1% 
(–27·2 to 
–20·6)*
1783·8 
(1698·5 to 
1864·7)
–24·1% 
(–27·2 to 
–20·6)*
·· ·· ·· ·· ·· ·· ·· ··
Neonatal preterm 
birth
649·4 
(605·4 to 
721·3)
–26·2% 
(–31·3 to 
–21·5)*
649·4 
(605·4 to 
721·3)
–26·2% 
(–31·3 to 
–21·5)*
·· ·· ·· ·· ·· ·· ·· ··
(Table 2 continues on next page)
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All-age deaths 
(thousands)
Under-5 deaths 
(thousands)
Deaths at age 
5–14 years (thousands)
Deaths at age 
15–49 years (thousands)
Deaths at age 
50–69 years (thousands)
Deaths at age ≥70 years 
(thousands)
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–2017
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
(Continued from previous page)
Neonatal 
encephalopathy 
due to birth 
asphyxia and 
trauma
533·3 
(476·9 to 
580·3)
–24·5% 
(–30·2 to 
–18·0)*
533·3 
(476·9 to 
580·3)
–24·5% 
(–30·2 to 
–18·0)*
·· ·· ·· ·· ·· ·· ·· ··
Other neonatal 
disorders
349·0 
(294·9 to 
382·3)
–23·6% 
(–29·8 to 
–15·5)*
349·0 
(294·9 to 
382·3)
–23·6% 
(–29·8 to 
–15·5)*
·· ·· ·· ·· ·· ·· ·· ··
Nutritional 
deficiencies
270·0 
(249·3 to 
295·5)
–23·9% 
(–29·2 to 
–15·7)*
145·1 
(128·0 to 
163·6)
–38·7% 
(–44·8 to 
–30·2)*
8·5 
(7·3 to 
9·9)
–35·3% 
(–42·7 to 
–25·8)*
16·9 
(15·6 to 
18·8)
–12·9% 
(–17·8 to 
–4·5)*
28·3 
(26·6 to 
31·0)
8·1% 
(1·6 to 
18·4)*
71·2 
(68·7 to 
75·1)
20·5% 
(15·6 to 
27·9)*
Protein‐energy 
malnutrition
231·8 
(212·4 to 
254·2)
–26·1% 
(–31·7 to 
–17·9)*
140·3 
(123·6 to 
158·8)
–38·3% 
(–44·4 to 
–29·8)*
7·3 
(6·2 to 
8·5)
–32·1% 
(–39·8 to 
–21·3)*
11·5 
(10·4 to 
13·1)
–10·6% 
(–15·9 to 
–1·1)*
19·2 
(17·6 to 
21·1)
6·2% 
(0·7 to 
15·5)*
53·6 
(49·3 to 
56·7)
20·2% 
(16·3 to 
26·0)*
Non-communicable 
diseases
41071·1 
(40470·9 
to 
41548·9)
22·7% 
(21·5 to 
23·9)*
754·6 
(707·5 to 
804·4)
–16·9% 
(–21·7 to 
–12·6)*
170·9 
(157·6 to 
182·2)
–9·1% 
(–12·5 to 
–5·5)*
3654·7 
(3583·2 to 
3726·5)
3·2% 
(1·7 to 
4·7)*
12516·7 
(12332·4 
to 
12686·5)
26·7% 
(25·1 to 
28·2)*
23974·3 
(23625·0 
to 
24257·0)
26·5% 
(25·3 to 
27·7)*
Neoplasms 9556·2 
(9395·7 to 
9692·3)
25·4% 
(23·9 to 
27·0)*
49·9 
(44·4 to 
54·8)
–4·8% 
(–21·5 to 
12·6)
62·0 
(56·7 to 
66·8)
–2·8% 
(–9·6 to 
3·4)
1048·5 
(1024·9 
to 1072·5)
5·7% 
(3·8 to 
7·8)*
3962·3 
(3896·5 
to 
4024·2)
31·0% 
(29·2 to 
32·9)*
4433·5 
(4351·5 to 
4493·0)
27·2% 
(25·7 to 
28·7)*
Colon and rectum 
cancer
896·0 
(876·3 to 
915·7)
27·8% 
(24·0 to 
31·3)*
·· ·· ·· ·· 68·2 
(66·1 to 
70·0)
11·8% 
(6·0 to 
16·3)*
323·2 
(314·8 to 
331·3)
32·2% 
(27·3 to 
36·5)*
504·7 
(494·2 to 
515·3)
27·5% 
(24·5 to 
30·5)*
Tracheal, bronchus, 
and lung cancer
1883·1 
(1844·2 to 
1922·8)
29·6% 
(26·5 to 
32·5)*
·· ·· ·· ·· 105·5 
(102·5 to 
108·9)
–1·0% 
(–4·1 to 1·8)
861·5 
(841·1 to 
882·3)
34·9% 
(31·3 to 
38·1)*
916·1 
(897·6 to 
934·8)
29·5% 
(26·7 to 
32·3)*
Cardiovascular 
diseases
17790·9 
(17527·1 to 
18042·7)
21·1% 
(19·7 to 
22·6)*
30·1 
(28·2 to 
32·3)
–31·3% 
(–35·2 to 
–27·2)*
15·6 
(14·5 to 
16·9)
–18·7% 
(–22·9 to 
–15·4)*
1258·0 
(1234·6 to 
1284·7)
1·6% 
(–0·2 to 
3·4)
5152·1 
(5068·6 
to 5233·7)
23·6% 
(21·7 to 
25·5)*
11335·1 
(11173·0 
to 
11494·9)
22·9% 
(21·6 to 
24·3)*
Ischaemic heart 
disease
8930·4 
(8790·7 to 
9138·7)
22·3% 
(20·6 to 
23·8)*
·· ·· ·· ·· 643·8 
(628·9 to 
661·2)
5·9% 
(3·7 to 
8·3)*
2649·1 
(2602·9 to 
2699·1)
24·5% 
(22·3 to 
26·6)*
5637·5 
(5547·9 to 
5786·4)
23·4% 
(21·8 to 
24·8)*
Stroke 6167·3 
(6044·3 to 
6327·6)
16·6% 
(14·7 to 
18·6)*
7·5 
(6·7 to 8·5)
–40·2% 
(–45·3 to 
–35·0)*
5·1 
(4·7 to 
5·6)
–18·1% 
(–23·8 to 
–13·2)*
364·2 
(354·9 to 
375·0)
0·1% 
(–2·3 to 2·4)
1836·6 
(1795·9 to 
1879·2)
21·7% 
(19·2 to 
24·3)*
3953·8 
(3875·7 to 
4067·2)
16·4% 
(14·6 to 
18·3)*
Ischaemic stroke 2747·4 
(2657·1 to 
2857·6)
21·2% 
(19·0 to 
23·3)*
1·0 
(0·8 to 1·3)
–36·8% 
(–44·6 to 
–29·3)*
0·5 
(0·4 to 
0·6)
–18·1% 
(–27·8 to 
–10·6)*
58·3 
(53·4 to 
64·9)
2·0% 
(–1·6 to 5·5)
575·2 
(545·6 to 
619·7)
27·2% 
(23·7 to 
30·8)*
2112·4 
(2052·7 to 
2177·3)
20·3% 
(18·3 to 
22·3)*
Intracerebral 
haemorrhage
2974·9 
(2880·8 to 
3072·8)
12·5% 
(9·6 to 
15·1)*
3·3 
(2·7 to 4·4)
–44·5% 
(–49·5 to 
–40·1)*
2·7 
(2·5 to 2·9)
–18·6% 
(–25·9 to 
–12·9)*
238·9 
(230·5 to 
248·1)
–0·4% 
(–3·3 to 2·4)
1088·7 
(1050·2 to 
1121·4)
18·7% 
(15·8 to 
21·7)*
1641·3 
(1589·9 to 
1706·2)
11·1% 
(8·2 to 
13·6)*
Hypertensive heart 
disease
925·7 
(681·4 to 
994·9)
46·6% 
(26·3 to 
59·3)*
·· ·· ·· ·· 43·8 
(32·4 to 
49·2)
10·7% 
(–0·3 to 
21·3)
224·2 
(172·2 to 
242·8)
39·5% 
(25·0 to 
52·5)*
657·7 
(473·8 to 
710·6)
52·5% 
(29·1 to 
64·5)*
Chronic 
respiratory 
diseases
3914·2 
(3790·6 to 
4044·8)
15·8% 
(12·7 to 
19·3)*
10·7 
(9·3 to 
12·4)
–34·3% 
(–41·7 to 
–20·2)*
6·8 
(6·1 to 
8·2)
–24·9% 
(–29·0 to 
–18·8)*
163·0 
(156·2 to 
175·0)
–5·9% 
(–9·1 to 
–2·0)*
1004·4 
(971·0 to 
1040·7)
15·9% 
(12·4 to 
20·0)*
2729·3 
(2637·9 to 
2820·0)
17·9% 
(14·6 to 
21·4)*
Chronic obstructive 
pulmonary disease
3197·8 
(3029·0 to 
3358·9)
17·5% 
(13·3 to 
21·1)*
1·2 
(0·9 to 1·8)
–29·1% 
(–40·3 to 
–15·6)*
0·8 
(0·7 to 1·0)
–16·6% 
(–28·1 to 
–5·2)*
75·8 
(67·9 to 
90·1)
–2·9% 
(–8·6 to 
1·7)
760·8 
(700·2 to 
819·6)
17·8% 
(13·0 to 
22·6)*
2359·1 
(2256·9 to 
2448·6)
18·3% 
(14·3 to 
21·6)*
Digestive diseases 2377·7 
(2295·1 to 
2518·0)
15·3% 
(12·1 to 
19·7)*
40·2 
(34·5 to 
45·6)
–14·8% 
(–31·9 to 
0·2)
20·4 
(17·0 to 
23·3)
–14·0% 
(–23·9 to 
–3·2)*
478·2 
(454·0 to 
510·7)
–1·0% 
(–4·2 to 
3·6)
884·1 
(853·6 to 
951·9)
20·7% 
(16·6 to 
26·4)*
954·9 
(927·8 to 
1014·4)
23·1% 
(19·2 to 
28·9)*
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All-age deaths 
(thousands)
Under-5 deaths 
(thousands)
Deaths at age 
5–14 years (thousands)
Deaths at age 
15–49 years (thousands)
Deaths at age 
50–69 years (thousands)
Deaths at age ≥70 years 
(thousands)
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–2017
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
(Continued from previous page)
Cirrhosis and other 
chronic liver 
diseases
1322·9 
(1268·2 to 
1449·1)
15·0% 
(8·7 to 
21·5)*
7·8 
(6·3 to 9·6)
–14·9% 
(–36·9 to 
11·1)
8·4 
(7·0 to 
10·0)
–14·1% 
(–23·5 to 
–0·1)*
332·1 
(316·4 to 
362·3)
–0·4% 
(–5·2 to 4·7)
592·2 
(567·4 to 
653·6)
21·0% 
(14·4 to 
28·7)*
382·3 
(364·3 to 
425·8)
24·0% 
(15·6 to 
33·9)*
Neurological 
disorders
3094·2 
(3039·6 to 
3142·6)
42·1% 
(40·2 to 
43·9)*
18·2 
(16·1 to 
21·4)
–18·2% 
(–27·7 to 
6·6)
11·4 
(10·2 to 
13·2)
–14·1% 
(–21·2 to 
–0·7)*
86·6 
(80·8 to 
98·1)
0·5% 
(–3·7 to 
8·1)
244·5 
(239·4 to 
250·8)
38·2% 
(36·0 to 
40·6)*
2733·5 
(2683·3 to 
2772·6)
45·5% 
(43·5 to 
47·2)*
Alzheimer’s disease 
and other 
dementias
2514·6 
(2470·5 to 
2550·3)
46·2% 
(43·9 to 
48·0)*
·· ·· ·· ·· 2·8 
(2·8 to 
2·9)
11·2% 
(7·5 to 
14·9)*
138·3 
(135·4 to 
141·4)
39·6% 
(36·0 to 
42·5)*
2373·5 
(2329·6 to 
2407·2)
46·7% 
(44·4 to 
48·5)*
Diabetes and 
kidney diseases
2611·2 
(2557·8 to 
2667·2)
34·2% 
(32·0 to 
36·2)*
15·0 
(13·6 to 
16·5)
–22·3% 
(–27·6 to 
–16·3)*
10·2 
(9·3 to 
11·1)
–14·6% 
(–20·0 to 
–9·9)*
278·3 
(270·4 to 
287·1)
8·5% 
(6·2 to 
11·0)*
940·9 
(921·7 to 
959·9)
39·4% 
(36·7 to 
42·0)*
1366·7 
(1338·8 to 
1395·2)
38·9% 
(36·8 to 
40·8)*
Diabetes mellitus 1369·8 
(1340·3 to 
1401·9)
34·7% 
(32·2 to 
37·3)*
1·7 
(1·4 to 2·0)
–11·2% 
(–19·6 to 
–2·9)*
1·9 
(1·5 to 2·2)
–10·6% 
(–21·1 to 
–1·2)*
113·8 
(111·0 to 
116·8)
13·5% 
(10·5 to 
16·2)*
535·0 
(523·9 to 
547·0)
38·9% 
(36·0 to 
41·9)*
717·4 
(700·6 to 
736·2)
36·1% 
(33·4 to 
38·7)*
Type 2 diabetes 
mellitus
1024·3 
(985·5 to 
1066·8)
43·0% 
(40·4 to 
45·8)*
·· ·· ·· ·· 49·3 
(46·6 to 
52·3)
31·1% 
(26·2 to 
35·7)*
380·9 
(365·6 to 
396·6)
48·0% 
(44·6 to 
51·7)*
594·1 
(572·3 to 
620·5)
41·0% 
(38·6 to 
43·6)*
Chronic kidney 
disease
1230·2 
(1195·1 to 
1258·8)
33·7% 
(30·5 to 
36·1)*
13·0 
(11·7 to 
14·4)
–23·0% 
(–28·9 to 
–16·7)*
8·0 
(7·3 to 8·8)
–15·0% 
(–20·3 to 
–10·4)*
162·6 
(155·5 to 
169·4)
5·7% 
(3·0 to 
8·6)*
402·3 
(383·6 to 
412·1)
40·3% 
(35·6 to 
43·7)*
644·3 
(628·3 to 
659·3)
42·2% 
(38·9 to 
44·4)*
Other non-
communicable 
diseases
1153·3 
(1101·8 to 
1208·3)
0·8% 
(–3·9 to 
4·0)
584·4 
(544·2 to 
628·8)
–16·6% 
(–22·5 to 
–12·2)*
42·0 
(37·4 to 
46·4)
–5·0% 
(–10·5 to 
–0·6)*
130·3 
(120·8 to 
141·4)
5·6% 
(2·6 to 
8·3)*
142·8 
(131·2 to 
150·3)
39·3% 
(36·3 to 
42·3)*
253·7 
(236·5 to 
262·6)
46·4% 
(43·8 to 
49·4)*
Injuries 4484·7 
(4332·0 to 
4585·6)
2·3% 
(0·5 to 
4·0)*
270·5 
(249·7 to 
289·4)
–26·6% 
(–31·3 to 
–18·6)*
208·7 
(194·4 to 
221·4)
–16·5% 
(–18·7 to 
–13·7)*
2062·5 
(1998·4 
to 2105·8)
–5·8% 
(–7·2 to 
–4·4)*
1018·6 
(975·0 to 
1047·8)
18·9% 
(14·8 to 
21·9)*
924·5 
(889·7 to 
956·7)
28·3% 
(23·4 to 
33·6)*
Transport injuries 1335·0 
(1289·1 to 
1369·5)
–3·1% 
(–6·0 to 
–0·6)*
52·4 
(47·0 to 
57·7)
–30·1% 
(–36·1 to 
–16·0)*
66·7 
(61·9 to 
71·7)
–19·2% 
(–22·4 to 
–15·6)*
720·2 
(699·9 to 
740·6)
–10·3% 
(–13·3 to 
–7·5)*
335·0 
(316·0 to 
344·8)
19·9% 
(12·4 to 
24·4)*
160·7 
(153·8 to 
165·0)
16·9% 
(10·2 to 
20·7)*
Road injuries 1243·1 
(1191·9 to 
1276·9)
–3·2% 
(–6·3 to 
–0·5)*
49·1 
(44·0 to 
54·2)
–30·0% 
(–36·1 to 
–14·9)*
62·4 
(57·9 to 
67·3)
–19·3% 
(–22·4 to 
–15·4)*
669·1 
(644·9 to 
688·7)
–10·5% 
(–13·5 to 
–7·6)*
311·7 
(292·2 to 
321·5)
20·0% 
(12·3 to 
24·5)*
150·8 
(143·8 to 
155·1)
16·7% 
(9·8 to 
20·5)*
Pedestrian road 
injuries
486·2 
(459·7 to 
535·0)
–6·4% 
(–11·7 to 
–2·1)*
24·0 
(21·1 to 
28·3)
–36·8% 
(–42·8 to 
–26·4)*
31·2 
(28·0 to 
35·3)
–25·0% 
(–29·1 to 
–20·5)*
203·7 
(191·6 to 
227·0)
–15·2% 
(–19·8 to 
–10·5)*
141·8 
(133·0 to 
154·8)
14·7% 
(5·4 to 
21·5)*
85·5 
(80·8 to 
91·1)
12·7% 
(3·6 to 
18·2)*
Motorcyclist road 
injuries
225·7 
(196·1 to 
238·6)
–0·6% 
(–8·9 to 
5·2)
3·5 
(3·0 to 4·1)
–25·4% 
(–37·6 to 
–3·7)*
5·2 
(4·4 to 5·9)
–13·4% 
(–21·3 to 
–5·2)*
161·5 
(142·6 to 
171·6)
–8·0% 
(–15·0 to 
–2·6)*
45·6 
(37·4 to 
49·3)
36·8% 
(17·1 to 
48·9)*
9·8 
(7·9 to 
10·6)
32·5% 
(12·4 to 
44·8)*
Motor vehicle 
road injuries
451·1 
(423·4 to 
472·9)
–2·5% 
(–6·2 to 
1·3)
19·9 
(16·5 to 
22·9)
–21·5% 
(–31·6 to 
3·0)
21·3 
(19·2 to 
23·4)
–12·3% 
(–17·1 to 
–3·0)*
268·5 
(254·4 to 
284·6)
–8·9% 
(–12·5 to 
–5·5)*
97·6 
(88·9 to 
103·9)
19·8% 
(10·1 to 
25·2)*
43·7 
(40·5 to 
46·1)
18·8% 
(9·9 to 
23·4)*
Unintentional 
injuries
1804·9 
(1695·7 to 
1872·0)
2·9% 
(0·5 to 
6·0)*
191·5 
(175·1 to 
206·9)
–29·2% 
(–34·2 to 
–22·4)*
106·2 
(96·6 to 
114·9)
–22·7% 
(–25·6 to 
–19·4)*
486·0 
(447·7 to 
509·0)
–12·3% 
(–14·0 to 
–10·2)*
395·8 
(363·7 to 
416·0)
19·4% 
(15·0 to 
24·2)*
625·4 
(591·5 to 
653·4)
35·9% 
(29·8 to 
42·9)*
Falls 695·8 
(644·9 to 
741·7)
27·4% 
(21·2 to 
35·6)*
20·4 
(17·5 to 
22·9)
–16·7% 
(–31·4 to 
1·0)
12·9 
(11·1 to 
14·7)
–7·0% 
(–18·0 to 
4·0)
102·6 
(90·7 to 
109·2)
–1·0% 
(–5·6 to 
5·7)
155·4 
(140·0 to 
169·0)
31·1% 
(22·9 to 
42·0)*
404·5 
(381·7 to 
433·2)
41·6% 
(33·4 to 
52·1)*
Drowning 295·2 
(284·5 to 
306·2)
–17·2% 
(–19·8 to 
–14·1)*
59·8 
(54·3 to 
65·9)
–41·8% 
(–46·7 to 
–34·9)*
49·7 
(45·8 to 
53·5)
–26·3% 
(–29·5 to 
–22·9)*
99·2 
(96·5 to 
102·3)
–14·5% 
(–16·9 to 
–11·7)*
48·8 
(46·6 to 
50·2)
19·6% 
(16·2 to 
22·9)*
37·6 
(35·1 to 
38·7)
28·6% 
(24·7 to 
32·0)*
Fire, heat, and hot 
substances
120·6 
(101·6 to 
129·4)
–7·9% 
(–10·9 to 
–1·2)*
17·2 
(13·1 to 
20·0)
–25·3% 
(–34·6 to 
–5·2)*
5·9 
(4·7 to 7·0)
–22·4% 
(–28·2 to 
–12·2)*
40·8 
(32·6 to 
45·8)
–16·1% 
(–19·8 to 
–9·7)*
25·1 
(21·5 to 
26·8)
4·0% 
(–4·5 to 
9·6)
31·6 
(28·3 to 
33·1)
14·4% 
(7·4 to 
19·2)*
Exposure to 
mechanical forces
136·5 
(117·6 to 
143·2)
–6·7% 
(–9·8 to 
–3·7)*
13·5 
(11·0 to 
15·2)
–22·4% 
(–28·4 to 
–15·2)*
7·1 
(6·2 to 7·8)
–19·9% 
(–23·6 to 
–15·9)*
63·0 
(54·9 to 
66·0)
–15·9% 
(–19·1 to 
–12·2)*
33·3 
(27·5 to 
35·2)
14·0% 
(9·1 to 
18·6)*
19·6 
(17·3 to 
20·9)
22·8% 
(17·8 to 
28·0)*
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category. Deaths from conflict and terrorism, despite 
substantial limitations to their enumeration, were 
estimated to have increased greatly, rising by 118·0% 
(95% UI 88·8–148·6) in 2007–17 (table 1). Of deaths 
related to conflict and terrorism, 16 200 (13 400–19 800) 
were among people aged 5–14 years and 14 300 
(11 700–17 300) occurred for children younger than 5 years; 
combined, these deaths represented 23·5% (20·5–26·9) 
of all deaths from conflict and terrorism (table 2).
Age-specific and sex-specific mortality for causes of 
death
Progress in reducing deaths was not equal between age 
groups (table 2). Total deaths from lower respiratory 
infections decreased by 36·4% (95% UI 32·2–40·6) 
between 2007 and 2017 for children younger than 
5 years, while an increase of 33·6% (31·2–36·1) was 
estimated among older adults (≥70 years). A parallel 
pattern occurred for deaths from diarrhoeal diseases 
between 2007 and 2017, which decreased by 40·6% 
(32·2–47·8) for children younger than 5 years, and 
increased by 15·0% (4·5–31·1) for adults older than 
70 years.
Decreases among aetiologies of infection over 
the wider time period 1990–2017 included decreases 
in deaths from pneumococcal pneumonia (71·2% 
[95% UI 67·1–75·1]), respiratory syncytial virus pneu-
monia (64·2% [59·4–68·2]), influenza (66·0% 
[61·6–69·9]), and H influenzae type B pneumonia 
(82·5% [80·0–85·2]) for children younger than 5 years 
(appendix 2). Among adults older than 70 years, deaths 
increased from pneumococcal pneumonia (60·4% 
[39·7–79·9]), influenza (91·1% [82·3–99·6]), and 
respiratory syncytial virus pneumonia (100·3% 
[92·4–108·6]) between 1990 and 2017. Diarrhoeal deaths 
due to C difficile increased among adults older than 
70 years (779·9% [736·7–831·0]), and for diarrhoeal 
diseases overall (44·0% [24·7–84·6]); by contrast, 
All-age deaths 
(thousands)
Under-5 deaths 
(thousands)
Deaths at age 
5–14 years (thousands)
Deaths at age 
15–49 years (thousands)
Deaths at age 
50–69 years (thousands)
Deaths at age ≥70 years 
(thousands)
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–2017
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
2017 Percentage 
change, 
2007–17
(Continued from previous page)
Adverse effects of 
medical treatment
121·6 
(103·6 to 
137·6)
16·6% 
(12·0 to 
20·9)*
13·5 
(9·8 to 
20·0)
–12·1% 
(–24·2 to 
4·9)
3·4 
(2·9 to 
4·0)
–9·4% 
(–16·9 to 
1·4)
28·6 
(23·7 to 
31·1)
4·1% 
(–1·7 to 
10·2)
31·6 
(26·7 to 
34·8)
30·8% 
(22·7 to 
40·5)*
44·5 
(39·4 to 
49·8)
32·9% 
(26·4 to 
40·6)*
Foreign body 124·1 
(119·3 to 
130·0)
1·7% 
(–1·9 to 
4·8)
38·5 
(34·9 to 
42·0)
–21·8% 
(–26·8 to 
–15·7)*
5·1 
(4·7 to 
5·6)
–4·2% 
(–9·7 to 
0·7)
21·8 
(21·0 to 
22·8)
–4·5% 
(–7·4 to 
–2·6)*
21·3 
(20·6 to 
21·9)
17·4% 
(14·4 to 
19·5)*
37·4 
(36·5 to 
38·5)
41·3% 
(38·3 to 
44·1)*
Pulmonary 
aspiration and 
foreign body in 
airway
115·7 
(111·4 to 
121·3)
1·9% 
(–1·9 to 
5·0)
37·0 
(33·9 to 
40·5)
–21·3% 
(–26·5 to 
–15·3)*
4·7 
(4·3 to 5·1)
–2·2% 
(–8·2 to 
3·2)
19·0 
(18·3 to 
19·8)
–4·5% 
(–7·2 to 
–2·5)*
19·8 
(19·1 to 
20·3)
17·1% 
(14·2 to 
19·2)*
35·3 
(34·3 to 
36·2)
41·3% 
(38·3 to 
44·2)*
Self-harm and 
interpersonal 
violence
1344·8 
(1283·1 to 
1380·4)
7·3% 
(4·6 to 
9·7)*
26·6 
(24·2 to 
28·6)
15·0% 
(8·1 to 
25·1)*
35·8 
(34·1 to 
37·4)
19·9% 
(15·8 to 
24·3)*
856·3 
(817·6 to 
882·2)
2·9% 
(0·3 to 
5·2)*
287·7 
(273·1 to 
295·9)
17·2% 
(13·2 to 
21·4)*
138·4 
(131·3 to 
143·1)
12·9% 
(8·6 to 
20·6)*
Self‐harm 793·8 
(743·5 to 
819·7)
1·1% 
(–2·6 to 
3·7)
·· ·· 8·1 
(7·3 to 
8·8)
–13·0% 
(–19·5 to 
–7·2)*
453·8 
(425·2 to 
469·5)
–6·1% 
(–9·8 to 
–3·3)*
213·1 
(199·0 to 
219·5)
14·6% 
(10·4 to 
19·0)*
118·8 
(111·8 to 
123·1)
11·2% 
(6·8 to 
19·5)*
Self‐harm by 
other specified 
means
730·0 
(678·5 to 
754·9)
0·6% 
(–3·2 to 
3·4)
·· ·· 7·7 
(6·9 to 
8·5)
–13·2% 
(–19·9 to 
–7·2)*
418·6 
(389·8 to 
434·5)
–6·2% 
(–10·1 to 
–3·4)*
195·1 
(180·2 to 
201·8)
13·8% 
(9·5 to 
18·2)*
108·6 
(101·2 to 
112·8)
10·1% 
(5·6 to 
18·7)*
Interpersonal 
violence
405·3 
(365·2 to 
431·7)
0·5% 
(–2·0 to 
3·2)
11·8 
(9·5 to 
13·7)
–21·2% 
(–29·1 to 
–7·7)*
10·8 
(9·2 to 
12·3)
–15·6% 
(–20·1 to 
–10·4)*
304·7 
(275·0 to 
322·3)
–0·5% 
(–3·1 to 2·4)
62·4 
(56·2 to 
68·5)
13·0% 
(8·0 to 
17·8)*
15·6 
(13·9 to 
17·1)
10·1% 
(4·5 to 
14·9)*
Physical violence 
by firearm
174·4 
(147·9 to 
188·9)
7·5% 
(4·3 to 
10·8)*
2·0 
(1·3 to 2·5)
–14·0% 
(–24·6 to 
2·6)
2·8 
(2·3 to 3·2)
–12·8% 
(–17·3 to 
–7·7)*
145·5 
(124·4 to 
156·8)
5·6% 
(2·3 to 
9·3)*
20·4 
(16·8 to 
22·8)
27·2% 
(22·6 to 
32·0)*
3·8 
(3·0 to 4·4)
24·7% 
(20·1 to 
29·8)*
Physical violence 
by other means
139·5 
(123·6 to 
164·4)
1·3% 
(–3·4 to 
5·6)
8·4 
(6·9 to 
9·9)
–23·8% 
(–31·7 to 
–10·5)*
6·5 
(5·5 to 7·7)
–16·4% 
(–21·9 to 
–9·7)*
90·9 
(79·9 to 
107·7)
3·5% 
(–1·9 to 
8·3)
25·9 
(23·3 to 
30·3)
8·8% 
(0·3 to 
16·3)*
7·9 
(7·0 to 9·1)
6·6% 
(–2·5 to 
13·7)
Conflict and 
terrorism
129·7 
(118·1 to 
143·2)
118·0% 
(88·8 to 
148·6)*
14·3 
(11·7 to 
17·4)
78·7% 
(33·3 to 
136·7)*
16·2 
(13·4 to 
19·9)
116·3% 
(64·0 to 
187·1)*
85·4 
(75·1 to 
98·4)
121·3% 
(80·6 to 
165·5)*
10·1 
(8·6 to 
12·1)
158·6% 
(108·0 to 
220·8)*
3·7 
(3·2 to 4·3)
144·1% 
(103·4 to 
193·7)*
Data in parentheses are 95% uncertainty intervals. YLL=years of life lost. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. *Statistically significant increases or decreases. 
Table 2: Selected causes of global deaths by age groups (<5 years, 5–14 years, 15–49 years, 50–69 years, and ≥70 years) in 2017, with percentage change between 2007 and 2017, for both 
sexes combined
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diarrhoeal disease deaths declined by 67·9% (61·1–73·1) 
between 1990 and 2017 for children younger than 5 years.
At a global scale, total deaths were greater for men than 
for women at most ages in 2017; exceptions included 
ages 80–84 years (women, 3·30 million [95% UI 
3·26–3·35] deaths; men, 3·14 million [3·10–3·18] 
deaths), 85–89 years (women, 3·02 million [2·99–3·05] 
deaths; men, 2·29 million [2·27–2·32] deaths), 
90–94 years (women, 1·94 million [1·92–1·96] deaths; 
men, 1·09 million [1·09–1·10] deaths), and 95 years 
and older (women, 858 000 deaths [852 000–864 000]; 
men, 329 000 deaths [327 000–331 000]; figure 4). Across 
causes, the largest female-to-male ratio of deaths 
occurred for neurological disorders (women ≥85 years, 
1·05 million [1·04–1·07] deaths; men ≥85 years, 
475 000 deaths [464 000–483 000]) and for cardiovascular 
diseases (women ≥85 years, 2·65 million [2·61–2·69] 
deaths; men ≥85 years, 1·56 million [1·53–1·58] deaths). 
Overall, deaths from injury were also greater for men 
than for women (3·07 million [2·95–3·14] vs 1·42 million 
[1·36–1·46]) and in each five-year age group up to age 
85 years (122 000 deaths [112 000–128 000] for men aged 
≥85 years vs 173 000 deaths [166 000–181 000] for women 
aged ≥85 years).
Patterns in rates of change in global cause-specific 
mortality rate
To better understand recent changes across a wide range 
of causes, we present the distribution of the percentage 
change in mortality rate at the country level by 
Level 1 causes and over three time periods (2003–07, 
2008–12, and 2013–17; figure 5A, 5B, 5C). At Level 1 of the 
GBD cause hierarchy, a decrease in the global percentage 
change in CSMR was evident between time periods, 
particularly for NCDs, although this varied by SDI 
quintile. Globally, the percentage change in mortality 
Figure 4: Sex difference in global mortality for 21 Level 2 causes by age, 2017
This figure represents the difference in mortality between females and males, as well as the cause composition of those differences for each GBD age group for the 
Level 2 causes in GBD 2017. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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rate for NCDs was smaller in the most recent period, 
slowing from a decrease of 7·8% (95% UI 7·5–8·2) over 
the 2003–07 period to a decrease of 2·1% (1·5–2·7) for 
2013–17. For CMNN causes, the largest decrease in 
percentage change occurred at high SDI quintiles, from 
a decrease of 8·8% (8·1–9·4) for 2003–07 to a decrease of 
3·0% (1·7–4·2) for 2013–17. Increases in the magnitude 
of the percentage change between 2003–07 and 2013–17 
for CMNN causes were estim ated at low SDI quintiles 
(from a decrease of 12·9% [11·6–14·1] for 2003–07 to a 
decrease of 13·9% [12·1–15·5] for 2013–17), low-middle 
SDI quintiles (from a decrease of 11·2% [9·8–12·6] for 
2003–07 to a decrease of 13·5% [11·4–15·5] for 2013–17), 
and middle SDI quintiles (from a decrease of 11·8% 
[10·8–12·8] for 2003–07 to a decrease of 15·6% 
[14·3–16·7] for 2013–17; figure 5A). For NCDs, the largest 
decrease in percen tage change was for high-middle SDI 
quintiles, from 11·5% (10·8–12·2) in 2003–07 to 4·5% 
(3·2–5·7) in 2013–17 (figure 5B). Across injury causes of 
death, the largest decrease in the magnitude of change 
occurred at high-middle SDI quintiles (from a decrease 
of 16·1% [15·2–16·9] for 2003–07 to a decrease of 7·0% 
[5·5–8·3] for 2013–17), while an increase in magnitude 
was estimated at low-middle SDI quintiles (from a 
decrease of 2·1% [0·7–3·6] for 2003–07 to a decrease of 
6·3% [4·0–8·6] for 2013–17; figure 5C).
Epidemiological transitions
The five leading causes of YLLs at Level 2 of the GBD cause 
hierarchy, together with injuries, by SDI level are shown in 
figure 6A. The greatest total YLLs for enteric infections in 
2017 were at low SDI (42·6 million [95% UI 37·1–50·5] 
YLLs) and low-middle SDI quintiles (33·4 million 
[28·4–40·3] YLLs), but with a large decrease from 1990, 
when YLLs were 83·2 million (69·6–95·8) in low SDI 
countries and 76·9 million (63·9–89·4) in low-middle SDI 
countries; changes in respiratory infections and tubercu-
losis followed a similar pattern. Similarly, YLLs from 
maternal and neonatal disorders remained high for both 
low SDI and low-middle SDI countries, despite a large 
decrease in total YLLs from 87·5 million (76·0–103·0) in 
1980 to 71·1 million (66·9–75·5) in 2017 for low SDI 
countries and from 98·0 million (89·2–108·0) in 1980 to 
67·3 million (62·3–72·4) in 2017 for low-middle SDI 
countries. The impact of premature death due to 
neoplasms has risen across SDI levels but with the largest 
increases in low-middle SDI countries (15·1 million 
[13·6–17·3] YLLs in 1980 vs 35·0 million [33·4–36·8] YLLs 
in 2017) and middle SDI countries (30·6 million 
[28·9–33·5] YLLs in 1980 vs 62·0 million [60·1–63·8] YLLs 
in 2017). YLLs from cardiovascular diseases increased at all 
SDI levels with the exception of high SDI countries, where 
total YLLs fell from 60·6 million (60·2–61·0) in 1980 to 
41·4 million (40·8–42·2) in 2017. Total YLLs from injuries 
(self-harm and interpersonal violence, transport injuries, 
and unintentional injuries) at certain time periods 
exceeded those from the global leading causes of death; 
from 1980 to 2017 this increase occurred most often at 
lower SDI levels, and even with YLL rates slowly decreasing 
during this time period. Low SDI countries had a decrease 
in the rate of YLLs due to self-harm, falling from 604·4 
(499·7–712·0) per 100 000 in 1980 to 441·4 (410·9–479·2) 
per 100 000 in 2017, but still remained higher than in all 
other SDI quintiles. In general, the precision of estimates 
was lower at lower SDI levels, represented by the wider 
95% UIs across causes, which reflects the availability of 
data for these locations.
Despite increasing populations and changes in 
population age-structure, YLL rates decreased across the 
five leading Level 2 GBD causes of YLLs in all SDI 
quintiles (figure 6B). Large decreases in YLL rates were 
estimated at low SDI levels for respiratory infections and 
tuberculosis (from 14 900 [95% UI 13 000–16 600] YLLs per 
100 000 in 1980 to 4750 [4505–4990] YLLs per 100 000 in 
2017). Rates for enteric infections also decreased rapidly 
at low SDI levels (from 12 600 [9990–15 300] YLLs per 
100 000 in 1980 to 3180 [2670–4090] YLLs per 100 000 in 
2017) and low-middle SDI levels (9310 [7640–11 300] YLLs 
per 100 000 in 1980 to 2020 [1670–2500] YLLs per 100 000 in 
2017). The YLL rate also decreased for cardiovascular 
diseases and for neoplasms across all SDI levels despite 
increases in the total number of YLLs. YLL rates for 
cervical cancer at low SDI levels—a cancer of infectious 
aetiology—decreased from 317 (242–373) YLLs per 
100 000 to 191 (173–211) YLLs per 100 000 (appendix 2). At 
the same time, cancers such as pancreatic cancer—driven 
substantially by non-infectious risks—increased at low 
SDI levels from 38·6 (31·2–50·0) YLLs per 100 000 to 
55·9 (51·9–60·0) YLLs per 100 000 (appendix 2).
Leading causes of global YLLs
Figure 7 shows the ongoing epidemiological shift in 
leading causes of total YLLs from CMNN diseases to NCDs 
at Level 3 of the GBD cause hierarchy over the 1990–2007 
period and for 2007–17. Globally, the leading causes of YLLs 
in 1990 were neonatal disorders (ranked first), lower 
respiratory infections (second), and diarrhoeal diseases 
(third). Estimated YLLs decreased by 21·2% (95% UI 
16·6–25·8) for neonatal disorders, by 38·6% (34·3–42·0) 
for lower respiratory infections, and by 39·5% (32·6– 45·4) 
for diarrhoeal diseases, from 1990 to 2007, and by a further 
24·1% (20·6–27·2), 25·9% (22·2–29·2), and 32·0% 
(23·9–38·6), from 2007 to 2017. YLL rates also decreased 
during the entire 1990–2017 time period for neonatal 
disorders (from 4059·1 [3802·1–4336·0] YLLs per 100 000 
to 2377·2 [2263·7–2485·1] YLLs per 100 000), lower respira-
tory infections (from 3821·4 [3509·9–4093·3] YLLs 
per 100 000 to 1515·1 [1424·8–1602·2] YLLs per 100 000), 
and diarrhoeal diseases (from 2843·6 [2415·0–3280·8] 
YLLs per 100 000 to 1009·1 [870·5–1211·0] YLLs per 
100 000). In 2017, neonatal disorders were ranked second, 
lower respiratory infections fourth, and diarrhoeal diseases 
fifth in terms of total YLLs. Estimated YLLs from ischaemic 
heart disease, ranked first, increased by 20·9% (19·0–22·9) 
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Figure 5: Distribution of percentage change in age-standardised mortality 
rate for Level 1 causes by SDI quintile
(A) Communicable, maternal, neonatal, and nutritional diseases. 
(B) Non‐communicable diseases. (C) Injuries. The figure shows the distribution of 
the percentage change in the age‐standardised mortality rate by Level 1 cause over 
the three 5‐year periods (2003–07, 2008–12, and 2013–17). The colours represent 
SDI quintiles. The solid line represents no change in the age‐standardised mortality 
rate during the specified 5‐year period. The dotted line represents the median over 
all countries in the percentage change. Countries that were outliers (>30% decrease 
or a 10% increase in a given time period) were removed from the figure in order to 
better distinguish the shape of the distribution. For communicable, maternal, 
neonatal, and nutritional diseases, the following countries were excluded: Finland, 
Georgia, Lithuania, Rwanda, Serbia, South Africa, Turkey, and Ukraine in 2003–07; 
Botswana, Croatia, Dominica, Malawi, Namibia, Zambia, and Zimbabwe in 
2008–12; and Botswana, Lesotho, South Africa, and Swaziland in 2013–17. For 
injuries, the following were excluded: Afghanistan, Burundi, Cape Verde, Comoros, 
Georgia, Iran, Iraq, Jamaica, Liberia, São Tomé and Príncipe, Spain, and Trinidad and 
Tobago in 2003–07; El Salvador, Honduras, Israel, Libya, Mexico, Myanmar, 
Palestine, Samoa, South Sudan, Sri Lanka, Syria, and Ukraine in 2008–12; and 
Afghanistan, Honduras, Iraq, Libya, Puerto Rico, Ukraine, and Yemen in 2013–17. 
SDI=Socio‐demographic Index.
from 1990 to 2007, and by a further 17·3% (15·4–19·0) 
from 2007 to 2017, while estimated YLLs from stroke, 
ranked third, increased by 12·9% (10·6–15·2) from 1990 to 
2007, and by a further 12·1% (9·9–14·1) from 2007 to 2017. 
However, decreases in YLL rates were estimated for 
ischaemic heart disease between 1990 and 2007 (20·2% 
[19·0–21·4]), and from 2007 to 2017 (9·8% [8·5–11·2]). YLL 
rates for stroke decreased by 24·0% (22·5–25·4) from 1990 
to 2007, and by 13·8% (12·3–15·5) from 2007 to 2017. Other 
leading NCD causes of YLLs in 2017 included congenital 
anomalies (ranked ninth), and chronic obstructive 
pulmonary disease (seventh); other leading CMNN causes 
included lower respiratory infections (fourth), diarrhoeal 
diseases (fifth), HIV/AIDS (eighth), and malaria (tenth). 
The only injury cause of death in the leading ten causes of 
YLLs in 2017 was road injuries, for which the YLL rate 
decreased by 18·4% (14·4–22·0) from 1990 to 2007, with a 
further decrease of 19·6% (17·5–21·6) from 2007 to 2017, 
but with an increase in relative rank as a source of total 
YLLs from eighth in 1990 to sixth in 2017.
YLLs and Socio-demographic Index level
The association between SDI level and YLL rates for 
each GBD region for each year between 1990 and 2017 is 
illustrated for CMNN causes, NCDs, and injuries in 
figure 8. In general, YLL rates decreased as SDI for a 
given region increased, with some exceptions. Among 
these, the YLL rate in southern sub-Saharan Africa was 
distinctly non-linear, increasing across CMNN causes 
even as SDI level increased before decreasing by a 
similar amount against a backdrop of rising SDI level. 
Southern sub-Saharan Africa achieved a higher SDI 
level than did other regions of sub-Saharan Africa, 
although not necessarily consistently lower YLL rates 
for CMNN causes than the other regions of sub-Saharan 
Africa. Variation in the association between YLL rate for 
NCDs and SDI in the regions of central Asia and eastern 
Europe was observed, with the highest YLL rate observed 
in 2005 for central Asia, and in 1994 for eastern Europe. 
An end to previous declines in the YLL rate for NCDs at 
highest SDI (in the most recent years) was observed for 
high-income North America and Australasia. The 
impact of fatal discontinuities can be seen in the large 
spikes in YLL rates estimated in eastern sub-Saharan 
Africa in 1994, reflecting mortality from the genocide in 
Rwanda, and in the Caribbean region where the 2010 
earthquake in Haiti resulted in a YLL rate 2·5 times 
greater than the level expected in that year given the 
SDI level.
Decomposition of driving factors in epidemiological 
change for selected causes
Changes in mortality are driven by population growth, 
population ageing, and changes in CSMR. The relative 
contributions of these factors to the change in total 
mortality for the 20 leading Level 2 causes of mortality 
from 2007 to 2017 are shown in figure 9. Population 
growth was an important contributor to increased levels 
of mortality across all causes. Declines in CSMR 
counterbalanced this effect for all but three causes—
substance use disorders, neurological disorders, and 
skin and subcutaneous diseases. Without these de-
creases in CSMR, population ageing and growth would 
have resulted in increased mortality for most causes. 
Although population ageing led to increases in total 
deaths for most leading causes, for some causes—
particularly neonatal conditions or other causes that 
primarily affect children—population ageing con-
tributed to reductions for maternal and neonatal dis-
orders (13·0%), neglected tropical diseases and malaria 
(3·9%), other infectious diseases (3·3%), other NCDs 
(1·6%), and nutritional deficiencies (1·3%). Changes in 
CSMR contributed the largest fraction to estimated 
changes in total deaths for 12 leading causes. CSMR 
contributed to 66·5% of the decrease in deaths from 
HIV/AIDS and to 8·1% of the increase in substance use 
disorders.
Discussion
High-level conclusions from the new health estimates 
of GBD 2017
General trends
The results of GBD 2017 show that, globally, CMNN 
diseases have declined steadily since 1990 in terms of 
total numbers of deaths and death rates. Global malaria 
deaths peaked in 2004 and HIV/AIDS-related deaths 
peaked in 2006, reflecting investments in the delivery of 
antiretroviral therapies, insecticide-treated bednets, and 
other interventions. NCDs, including both cardiovascular 
diseases and cancers, have risen steadily since 1990 in 
terms of total number of deaths, driven by ageing and 
population growth, while death rates have decreased, 
more slowly in the most recent years, as a result of 
improvements in prevention strategies and health-care 
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Figure 6: Trends of total YLLs 
(A) and age-standardised YLL 
rates (B) for both sexes 
combined from 1980 to 
2017, by top five GBD Level 2 
causes in 2017, by SDI quintile
Shaded areas show 
95% uncertainty intervals. 
GBD=Global Burden of 
Diseases, Injuries, and Risk 
Factors Study. 
SDI=Socio‐demographic Index. 
YLLs=years of life lost.
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Figure 7: Leading 20 Level 3 causes of global YLLs for 1990, 2007, and 2017 with percentage change in number of YLLs, in all-age and age-standardised rates for both sexes combined
Causes are connected by lines between time periods; solid lines are increases and dashed lines are decreases. For the time period 1990–2007 and for 2007–17, three measures of change are shown: 
percentage change in the number of YLLs, percentage change in the all‐age YLL rate, and percentage change in the age‐standardised YLL rate. Communicable, maternal, neonatal, and nutritional diseases 
are shown in red, non‐communicable causes in blue, and injuries in green. Statistically significant changes are shown in bold. COPD=chronic obstructive pulmonary disease. YLLs=years of life lost.
Leading causes 1990 Leading causes 2007
Mean
percentage
change
in number
of YLLs,
1990–2007
Mean
percentage
change
in all-age
YLL rate,
1990–2007
Mean
percentage
change in age-
standardised
YLL rate,
1990–2007 Leading causes 2017
Mean
percentage
change
number
of YLLs,
2007–17
Mean
percentage
change
in all-age
YLL rate,
2007–17
Mean
percentage
change in age-
standardised
YLL rate,
2007–17
Communicable, maternal, 
neonatal, and nutritional diseases
Non-communicable diseases
Injuries
  1 Neonatal disorders    1 Neonatal disorders –21·2 –37·2 –20·7    1 Ischaemic heart disease  17·3 3·9 –9·8
  2 Lower respiratory infections   2 Lower respiratory infections –38·6 –51·0 –41·1   2 Neonatal disorders –24·1 –32·8 –26·2
  3 Diarrhoeal diseases   3 Ischaemic heart disease 20·9 –3·6 –20·2   3 Stroke 12·1 –0·7 –13·8
  4 Ischaemic heart disease   4 Diarrhoeal diseases –39·5 –51·8 –42·6   4 Lower respiratory infections –25·9 –34·4 –32·6
  5 Stroke   5 HIV/AIDS 419·0 313·7 316·4   5 Diarrhoeal diseases –32·0 –39·8 –38·1
  6 Congenital anomalies   6 Stroke 12·9 –10·0 –24·0   6 Road injuries –9·7 –20·0 –19·6
  7 Tuberculosis   7 Malaria 30·1 3·7 24·2   7 COPD 13·2 0·3 –14·3
  8 Road injuries   8 Road injuries 1·3 –19·3 –18·4   8 HIV/AIDS –51·2 –56·8 –56·6
  9 Measles   9 Congenital anomalies –18·3 –34·9 –19·1   9 Congenital anomalies –15·3 –25·0 –18·8
10 Malaria 10 Tuberculosis –19·1 –35·6 –38·2 10 Malaria –34·5 –42·0 –39·2
11 COPD 11 COPD –6·9 –25·8 –37·4 11 Tuberculosis –21·2 –30·2 –33·3
12 Protein-energy malnutrition 12 Cirrhosis 22·7 –2·2 –13·6 12 Lung cancer 24·8 10·6 –4·1
13 Drowning 13 Self-harm –3·4 –23·0 –26·6 13 Cirrhosis 8·9 –3·5 –11·3
14 Self-harm 14 Lung cancer 28·8 2·6 –11·9 14 Self-harm –3·4 –14·4 –15·1
15 Meningitis 15 Meningitis –25·6 –40·7 –29·4 15 Diabetes 29·9 15·0 0·7
16 Cirrhosis 16 Chronic kidney disease 26·2 0·6 –7·2 16 Chronic kidney disease 21·0 7·2 –2·5
17 Lung cancer 17 Diabetes 56·0 24·4 7·1 17 Alzheimer's disease 38·6 22·8 –0·3
18 Tetanus 18 Drowning –40·9 –52·9 –46·3 18 Interpersonal violence –1·6 –12·9 –10·9
19 HIV/AIDS 19 Protein-energy malnutrition –43·4 –54·9 –44·7 19 Liver cancer 21·2 7·4 –4·6
20 Interpersonal violence 20 Interpersonal violence 9·5 –12·7 –13·1 20 Meningitis –25·2 –33·7 –30·2
24 Chronic kidney disease 21 Measles     24 Drowning
28 Diabetes 23 Alzheimer's disease    27 Protein-energy malnutrition
30 Liver cancer 24 Liver cancer     39 Measles
33 Alzheimer’s disease 51 Tetanus    79 Tetanus
interventions. Injury-related death rates have continued 
to decline since 1990.
Diseases of obesity
Our results show that a large number of deaths are known 
to be caused by high body-mass index, including cardio-
vascular diseases, neoplasms, dementia, asthma, hepato-
biliary diseases, as well as diabetes and kidney diseases.23 
The prevalence of obesity continues to rise in almost 
every country in the world, with more than 1 million 
deaths estimated as being due to type 2 diabetes, half a 
million deaths due to diabetes-related chronic kidney 
disease, and 180 000 due to NASH-related liver cancer 
and cirrhosis in this analysis.24 NASH is most often due to 
chronic insulin resistance secondary to obesity and might 
be present among 10–35% of the global adult population.25 
The increasing prevalence of obesity might explain 
why death rates for cardiovascular disease are no 
longer declining in Australia, Austria, Brazil, Germany, 
Netherlands, the UK, and the USA.26  There is concern 
that global rates of ischaemic heart disease and ischaemic 
stroke might begin to rise for the first time since the 
1970s.27 Increasing obesity could be the result of increased 
national wealth leading to complex changes in food 
systems, food quality, nutrition, technology, and levels of 
physical activity.28 Adult obesity has been identified as a 
key challenge to global nutrition, in particular for 
locations where malnutrition and obesity co-occur.29 
Evidence-based nutrition policies should address this 
double burden, including in countries where obesity 
prevalence is low but estimated to be increasing.24 At the 
same time, cost-effective therapies that lower elevated 
blood pressure, cholesterol, and glucose, and reductions 
in tobacco smoking will remain important interventions.
Lower respiratory and enteric infections
Given the UN General Assembly High-level Meeting on 
tuberculosis in September, 2018, it is notable that total 
deaths due to tuberculosis have decreased since 2007, 
falling most rapidly for children younger than 5 years, but 
also that the majority of tuberculosis deaths were due to 
drug-susceptible tuberculosis (88·2% [95% UI 81·4–93·3] 
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Figure 8: Co-evolution of age-standardised YLLs with SDI globally and for 
GBD regions for Level 1 causes, for both sexes combined, 1990–2017
(A) Communicable, maternal, neonatal, and nutritional diseases. 
(B) Non‐communicable diseases. (C) Injuries. Coloured lines show global and 
region values for YLL rates. Each point in a line represents one year starting at 
1990 and ending at 2017. In all regions, SDI has increased over time so progress 
in SDI is associated with points further to the right and later years for a given 
region. The black lines indicate expected trajectories for each geography 
expected on the basis of SDI alone. GBD=Global Burden of Diseases, Injuries, and 
Risk Factors Study. SDI=Socio‐demographic Index. YLLs=years of life lost. *Values 
denoted by asterisks are 18 926·3 for eastern sub‐Saharan Africa in 1994 and 
35 078·7 for the Caribbean in 2010. 
of total tuberculosis deaths in 2017). Deaths due to other 
lower respiratory infections remain a greater concern for 
children younger than 5 years due to a mortality rate more 
than ten times higher than that of tuberculosis.
Pneumococcal pneumonia was estimated to be the 
leading cause of death due to LRI in 2017 for children 
younger than 5 years, followed by respiratory syncytial 
virus pneumonia, H influenzae type B pneumonia, and 
influenza (appendix 2). Although the GBD counter factual 
methodology for causes of death does smooth over some 
epidemics, our results show that over the past 27 years, 
mortality due to influenza and pneumococcal pneumonia 
has decreased but not at the same rate, reflecting differences 
in the age patterns and vaccination trends during this time 
period.30 Declines in other vaccine-preventable causes of 
child mortality, such as measles, suggest that achievements 
are possible over short periods of time.
Reductions in deaths due to pneumonia between 1990 
and 2017 have been far larger for children than for older 
adults, with death rates due to pneumococcal pneumonia 
in adults older than 70 years having fallen by less than 
half as much as those of children, while death rates due 
to influenza and respiratory syncytial virus pneumonia 
have changed only minimally (appendix 2). 
Similar patterns are seen for deaths due to enteric 
infections. Deaths related to C difficile increased among 
older adults, with only moderate declines in deaths due to 
other infectious causes of diarrhoea, while diarrhoeal 
deaths for children younger than 5 years continued to 
decline. The epidemic of C difficile might reflect increased 
incidence and pathogenicity of this bacterium, due to 
changing patterns of antibiotic resistance, comorbidity, 
and susceptibility among an ageing adult population.31 The 
age pattern for deaths due to multiple infectious diseases 
reflects investments in interventions that reduce childhood 
mortality as well as the challenges of delivering more 
complex health interventions to older adults with comorbid 
conditions. Evidence-based health policies will need to 
consider whether large increases in the use of antibiotics32 
are leading to meaningful reductions in adult infections.33
The geography of conflict
Conflict-related deaths represent the fastest growing cause 
of injury-related deaths. Since 2007, conflicts have resulted 
in 1·14 million deaths, concentrated in the North Africa 
and Middle East region.34 Parts of South Asia, sub-
Saharan Africa, and Latin America are also ex periencing 
increasing rates of conflict-related deaths since 2007. 
Childhood deaths due to conflict were dis proportionate. 
Regions with ongoing conflict are likely to face recurring 
health emergencies and present a particular challenge for 
achieving global development targets.35 Regional efforts to 
promote public health in areas with ongoing conflict, such 
as the recently established Africa Centres for Disease 
Control and Prevention,36 might help to support 
surveillance and implementation of evidence-based health 
policies in these often dire situations.
Countervailing patterns
The identification of exceptions to any large-scale patterns 
is an important result of GBD 2017. There are notable 
exceptions to the overall pattern of increasing total deaths 
from NCDs. For example, the total number of deaths from 
various congenital anomalies, including neural tube 
defects, congenital heart anomalies, and orofacial clefts 
decreased during the past decade. Some of the decline 
in neural tube defects and orofacial clefts could be related 
to improved nutritional status of women and more 
widespread introduction of folic acid fort ification 
programmes, and some reductions might also be related 
to improvements in prenatal screening, access to abortion, 
supportive and interventional care services for infants 
born with birth defects, and broader reductions in 
infectious diseases to which such infants are especially 
susceptible.37 Conversely, for selected causes, both the 
number of deaths and death rate are increasing, including 
opioid, cocaine, amphetamine, and other drug use dis-
orders, and liver cancers due to hepatitis B and hepatitis C. 
Inadequate access to treatment for hepatitis C, and 
restricted implementation of risk-prevention and treat-
ment strategies for addiction and substance abuse might 
explain, in part, why death rates due to these preventable 
diseases are increasing.38 The total number of fall-related 
deaths has also risen steadily with no decline in rates, 
reflecting the way in which population ageing might be 
having a differential effect on injury-related deaths.
Public health significance
Recent plateaus in mortality rates
The results of GBD 2017 show that declines in death 
rates of some common diseases are slowing or have 
ceased, primarily for NCDs. Declines in cardiovascular 
disease and neoplasms are slowing for many high-
income countries. This observation is clearest for 
estimates at the subnational level, where deaths from 
these causes are increasing for some states in the USA 
and local authorities in the UK. Medications that lower 
blood pressure and blood cholesterol, and therefore the 
risk of atherosclerotic vascular disease events and deaths, 
are among the most cost-effective interventions available 
to health systems but are not being delivered effectively. 
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Increasing evidence of a plateau in the decline, or even 
increases, in atherosclerotic vascular diseases should 
drive investment towards innovative systems that can 
effectively deliver these medications as well as public 
health measures and behaviour changes that need to 
accompany them.39 Plateaus in mortality are not restricted 
to high-income countries and can also be seen for leading 
causes in low-income countries. Decreases in the death 
rate of malaria have slowed for many regions, perhaps 
related to a period of slowing in the decline in incident 
infections observed in many regions between 2011 and 
2013. Improved malaria mortality surveillance will be 
required to understand these most recent patterns.
Beyond the leading causes of death
Some common causes of death receive relatively less 
attention from the global community, because of their 
position as second or lower-ranked causes within a 
larger category. These highly ranked but non-leading 
causes include stomach cancer, asthma, syphilis, chronic 
kidney disease, congenital heart disease, and rheumatic 
heart disease. These causes combined resulted in more 
than 3 million deaths in 2017. Deaths due to these causes 
are at least partially amenable to primary or secondary 
pre vention strategies, suggesting that improvements 
in the continuum of care, including in food quality, 
sanitation, diagnosis and screening, ongoing case 
management, and increased access to essential 
medicines via expanded universal health coverage, will 
have an important role in their reduction.40 GBD 2017 
added several important but less heralded causes of 
death, including liver cancer due to NASH, subarachnoid 
haemorrhage, and non-rheumatic valvular heart dis-
eases. These diseases sometimes do not have the more 
easily addressed risk exposures associated with the 
leading causes of death such as LRI, HIV/AIDS, lung 
cancer, or ischaemic heart disease, or they might be 
prevalent in locations where medical technologies or 
effective health-care interventions are less widely 
available. Diseases ranked lower within a larger cause 
category also might not benefit from the large-scale, 
focused advocacy efforts for the leading causes of death 
yet represent important future targets for research and 
public health. A rational, disease-burden-based approach 
to priority setting for health policy, now being adopted in 
some countries,41 might help to accelerate the scale-up of 
interven tions that will have the largest impact on 
disability and pre mature death.
Emerging diseases and disorders due to antibiotic and opioid use
Although GBD provides estimates starting in the year 
1980, changes in the most recent years are of particular 
importance for governments working to improve 
re sponsive ness to emerging threats to human health. 
Figure 9: Percentage change in all-age mortality by Level 2 causes at the global level from 2007 to 2017, due to population growth, population ageing, 
and cause-specific mortality
Mental disorders, for which there were 272 deaths globally in 2007 and 327 deaths globally in 2017, are not shown separately but are included in the all‐cause category.
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Since 2007, rapid increases in death rates have been 
observed for a small number of diseases and disorders, 
including dengue, extensively drug-resistant tuberculosis, 
cellu litis, C difficile diarrhoea, and opioid, cocaine, and 
amphetamine use disorders. Of the infectious causes 
(other than dengue, the increase of which might reflect 
changes in the range of its primary vector, Aedes aegypti), 
increased patho genicity due to antibiotic use or resis tance 
is likely to be a major factor. Rapid increases in opioid-
related deaths, particularly in the USA and Canada42 
but also in other high SDI locations,43 have been attributed 
in part to wider availability of high-potency opioid 
analgesics44 and to international illegal trade of synthetic 
opioids.45
These emerging causes are associated with wider use 
of pharmaceuticals. The global health armamentarium 
will need to expand beyond its traditional approach of 
increasing access to treatment to include antimicrobial 
stewardship46 and programmes to manage the use of 
synthetic opioids. Policy makers will need particular 
expertise to balance these initiatives with equally vocal 
calls to address sepsis47 and cancer pain48,49 as global 
health priorities.
Epidemiological transition for injuries and cancer
The epidemiological transition is most commonly 
thought of as a decline in CMNN deaths and a rise in 
chronic NCDs. GBD 2017 shows that deaths due to 
injuries and cancers also undergo characteristic 
transitions. Although specific locations have substantial 
spikes in injury-related mortality during natural disasters 
or conflicts, the mortality rates from specific injuries 
can vary as a function of development along the SDI 
spectrum. Road injuries, for example, might initially 
increase early in development when more of the 
population has exposure to transport-related injuries. As 
development increases, however, it becomes increasingly 
important for countries to invest in specific resources 
that can protect against mortality from these injuries, 
such as advanced trauma care, emergency medical 
response, vehicle safety initiatives such as seatbelt laws, 
and interventions to reduce distractions while driving.50
By contrast, other injuries such as falls and self-harm 
might more reliably decline as SDI increases and access 
to medical care improves. For example, deaths related to 
self-harm have declined drastically throughout China, 
possibly because of improved economic prospects among 
the poorest individuals and decreased access to lethal 
pesticides.51 There are also exceptions where deaths 
related to self-harm are not declining, including Australia, 
Brazil, the Philippines, Turkey, and the USA. Further 
research is needed to fully examine the underlying factors 
driving these divergent trends.
The epidemiological transition can also be observed 
among the different types of cancer. In many countries 
with lower SDI, cancers of infectious aetiology52 or related 
to poor nutrition are decreasing, whereas cancers typically 
associated with obesity and alcohol consumption are 
becoming more common. The concept that future 
demands on health systems might be, at least in part, 
predictable is an attractive feature of the theory of 
epidemiological transition that merits further exploration, 
such as recent work to produce health forecasts using 
results of the GBD study and projections of SDI.53
Continuous quality improvement
GBD 2017 has developed new methods to address the 
observation that some common causes of death are 
reported by surveillance systems as having implausible 
trends across time and varying widely between coun-
tries.54,55 This concern has been noted for dementia and 
Parkinson’s disease, where there has been a rapid rise in 
reported deaths attributed to these causes despite stable 
incidence and case fatality in most epidemiological 
studies.56–60 A new analysis by GBD 2017 uses 35 years of 
person-level underlying and intermediate cause of death 
data from the USA—a database of 80·4 million deaths—
to better understand how physicians are choosing from a 
range of alternative diseases when selecting an underlying 
cause of death that was actually dementia. Countries 
should consider better use of important contextual 
data already being collected, such as intermediate and 
immediate causes of death, to improve the stability and 
robustness of their mortality surveillance systems. Both 
New Zealand and Brazil have already made intermediate 
cause of death data available for this kind of analysis, and 
other countries should consider this low-cost, high-
impact path in the future.
Changes in health estimates between GBD 2016 and 
GBD 2017
Each iteration of GBD re-analyses the entire time series 
by use of newly available data sources from across all 
estimation years and continually improved methods. 
New data and modelling approaches effectively improve 
model validity and decrease uncertainty from various 
sources with the consequence that estimates for a given 
cause, location, and year might differ between GBD 
iterations. The magnitude of these differences between 
GBD 2017 and GBD 2016 is presented in figure 1. Below 
we discuss some specific data and methodology changes 
underlying distinct differences in estimation.
A novel, integrated demographic assessment of popu-
lation, fertility, and all-cause mortality was completed for 
GBD 2017. This development affected all causes because of 
the inclusion of population estimates in age-sex splitting 
algorithms, but most directly affected maternal and 
HIV/AIDS-related mortality estimates. The GBD 2017 
assess ment of the proportion of all-cause deaths due to 
maternal and neonatal disorders (3·7% [95% UI 3·5–3·8]) 
was similar to that of GBD 2016 (3·6% [3·4–3·8]), with the 
difference largely due to addition of new data and expanded 
subnational estimation. Additionally, GBD 2017 combined 
maternal and neonatal conditions as a category at Level 2 of 
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the cause hierarchy; as a result, causes within this grouping 
are now separately reported at Level 3 (rather than Level 2), 
with neonatal conditions appearing for the first time as the 
second most common Level 3 source of YLLs.
Access to additional data sources led to several 
differences in estimation, including the addition of 
2778 deaths in children younger than 5 years attributable 
to the inclusion of additional VA data for Nigeria61—a high-
population, high-burden location—in GBD 2017. Similarly, 
introduction of these new data resulted in a decrease in 
estimated mortality from malaria, so that the GBD 2017 
estimate for the year 2016 included 78 200 fewer deaths for 
Nigeria than were estimated by GBD 2016 for that year.
GBD 2017 also included an additional 502 country-
years of cancer registry data and 127 country-years of 
VR system data compared with GBD 2016; 49·6% of the 
new cancer registry data came from the newly released 
Cancer Incidence in Five Continents (CI5 XI) database.62
For GBD 2017, major changes to the modelling strategy 
for dementia and Parkinson’s disease included reallocating 
deaths from causes identified in multiple cause of death 
data in the USA as the likely alternative cause of death if 
dementia had not been assigned as the underlying cause. 
This approach allowed for more accurate identification of 
deaths to be reassigned to dementia and Parkinson’s 
disease, including a sizeable proportion that had been 
assigned to garbage code categories as well as common, 
more specific causes of death in people with dementia or 
Parkinson’s disease.
Changes in data sources and methods have led to 
improved estimates for several causes. Comparing the 
most recent decade between GBD 2016 and GBD 2017, 
2006 to 2016, the estimated increase in deaths from drug 
use disorders in GBD 2017 (55·9% [95% UI 53·1–58·8]) 
was greater than the estimated increase for the same 
period in GBD 2016 (15·2% [4·8–26·4]), driven by a better 
fit to most recent years of data in the USA and the use 
of more appropriate covariates, including sales of pre-
scription opioids by country and the prevalence of 
injecting drug use. Estimates of HIV/AIDS deaths among 
children in 2016 were higher in GBD 2017 (84 500 deaths 
[75 800–94 200]) than those (61 700 deaths [56 000–68 000]) 
estimated by GBD 2016 for the same year. In countries 
with high-quality VR data, child incidence was adjusted to 
produce mortality estimates that better align with 
recorded HIV/AIDS deaths. Additionally, the paediatric 
HIV/AIDS mortality estimates were produced with the 
CD4-count-specific mortality and progression parameters 
developed by UNAIDS.63
Comparison of GBD 2017 to other estimates
The primary comparison dataset for malaria is the World 
Malaria Report (WMR)64 produced by WHO. As the 
Malaria Atlas Project produces results for both GBD and 
the many countries in the WMR, it is not surprising that 
these results align closely. WHO hepatitis estimates for 
2015 present combined mortality results for different 
stages of viral hepatitis infection (acute hepatitis, 
cirrhosis, and liver cancer), but the methods and data 
sources used to generate these estimates are incompletely 
described;65 at least some results were based on additional 
modelling of GBD 2013 results. Total deaths were 
estimated at 1·34 million by WHO in 2015, compared 
with 1·07 million (95% UI 1·02–1·11) for the same year 
in the present analysis (139 000 deaths [116 000–158 000] 
for acute hepa titis, 306 000 deaths [281 000–305 000] for 
hepatitis B cirrhosis, 165 000 deaths [159 000–172 000] for 
hepatitis B liver cancer, 294 000 deaths [268 000–319 000] 
for hepatitis C cirrhosis, and 165 000 deaths 
[159 000–172 000] for hepatitis C liver cancer).
The estimates from the WHO Maternal Child 
Epidemiology Estimation (MCEE) for cause-specific 
under-5 mortality in 2016 at the global level differ from 
those produced by GBD 2017. Notable differences 
include the absence of estimates for haemoglobino-
pathies by WHO-MCEE and estimates of deaths from 
congenital anomalies (303 000 deaths) that are lower 
than those estimated by GBD (516 000 deaths [95% UI 
446 000–595 000]). Lower congenital estimates are 
primarily due to inclusion of VA studies by WHO-MCEE 
that were assessed for GBD but found to be unreliable 
and implausibly low, as described above.66 The number of 
LRI deaths estimated by GBD 2017 for children younger 
than 5 years (828 000 deaths [774 000–884 000]) was 
smaller globally than the number estimated by the MCEE 
group (920 000 deaths in 2015), with the main differences 
in India and Pakistan. GBD uses the sample registration 
system by Indian state, whereas the MCEE group uses 
the Million Deaths Study and the INDEPTH network 
mortality data,66 driving much of the difference between 
those estimates and those from the present study. Iuliano 
and colleagues67 recently estimated 290 000–650 000 seas-
onal influenza-associated respiratory deaths globally. 
Differences in modelling strategy and underlying premise 
account for much of the difference in that estimate from 
those of the present study. Chiefly, the estimate of Iuliano 
and colleagues accounts for any deaths that potentially 
could be associated with influenza, whereas the GBD 2017 
approach estimates only LRI deaths attributable to 
influenza within the GBD counterfactual framework. The 
UN Maternal Mortality Estimation Inter-Agency Group 
(MMEIG) has not updated its estimates since 2015.68
The Globocan project, led by the International Agency 
for Research on Cancer (IARC),69 provides estimates of the 
global and national-level cancer burden for 2012. Whereas 
Globocan only estimates cancer mortality for a single year, 
GBD provides mortality estimates for all diseases over 
time, including for selected subnational locations. This 
approach allows GBD to account for unknown causes of 
death by redistributing these to the most likely underlying 
cause—including cancer. To estimate cancer mortality, 
six different methods are used in Globocan. In GBD, 
cancer mortality was estimated with a single ensemble 
model approach. Despite these differences, estimates at 
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the global level were similar, with Globocan estimating 
8·2 million cancer deaths and GBD estimating 
8·38 million (95% UI 8·26–8·48) for the year 2012 
(appendix 2).
GBD 2017 estimates of deaths from all cardiovascular 
diseases were generally similar to WHO estimates from 
recent years. Non-GBD estimates for specific cardio-
vascular diseases are less common. A recent study 
estimating global and national deaths due to alcoholic 
cardiomyopathy used a model based on all-cause mortality 
and alcohol-attributable fractions.70 The investigators esti-
mated 25 997 deaths (95% CI 17 358–49 096) in 2015 
compared with GBD 2017 estimates of 90 700 (95% UI 
82 800–97 500). Higher GBD estimates are the result of 
the garbage code redistribution method used by GBD, 
although the geo graphical distribution of deaths by 
country is similar for both studies. In GBD, a substantial 
number of garbage-coded deaths (eg, heart failure, senility, 
and atherosclerosis) are redistributed to cardiovascular 
disease causes, including ischaemic heart disease and 
alcoholic cardiomyopathy.
In this iteration, we estimated that 136 000 deaths were 
from drug use disorders globally in 2015; by contrast, the 
2017 World Drug Report by the UN Office on Drugs 
and Crime (UNODC) estimated a total of 191 000 drug-
attributable deaths in 2015. Differences might reflect the 
fact that UNODC data are reported directly by member 
states and the definition of drug-related deaths differs 
between countries; some countries include overdose 
deaths, whereas others can include deaths for which 
drug use was considered to be a contributing factor.
A direct comparison on a global level is possible for 
selected injuries and locations. Globally, WHO estimated 
1·25 million road traffic deaths in 2013,71 a lower figure 
than that of GBD 2017, which estimated 1·32 million 
(95% UI 1·29–1·36) road traffic deaths for the year 2013. 
Although this difference might be partly due to different 
modelling strategies, the relatively lower estimate 
was also present in locations with reliable VR data—
for example, for the USA, WHO estimated 34 064 deaths 
for 2013, whereas the GBD 2017 study estimated 41 600 
deaths (39 800–43 000). These differences might also 
be partly due to modelling differences from internal 
consistency requirements in the GBD framework, as 
well as differences in ICD mapping to the underlying 
cause of death. Our estimate of 645 000 deaths 
(559 000–679 000) globally due to falls was only slightly 
lower than WHO’s estimate for 2015 of 646 000 deaths,72 
and a similar difference was present for estimates 
of deaths from self-harm,73 with WHO estimating 
approximately 800 000 deaths annually in recent years 
and GBD esti mating approximately 800 000–820 000 
deaths annually in recent years.
Limitations
Limitations remain in GBD 2017 despite advances in 
methodology that addressed some of the difficulties of 
estimating cause-specific mortality at global, regional, 
national, and subnational scales. Limitations that 
primarily affect specific causes—such as identification of 
covariates to address the non-linearity in the association 
between some injuries and the SDI or accounting for 
changes in awareness of NASH as an explanation for 
estimated increased mortality—are described in detail in 
appendix 1 (section 3). Here, we identify limitations with 
applicability across many causes. First, time lags in 
available data, absence of data from specific regions, age 
groups, or time periods, or unreliability in the data that 
are available—as is the case for malaria estimation, where 
a key limitation is the rare and punctuated nature of 
nationally representative surveys of parasite rate; or 
diarrhoea mortality estimation, where data are restricted 
among adults and for the geographical areas with the 
highest mortality levels—can affect the precision of 
estimations. Second, the accuracy with which underlying 
cause of death is assigned is a key limitation for both VR 
data and VA data sources, which is complicated by 
multimorbidity at the time of death. GBD 2017 makes 
substantial efforts to enhance the comparability of results 
by applying corrections for under-registration and garbage 
code redistribution algorithms. Levels or estimated time 
trends might still be affected by systematic problems in 
selected locations. Third, to separately estimate type 1 and 
type 2 diabetes we used a regression method to redistribute 
unspecified diabetes deaths on the basis of the specified 
type 1 and type 2 deaths. As the proportion of unspecified 
deaths is high, even in many good-quality VR systems, the 
type-specific estimates are more uncertain. An additional 
complication is that many excess deaths in people 
with diabetes are preferentially coded to macrovascular 
complications such as stroke and ischaemic heart disease. 
This approach leaves the more direct consequences of 
diabetes such as ketoacidosis or hyperosmolar coma as 
reasons to code a death to diabetes as the underlying 
cause. These complications can affect type 1 and type 2 
diabetes differently. Ascertaining the correct proportions 
of diabetes deaths that should be assigned to type 1 or 
type 2 diabetes is difficult. Fourth, the percentage of well 
certified data is a useful indicator of data completeness; 
however, quality or accuracy in cause of death certification 
is not necessarily indicated by a low level of identified 
garbage coding for a given location. Fifth, some sources of 
uncertainty will not have been captured by the GBD 2017 
estimation process, including among the covariates used 
in models. Sixth, although some causes use negative 
binomial modelling approaches to improve estimation 
with overdispersed data, we have not yet developed a 
standardised empirical approach for selecting causes to 
use this method. Seventh, the ICD coding convention 
does not distinguish between suicide and deaths associ-
ated with self-harm, and thus our estimate includes both 
intentional and unintentional self-harm. Finally, because 
GBD results are a combination of data and estimation, 
lags in data reporting mean that estimates for the most 
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recent years rely more on the modelling process, as do 
estimates for locations with low levels of data complete-
ness. However, for causes with scarce data, the provision 
of an estimate with an adequate measure of uncertainty is 
preferable to no information, and identification of these 
causes is an important step in improving the certification 
of deaths globally.
Future directions
Re-estimation of the entire GBD mortality time series 
from 1980 onwards as part of the GBD annual cycle 
offers multiple opportunities for strengthening global 
health estimates. This kind of continuous quality 
improvement74 remains a hallmark of GBD. However, 
the task of informing national and global policy responses 
to changing mortality patterns is still reliant on cause of 
death information that in many cases remains sparse or 
outdated. The improvements in estimation methods 
represented in each iteration of GBD do not mitigate the 
pressing need for investments in data and surveillance 
on a global scale.
Further work is needed to address the misclassification 
that occurs in VR data. For example, multiple death codes 
can be assigned for drug overdoses, and these coding and 
attribution issues can vary across countries. Additional 
work is needed to understand the impact of rapid 
diagnostic testing on the GBD malaria model. Better 
approaches are needed to make use of location, age, and 
time patterns when assigning deaths where the disease 
subtype remains unspecified, such as for diabetes and 
stroke. More specific subtypes will need to be added for 
other conditions, such as vascular dementia, breast cancer, 
and lung cancer. Multiple cause of death data should be 
put to wider use. Information about intermediate causes 
of death can be used to improve estimation of disorders 
that exist as final common pathways to death, including 
sepsis, heart failure, and acute kidney injury. Multiple 
cause of death data might also better inform maternal 
and neonatal death estimates, especially if combined 
models can borrow strength across related conditions. 
Associations between inborn and congenital diseases, 
developmental disorders, and infectious or malnutrition-
related deaths are also likely. Additional data about 
maternal exposures, including tobacco, air pollution, 
alcohol, and obesity, could lead to cause-specific mortality 
estimates among newborn babies.
An important goal of the GBD collaboration is the 
production of estimates for increasingly granular 
locations, down to areas as small as a 5 × 5 km grid. 
Estimates of diarrhoea, LRI, and tuberculosis mortality 
would all have greater impact if produced with a higher 
degree of geographical precision. Ascertaining the 
location of injury for causes such as road injuries, falls, 
drowning, and fires is also an important goal and could 
improve understanding of where investments in civil 
infrastructure might most benefit the population. Injury 
models could also make use of satellite and other open 
data sources to incorporate more information about the 
presence and use of improved roads, use of seatbelts, or 
availability of firearms.
Conclusion
GBD 2017 reveals both long-term and more recent 
patterns in global health. The number of deaths due to 
communicable, maternal, neonatal, and nutritional 
causes continues to decline, although at varying rates, 
whereas the number of deaths from NCDs is increasing 
and those from injuries remains stable. There is evidence 
that previously observed declines in death rates of some 
common diseases are now either slowing or have ceased, 
primarily for NCDs. Mortality estimates are being made 
with increasing detail as a result of improved methods 
for correcting biases in the data and the addition of new 
data sources, new causes, and new subnational locations. 
The GBD collaboration has expanded to include experts 
from 140 countries, with formal government engagement 
leading to the production of subnational estimates. 
Investments are being made to extend the reach of high-
quality mortality surveillance and VR. SDG targets tied to 
mortality rates will be able to use annual GBD results to 
benchmark progress and identify best practices in 
every country.
GBD 2017 Causes of Death Collaborators
Gregory A Roth, Degu Abate, Kalkidan Hassen Abate, Solomon M Abay, 
Cristiana Abbafati, Nooshin Abbasi, Hedayat Abbastabar, Foad Abd-Allah, 
Jemal Abdela, Ahmed Abdelalim, Ibrahim Abdollahpour, 
Rizwan Suliankatchi Abdulkader, Haftom Temesgen Abebe, Molla Abebe, 
Zegeye Abebe, Ayenew Negesse Abejie, Semaw F Abera, 
Olifan Zewdie Abil, Haftom Niguse Abraha, Aklilu Roba Abrham, 
Laith Jamal Abu-Raddad, Manfred Mario Kokou Accrombessi, 
Dilaram Acharya, Abdu A Adamu, Oladimeji M Adebayo, 
Rufus Adesoji Adedoyin, Victor Adekanmbi, Olatunji O Adetokunboh, 
Beyene Meressa Adhena, Mina G Adib, Amha Admasie, Ashkan Afshin, 
Gina Agarwal, Kareha M Agesa, Anurag Agrawal, Sutapa Agrawal, 
Alireza Ahmadi, Mehdi Ahmadi, Muktar Beshir Ahmed, Sayem Ahmed, 
Amani Nidhal Aichour, Ibtihel Aichour, Miloud Taki Eddine Aichour, 
Mohammad Esmaeil Akbari, Rufus Olusola Akinyemi, Nadia Akseer, 
Ziyad Al-Aly, Ayman Al-Eyadhy, Rajaa M Al-Raddadi, Fares Alahdab, 
Khurshid Alam, Tahiya Alam, Animut Alebel, Kefyalew Addis Alene, 
Mehran Alijanzadeh, Reza Alizadeh-Navaei, Syed Mohamed Aljunid, 
Ala’a Alkerwi, François Alla, Peter Allebeck, Jordi Alonso, 
Khalid Altirkawi, Nelson Alvis-Guzman, Azmeraw T Amare, 
Leopold N Aminde, Erfan Amini, Walid Ammar, Yaw Ampem Amoako, 
Nahla Hamed Anber, Catalina Liliana Andrei, Sofia Androudi, 
Megbaru Debalkie Animut, Mina Anjomshoa, Hossein Ansari, 
Mustafa Geleto Ansha, Carl Abelardo T Antonio, Palwasha Anwari, 
Olatunde Aremu, Johan Ärnlöv, Amit Arora, Monika Arora, Al Artaman, 
Krishna K Aryal, Hamid Asayesh, Ephrem Tsegay Asfaw, Zerihun Ataro, 
Suleman Atique, Sachin R Atre, Marcel Ausloos, 
Euripide F G A Avokpaho, Ashish Awasthi, 
Beatriz Paulina Ayala Quintanilla, Yohanes Ayele, Rakesh Ayer, 
Peter S Azzopardi, Arefeh Babazadeh, Umar Bacha, Hamid Badali, 
Alaa Badawi, Ayele Geleto Bali, Katherine E Ballesteros, Maciej Banach, 
Kajori Banerjee, Marlena S Bannick, Joseph Adel Mattar Banoub, 
Miguel A Barboza, Suzanne Lyn Barker-Collo, Till Winfried Bärnighausen, 
Simon Barquera, Lope H Barrero, Quique Bassat, Sanjay Basu, 
Bernhard T Baune, Habtamu Wondifraw Baynes, 
Shahrzad Bazargan-Hejazi, Neeraj Bedi, Ettore Beghi, 
Masoud Behzadifar, Meysam Behzadifar, Yannick Béjot, 
Bayu Begashaw Bekele, Abate Bekele Belachew, Ezra Belay, 
Yihalem Abebe Belay, Michelle L Bell, Aminu K Bello, Derrick A Bennett, 
Isabela M Bensenor, Adam E Berman, Eduardo Bernabe, 
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1775
Robert S Bernstein, Gregory J Bertolacci, Mircea Beuran, 
Tina Beyranvand, Ashish Bhalla, Suraj Bhattarai, Soumyadeeep Bhaumik, 
Zulfiqar A Bhutta, Belete Biadgo, Molly H Biehl, Ali Bijani, Boris Bikbov, 
Ver Bilano, Nigus Bililign, Muhammad Shahdaat Bin Sayeed, 
Donal Bisanzio, Tuhin Biswas, Brigette F Blacker, Berrak Bora Basara, 
Rohan Borschmann, Cristina Bosetti, Kayvan Bozorgmehr, 
Oliver J Brady, Luisa C Brant, Carol Brayne, Alexandra Brazinova, 
Nicholas J K Breitborde, Hermann Brenner, Paul Svitil Briant, 
Gabrielle Britton, Traolach Brugha, Reinhard Busse, Zahid A Butt, 
Charlton S K H Callender, Ismael R Campos-Nonato, 
Julio Cesar Campuzano Rincon, Jorge Cano, Mate Car, Rosario Cárdenas, 
Giulia Carreras, Juan J Carrero, Austin Carter, Félix Carvalho, 
Carlos A Castañeda-Orjuela, Jacqueline Castillo Rivas, Chris D Castle, 
Clara Castro, Franz Castro, Ferrán Catalá-López, Ester Cerin, 
Yazan Chaiah, Jung-Chen Chang, Fiona J Charlson, Pankaj Chaturvedi, 
Peggy Pei-Chia Chiang, Odgerel Chimed-Ochir, 
Vesper Hichilombwe Chisumpa, Abdulaal Chitheer, Rajiv Chowdhury, 
Hanne Christensen, Devasahayam J Christopher, Sheng-Chia Chung, 
Flavia M Cicuttini, Liliana G Ciobanu, Massimo Cirillo, Aaron J Cohen, 
Leslie Trumbull Cooper, Paolo Angelo Cortesi, Monica Cortinovis, 
Ewerton Cousin, Benjamin C Cowie, Michael H Criqui, 
Elizabeth A Cromwell, Christopher Stephen Crowe, John A Crump, 
Matthew Cunningham, Alemneh Kabeta Daba, Abel Fekadu Dadi, 
Lalit Dandona, Rakhi Dandona, Anh Kim Dang, Paul I Dargan, 
Ahmad Daryani, Siddharth K Das, Rajat Das Gupta, José Das Neves, 
Tamirat Tesfaye Dasa, Aditya Prasad Dash, Adrian C Davis, 
Nicole Davis Weaver, Dragos Virgil Davitoiu, Kairat Davletov, 
Fernando Pio De La Hoz, Jan-Walter De Neve, Meaza Girma Degefa, 
Louisa Degenhardt, Tizta T Degfie, Selina Deiparine, 
Gebre Teklemariam Demoz, Balem Betsu Demtsu, 
Edgar Denova-Gutiérrez, Kebede Deribe, Nikolaos Dervenis, 
Don C Des Jarlais, Getenet Ayalew Dessie, Subhojit Dey, 
Samath D Dharmaratne, Daniel Dicker, Mesfin Tadese Dinberu, 
Eric L Ding, M Ashworth Dirac, Shirin Djalalinia, Klara Dokova, 
David Teye Doku, Christl A Donnelly, E Ray Dorsey, Pratik P Doshi, 
Dirk Douwes-Schultz, Kerrie E Doyle, Tim R Driscoll, Manisha Dubey, 
Eleonora Dubljanin, Eyasu Ejeta Duken, Bruce B Duncan, 
Andre R Duraes, Hedyeh Ebrahimi, Soheil Ebrahimpour, 
Dumessa Edessa, David Edvardsson, Anne Elise Eggen, 
Charbel El Bcheraoui, Maysaa El Sayed Zaki, Ziad El-Khatib, 
Hajer Elkout, Christian Lycke Ellingsen, Matthias Endres, 
Aman Yesuf Endries, Benjamin Er, Holly E Erskine, Babak Eshrati, 
Sharareh Eskandarieh, Reza Esmaeili, Alireza Esteghamati, 
Mahdi Fakhar, Hamed Fakhim, Mahbobeh Faramarzi, 
Mohammad Fareed, Farzaneh Farhadi, Carla Sofia E sá Farinha, 
Andre Faro, Maryam S Farvid, Farshad Farzadfar, 
Mohammad Hosein Farzaei, Valery L Feigin, Andrea B Feigl, 
Netsanet Fentahun, Seyed-Mohammad Fereshtehnejad, 
Eduarda Fernandes, Joao C Fernandes, Alize J Ferrari, 
Garumma Tolu Feyissa, Irina Filip, Samuel Finegold, Florian Fischer, 
Christina Fitzmaurice, Nataliya A Foigt, Kyle J Foreman, Carla Fornari, 
Tahvi D Frank, Takeshi Fukumoto, John E Fuller, Nancy Fullman, 
Thomas Fürst, João M Furtado, Neal D Futran, Silvano Gallus, 
Alberto L Garcia-Basteiro, Miguel A Garcia-Gordillo, William M Gardner, 
Abadi Kahsu Gebre, Tsegaye Tewelde Gebrehiwot, 
Amanuel Tesfay Gebremedhin, Bereket Gebremichael, 
Teklu Gebrehiwo Gebremichael, Tilayie Feto Gelano, 
Johanna M Geleijnse, Ricard Genova-Maleras, 
Yilma Chisha Dea Geramo, Peter W Gething, Kebede Embaye Gezae, 
Mohammad Rasoul Ghadami, Reza Ghadimi, 
Khalil Ghasemi Falavarjani, Maryam Ghasemi-Kasman, 
Mamata Ghimire, Katherine B Gibney, Paramjit Singh Gill, 
Tiffany K Gill, Richard F Gillum, Ibrahim Abdelmageed Ginawi, 
Maurice Giroud, Giorgia Giussani, Shifalika Goenka, Ellen M Goldberg, 
Srinivas Goli, Hector Gómez-Dantés, Philimon N Gona, 
Sameer Vali Gopalani, Taren M Gorman, Atsushi Goto, 
Alessandra C Goulart, Elena V Gnedovskaya, Ayman Grada, 
Giuseppe Grosso, Harish Chander Gugnani, 
Andre Luiz Sena Guimaraes, Yuming Guo, Prakash C Gupta, 
Rahul Gupta, Rajeev Gupta, Tanush Gupta, Reyna Alma Gutiérrez, 
Bishal Gyawali, Juanita A Haagsma, Nima Hafezi-Nejad, 
Tekleberhan B Hagos, Tewodros Tesfa Hailegiyorgis, 
Gessessew Bugssa Hailu, Arvin Haj-Mirzaian, Arya Haj-Mirzaian, 
Randah R Hamadeh, Samer Hamidi, Alexis J Handal, Graeme J Hankey, 
Hilda L Harb, Sivadasanpillai Harikrishnan, Josep Maria Haro, 
Mehedi Hasan, Hadi Hassankhani, Hamid Yimam Hassen, 
Rasmus Havmoeller, Roderick J Hay, Simon I Hay, Yihua He, 
Akbar Hedayatizadeh-Omran, Mohamed I Hegazy, Behzad Heibati, 
Mohsen Heidari, Delia Hendrie, Andualem Henok, Nathaniel J Henry, 
Claudiu Herteliu, Fatemeh Heydarpour, Pouria Heydarpour, 
Sousan Heydarpour, Desalegn Tsegaw Hibstu, Hans W Hoek, 
Michael K Hole, Enayatollah Homaie Rad, Praveen Hoogar, 
H Dean Hosgood, Seyed Mostafa Hosseini, Mehdi Hosseinzadeh, 
Mihaela Hostiuc, Sorin Hostiuc, Peter J Hotez, Damian G Hoy, 
Thomas Hsiao, Guoqing Hu, John J Huang, Abdullatif Husseini, 
Mohammedaman Mama Hussen, Susan Hutfless, Bulat Idrisov, 
Olayinka Stephen Ilesanmi, Usman Iqbal, Seyed Sina Naghibi Irvani, 
Caleb Mackay Salpeter Irvine, Nazrul Islam, 
Sheikh Mohammed Shariful Islam, Farhad Islami, Kathryn H Jacobsen, 
Leila Jahangiry, Nader Jahanmehr, Sudhir Kumar Jain, 
Mihajlo Jakovljevic, Moti Tolera Jalu, Spencer L James, Mehdi Javanbakht, 
Achala Upendra Jayatilleke, Panniyammakal Jeemon, Kathy J Jenkins, 
Ravi Prakash Jha, Vivekanand Jha, Catherine O Johnson, 
Sarah C Johnson, Jost B Jonas, Ankur Joshi, Jacek Jerzy Jozwiak, 
Suresh Banayya Jungari, Mikk Jürisson, Zubair Kabir, Rajendra Kadel, 
Amaha Kahsay, Rizwan Kalani, Manoochehr Karami, 
Behzad Karami Matin, André Karch, Corine Karema, 
Hamidreza Karimi-Sari, Amir Kasaeian, Dessalegn H Kassa, 
Getachew Mullu Kassa, Tesfaye Dessale Kassa, Nicholas J Kassebaum, 
Srinivasa Vittal Katikireddi, Anil Kaul, Zhila Kazemi, Ali Kazemi Karyani, 
Dhruv Satish Kazi, Adane Teshome Kefale, Peter Njenga Keiyoro, 
Grant Rodgers Kemp, Andre Pascal Kengne, Andre Keren, 
Chandrasekharan Nair Kesavachandran, Yousef Saleh Khader, 
Behzad Khafaei, Morteza Abdullatif Khafaie, Alireza Khajavi, 
Nauman Khalid, Ibrahim A Khalil, Ejaz Ahmad Khan, 
Muhammad Shahzeb Khan, Muhammad Ali Khan, Young-Ho Khang, 
Mona M Khater, Abdullah T Khoja, Ardeshir Khosravi, 
Mohammad Hossein Khosravi, Jagdish Khubchandani, 
Aliasghar A Kiadaliri, Getiye D Kibret, 
Zelalem Teklemariam Kidanemariam, Daniel N Kiirithio, Daniel Kim, 
Young-Eun Kim, Yun Jin Kim, Ruth W Kimokoti, Yohannes Kinfu, 
Adnan Kisa, Katarzyna Kissimova-Skarbek, Mika Kivimäki, 
Ann Kristin Skrindo Knudsen, Jonathan M Kocarnik, Sonali Kochhar, 
Yoshihiro Kokubo, Tufa Kolola, Jacek A Kopec, Parvaiz A Koul, 
Ai Koyanagi, Michael A Kravchenko, Kewal Krishan, 
Barthelemy Kuate Defo, Burcu Kucuk Bicer, G Anil Kumar, 
Manasi Kumar, Pushpendra Kumar, Michael J Kutz, Igor Kuzin, 
Hmwe Hmwe Kyu, Deepesh P Lad, Sheetal D Lad, 
Alessandra Lafranconi, Dharmesh Kumar Lal, Ratilal Lalloo, 
Tea Lallukka, Jennifer O Lam, Faris Hasan Lami, Van C Lansingh, 
Sonia Lansky, Heidi J Larson, Arman Latifi, Kathryn Mei-Ming Lau, 
Jeffrey V Lazarus, Georgy Lebedev, Paul H Lee, James Leigh, 
Mostafa Leili, Cheru Tesema Leshargie, Shanshan Li, Yichong Li, 
Juan Liang, Lee-Ling Lim, Stephen S Lim, Miteku Andualem Limenih, 
Shai Linn, Shiwei Liu, Yang Liu, Rakesh Lodha, Chris Lonsdale, 
Alan D Lopez, Stefan Lorkowski, Paulo A Lotufo, Rafael Lozano, 
Raimundas Lunevicius, Stefan Ma, Erlyn Rachelle King Macarayan, 
Mark T Mackay, Jennifer H MacLachlan, Emilie R Maddison, 
Fabiana Madotto, Hassan Magdy Abd El Razek, 
Muhammed Magdy Abd El Razek, Dhaval P Maghavani, Marek Majdan, 
Reza Majdzadeh, Azeem Majeed, Reza Malekzadeh, 
Deborah Carvalho Malta, Ana-Laura Manda, 
Luiz Garcia Mandarano-Filho, Helena Manguerra, 
Mohammad Ali Mansournia, Chabila Christopher Mapoma, 
Dadi Marami, Joemer C Maravilla, Wagner Marcenes, Laurie Marczak, 
Ashley Marks, Guy B Marks, Gabriel Martinez, 
Francisco Rogerlândio Martins-Melo, Ira Martopullo, Winfried März, 
Melvin B Marzan, Joseph R Masci, Benjamin Ballard Massenburg, 
Manu Raj Mathur, Prashant Mathur, Richard Matzopoulos, 
Pallab K Maulik, Mohsen Mazidi, Colm McAlinden, John J McGrath, 
Martin McKee, Brian J McMahon, Suresh Mehata, 
Man Mohan Mehndiratta, Ravi Mehrotra, Kala M Mehta, Varshil Mehta, 
Global Health Metrics
1776 www.thelancet.com   Vol 392   November 10, 2018
Tefera C Mekonnen, Addisu Melese, Mulugeta Melku, 
Peter T N Memiah, Ziad A Memish, Walter Mendoza, 
Desalegn Tadese Mengistu, Getnet Mengistu, George A Mensah, 
Seid Tiku Mereta, Atte Meretoja, Tuomo J Meretoja, Tomislav Mestrovic, 
Haftay Berhane Mezgebe, Bartosz Miazgowski, Tomasz Miazgowski, 
Anoushka I Millear, Ted R Miller, Molly Katherine Miller-Petrie, 
G K Mini, Parvaneh Mirabi, Mojde Mirarefin, Andreea Mirica, 
Erkin M Mirrakhimov, Awoke Temesgen Misganaw, Habtamu Mitiku, 
Babak Moazen, Karzan Abdulmuhsin Mohammad, 
Moslem Mohammadi, Noushin Mohammadifard, 
Mohammed A Mohammed, Shafiu Mohammed, Viswanathan Mohan, 
Ali H Mokdad, Mariam Molokhia, Lorenzo Monasta, Ghobad Moradi, 
Maziar Moradi-Lakeh, Mehdi Moradinazar, Paula Moraga, 
Lidia Morawska, Ilais Moreno Velásquez, Joana Morgado-Da-Costa, 
Shane Douglas Morrison, Marilita M Moschos, Simin Mouodi, 
Seyyed Meysam Mousavi, Kindie Fentahun Muchie, Ulrich Otto Mueller, 
Satinath Mukhopadhyay, Kate Muller, John Everett Mumford, 
Jonah Musa, Kamarul Imran Musa, Ghulam Mustafa, 
Saravanan Muthupandian, Jean B Nachega, Gabriele Nagel, 
Aliya Naheed, Azin Nahvijou, Gurudatta Naik, Sanjeev Nair, Farid Najafi, 
Luigi Naldi, Hae Sung Nam, Vinay Nangia, Jobert Richie Nansseu, 
Bruno Ramos Nascimento, Gopalakrishnan Natarajan, Nahid Neamati, 
Ionut Negoi, Ruxandra Irina Negoi, Subas Neupane, Charles R J Newton, 
Frida N Ngalesoni, Josephine W Ngunjiri, Anh Quynh Nguyen, 
Grant Nguyen, Ha Thu Nguyen, Huong Thanh Nguyen, 
Long Hoang Nguyen, Minh Nguyen, Trang Huyen Nguyen, 
Emma Nichols, Dina Nur Anggraini Ningrum, Yirga Legesse Nirayo, 
Molly R Nixon, Nomonde Nolutshungu, Shuhei Nomura, Ole F Norheim, 
Mehdi Noroozi, Bo Norrving, Jean Jacques Noubiap, Hamid Reza Nouri, 
Malihe Nourollahpour Shiadeh, Mohammad Reza Nowroozi, 
Peter S Nyasulu, Christopher M Odell, Richard Ofori-Asenso, 
Felix Akpojene Ogbo, In-Hwan Oh, Olanrewaju Oladimeji, 
Andrew T Olagunju, Pedro R Olivares, Helen Elizabeth Olsen, 
Bolajoko Olubukunola Olusanya, Jacob Olusegun Olusanya, 
Kanyin L Ong, Sok King Sk Ong, Eyal Oren, Heather M Orpana, 
Alberto Ortiz, Justin R Ortiz, Stanislav S Otstavnov, Simon Øverland, 
Mayowa Ojo Owolabi, Raziye Özdemir, Mahesh P A, Rosana Pacella, 
Smita Pakhale, Abhijit P Pakhare, Amir H Pakpour, Adrian Pana, 
Songhomitra Panda-Jonas, Jeyaraj Durai Pandian, Andrea Parisi, 
Eun-Kee Park, Charles D H Parry, Hadi Parsian, Shanti Patel, 
Sanghamitra Pati, George C Patton, Vishnupriya Rao Paturi, 
Katherine R Paulson, Alexandre Pereira, David M Pereira, 
Norberto Perico, Konrad Pesudovs, Max Petzold, Michael R Phillips, 
Frédéric B Piel, David M Pigott, Julian David Pillay, Meghdad Pirsaheb, 
Farhad Pishgar, Suzanne Polinder, Maarten J Postma, Akram Pourshams, 
Hossein Poustchi, Ashwini Pujar, Swayam Prakash, Narayan Prasad, 
Caroline A Purcell, Mostafa Qorbani, Hedley Quintana, 
D Alex Quistberg, Kirankumar Waman Rade, Amir Radfar, Anwar Rafay, 
Alireza Rafiei, Fakher Rahim, Kazem Rahimi, Afarin Rahimi-Movaghar, 
Mahfuzar Rahman, Mohammad Hifz Ur Rahman, 
Muhammad Aziz Rahman, Rajesh Kumar Rai, Sasa Rajsic, Usha Ram, 
Chhabi Lal Ranabhat, Prabhat Ranjan, Puja C Rao, David Laith Rawaf, 
Salman Rawaf, Christian Razo-García, K Srinath Reddy, Robert C Reiner, 
Marissa B Reitsma, Giuseppe Remuzzi, Andre M N Renzaho, 
Serge Resnikoff, Satar Rezaei, Shahab Rezaeian, 
Mohammad Sadegh Rezai, Seyed Mohammad Riahi, 
Antonio Luiz P Ribeiro, Maria Jesus Rios-Blancas, Kedir Teji Roba, 
Nicholas L S Roberts, Stephen R Robinson, Leonardo Roever, 
Luca Ronfani, Gholamreza Roshandel, Ali Rostami, 
Dietrich Rothenbacher, Ambuj Roy, Enrico Rubagotti, 
Perminder S Sachdev, Basema Saddik, Ehsan Sadeghi, Hosein Safari, 
Mahdi Safdarian, Sare Safi, Saeid Safiri, Rajesh Sagar, 
Amirhossein Sahebkar, Mohammad Ali Sahraian, Nasir Salam, 
Joseph S Salama, Payman Salamati, Raphael De Freitas Saldanha, 
Zikria Saleem, Yahya Salimi, Sundeep Santosh Salvi, Inbal Salz, 
Evanson Zondani Sambala, Abdallah M Samy, Juan Sanabria, 
Maria Dolores Sanchez-Niño, Damian Francesco Santomauro, 
Itamar S Santos, João Vasco Santos, Milena M Santric Milicevic, 
Bruno Piassi Sao Jose, Abdur Razzaque Sarker, 
Rodrigo Sarmiento-Suárez, Nizal Sarrafzadegan, Benn Sartorius, 
Shahabeddin Sarvi, Brijesh Sathian, Maheswar Satpathy, 
Arundhati R Sawant, Monika Sawhney, Sonia Saxena, Mehdi Sayyah, 
Elke Schaeffner, Maria Inês Schmidt, Ione J C Schneider, Ben Schöttker, 
Aletta Elisabeth Schutte, David C Schwebel, Falk Schwendicke, 
James G Scott, Mario Sekerija, Sadaf G Sepanlou, Edson Serván-Mori, 
Seyedmojtaba Seyedmousavi, Hosein Shabaninejad, 
Katya Anne Shackelford, Azadeh Shafieesabet, Mehdi Shahbazi, 
Amira A Shaheen, Masood Ali Shaikh, Mehran Shams-Beyranvand, 
Mohammadbagher Shamsi, Morteza Shamsizadeh, Kiomars Sharafi, 
Mehdi Sharif, Mahdi Sharif-Alhoseini, Rajesh Sharma, Jun She, 
Aziz Sheikh, Peilin Shi, Mekonnen Sisay Shiferaw, Mika Shigematsu, 
Rahman Shiri, Reza Shirkoohi, Ivy Shiue, Farhad Shokraneh, 
Mark G Shrime, Si Si, Soraya Siabani, Tariq J Siddiqi, 
Inga Dora Sigfusdottir, Rannveig Sigurvinsdottir, Donald H Silberberg, 
Diego Augusto Santos Silva, João Pedro Silva, Natacha Torres Da Silva, 
Dayane Gabriele Alves Silveira, Jasvinder A Singh, Narinder Pal Singh, 
Prashant Kumar Singh, Virendra Singh, Dhirendra Narain Sinha, 
Karen Sliwa, Mari Smith, Badr Hasan Sobaih, Soheila Sobhani, 
Eugène Sobngwi, Samir S Soneji, Moslem Soofi, Reed J D Sorensen, 
Joan B Soriano, Ireneous N Soyiri, Luciano A Sposato, 
Chandrashekhar T Sreeramareddy, Vinay Srinivasan, Jeffrey D Stanaway, 
Vladimir I Starodubov, Vasiliki Stathopoulou, Dan J Stein, 
Caitlyn Steiner, Leo G Stewart, Mark A Stokes, Michelle L Subart, 
Agus Sudaryanto, Mu’awiyyah Babale Sufiyan, Patrick John Sur, 
Ipsita Sutradhar, Bryan L Sykes, P N Sylaja, Dillon O Sylte, 
Cassandra E I Szoeke, Rafael Tabarés-Seisdedos, Takahiro Tabuchi, 
Santosh Kumar Tadakamadla, Ken Takahashi, Nikhil Tandon, 
Segen Gebremeskel Tassew, Nuno Taveira, Arash Tehrani-Banihashemi, 
Tigist Gashaw Tekalign, Merhawi Gebremedhin Tekle, 
Mohamad-Hani Temsah, Omar Temsah, Abdullah Sulieman Terkawi, 
Manaye Yihune Teshale, Belay Tessema, Gizachew Assefa Tessema, 
Kavumpurathu Raman Thankappan, Sathish Thirunavukkarasu, 
Nihal Thomas, Amanda G Thrift, George D Thurston, Binyam Tilahun, 
Quyen G To, Ruoyan Tobe-Gai, Marcello Tonelli, Roman Topor-Madry, 
Anna E Torre, Miguel Tortajada-Girbés, Mathilde Touvier, 
Marcos Roberto Tovani-Palone, Bach Xuan Tran, Khanh Bao Tran, 
Suryakant Tripathi, Christopher E Troeger, Thomas Clement Truelsen, 
Nu Thi Truong, Afewerki Gebremeskel Tsadik, Derrick Tsoi, 
Lorainne Tudor Car, E Murat Tuzcu, Stefanos Tyrovolas, 
Kingsley N Ukwaja, Irfan Ullah, Eduardo A Undurraga, Rachel L Updike, 
Muhammad Shariq Usman, Olalekan A Uthman, Selen Begüm Uzun, 
Muthiah Vaduganathan, Afsane Vaezi, Gaurang Vaidya, Pascual R Valdez, 
Elena Varavikova, Tommi Juhani Vasankari, 
Narayanaswamy Venketasubramanian, Santos Villafaina, 
Francesco S Violante, Sergey Konstantinovitch Vladimirov, Vasily Vlassov, 
Stein Emil Vollset, Theo Vos, Gregory R Wagner, Fasil Shiferaw Wagnew, 
Yasir Waheed, Mitchell Taylor Wallin, Judd L Walson, Yanping Wang, 
Yuan-Pang Wang, Molla Mesele Wassie, Elisabete Weiderpass, 
Robert G Weintraub, Fitsum Weldegebreal, Kidu Gidey Weldegwergs, 
Andrea Werdecker, Adhena Ayaliew Werkneh, T Eoin West, 
Ronny Westerman, Harvey A Whiteford, Justyna Widecka, 
Lauren B Wilner, Shadrach Wilson, Andrea Sylvia Winkler, 
Charles Shey Wiysonge, Charles D A Wolfe, Shouling Wu, 
Yun-Chun Wu, Grant M A Wyper, Denis Xavier, Gelin Xu, Simon Yadgir, 
Ali Yadollahpour, Seyed Hossein Yahyazadeh Jabbari, Bereket Yakob, 
Lijing L Yan, Yuichiro Yano, Mehdi Yaseri, Yasin Jemal Yasin, 
Gökalp Kadri Yentür, Alex Yeshaneh, Ebrahim M Yimer, Paul Yip, 
Biruck Desalegn Yirsaw, Engida Yisma, Naohiro Yonemoto, 
Gerald Yonga, Seok-Jun Yoon, Marcel Yotebieng, Mustafa Z Younis, 
Mahmoud Yousefifard, Chuanhua Yu, Vesna Zadnik, Zoubida Zaidi, 
Sojib Bin Zaman, Mohammad Zamani, Zohreh Zare, 
Ayalew Jejaw Zeleke, Zerihun Menlkalew Zenebe, Anthony Lin Zhang, 
Kai Zhang, Maigeng Zhou, Sanjay Zodpey, Liesl Joanna Zuhlke, 
Mohsen Naghavi, and Christopher J L Murray.
Affiliations
Division of Cardiology, Department of Medicine (G A Roth MD), 
Institute for Health Metrics and Evaluation (G A Roth MD, A Afshin MD, 
K M Agesa BA, T Alam MPH, K E Ballesteros PhD, M S Bannick BS, 
G J Bertolacci BS, M H Biehl MPH, B F Blacker MPH, P S Briant BS, 
C S Callender BS, A Carter MPH, C D Castle BS, A J Cohen DSc, 
E A Cromwell PhD, M Cunningham MSc, Prof L Dandona MD, 
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1777
Prof R Dandona PhD, N Davis Weaver MPH, Prof L Degenhardt PhD, 
S Deiparine BA, S D Dharmaratne MD, D Dicker BS, M A Dirac MD, 
D Douwes-Schultz BSc, C El Bcheraoui PhD, Prof V L Feigin PhD, 
S Finegold BS, K J Foreman PhD, T D Frank BS, J E Fuller, 
N Fullman MPH, W M Gardner AB, E M Goldberg MPH, 
T M Gorman BS, Prof S I Hay FMedSci, Y He MS, N J Henry BS, 
T Hsiao BS, C M S Irvine BS, S L James MD, C O Johnson PhD, 
S C Johnson MS, N J Kassebaum MD, G R Kemp BA, I A Khalil MD, 
J M Kocarnik PhD, M J Kutz BS, H H Kyu PhD, Prof H J Larson PhD, 
K M Lau BS, Prof S S Lim PhD, Prof A D Lopez PhD, 
Prof R Lozano PhD, E R Maddison BS, H Manguerra BS, 
L Marczak PhD, A Marks MA, I Martopullo MPH, A I Millear MPH, 
M K Miller-Petrie MSc, A T Misganaw PhD, Prof A H Mokdad PhD, 
J E Mumford BA, K Muller MPH, G Nguyen MPH, M Nguyen BS, 
E Nichols BA, M R Nixon PhD, E O Nsoesie PhD, C M Odell MPP, 
H E Olsen MA, K L Ong PhD, K R Paulson BS, D M Pigott DPhil, 
C A Purcell BA, P C Rao MPH, R C Reiner PhD, M B Reitsma BS, 
N L S Roberts BS, J S Salama MS, K A Shackelford BA, M Smith MPA, 
V Srinivasan BA, J D Stanaway PhD, C Steiner MPH, L G Stewart BS, 
M L Subart BA, P J Sur MPH, D O Sylte BA, A E Torre BS, 
C E Troeger MPH, D Tsoi BS, R L Updike BA, Prof S E Vollset DrPH, 
Prof T Vos PhD, Prof H A Whiteford PhD, L B Wilner MPH, 
S Wilson BS, S Yadgir BS, C Fitzmaurice MD, R J D Sorensen MPH, 
Prof M Naghavi MD, Prof C J L Murray DPhil), Department of Global 
Health (F J Charlson PhD, S Kochhar MD, Prof J R Ortiz MD, 
R J D Sorensen MPH, Prof J L Walson MD), Division of Plastic Surgery, 
Department of Surgery (C S Crowe MD, B B Massenburg MD), Division 
of Hematology, Department of Medicine (C Fitzmaurice MD), 
Department of Otolaryngology-Head and Neck Surgery 
(N D Futran MD), Department of Neurology (R Kalani MD), Department 
of Medicine (B J McMahon MD, T E West MD), Department of Surgery 
(S D Morrison MD), Department of Bioinformatics and Medical 
Education (E O Nsoesie PhD), Department of Health Metrics Sciences 
(A Afshin MD, E A Cromwell PhD, C El Bcheraoui PhD, 
Prof S I Hay FMedSci, H H Kyu PhD, Prof H J Larson PhD, 
Prof S S Lim PhD, A T Misganaw PhD, Prof A H Mokdad PhD, 
D M Pigott DPhil, R C Reiner PhD, J D Stanaway PhD, 
Prof S E Vollset DrPH, Prof T Vos PhD, M Zhou PhD, 
Prof M Naghavi MD, Prof C J L Murray DPhil), University of 
Washington, Seattle, WA, USA (I Kuzin MPH, Prof E Oren PhD); 
School of Pharmacy (J Abdela MSc, Y Ayele MSc, D Edessa MSc, 
G Mengistu MSc, Prof M S Shiferaw MSc), Department of Pediatrics 
(A R Abrham MSc), Department of Medical Laboratory Science 
(Z Ataro MSc, D Marami MSc, Prof H Mitiku MSc), School of Public 
Health (Prof A G Bali MPH, M G Tekle MPH), School of Nursing and 
Midwifery (T T Dasa MSc, K T Roba PhD), College of Health and 
Medical Sciences (Prof Z T Kidanemariam MSc), Haramaya University, 
Harar, Ethiopia (D Abate MSc, T F Gelano MSc, T Hailegiyorgis MSc, 
M T Jalu MPH, Prof H Mitiku MSc, T G Tekalign MS, 
Prof F Weldegebreal MPH); Department of Population and Family 
Health (Prof K H Abate PhD, A T Gebremedhin MPH), Department of 
Epidemiology (M B Ahmed MPH, Prof T T Gebrehiwot MPH), 
Mycobacteriology Research Center (Prof E Duken MSc), Department of 
Health Education & Behavioral Sciences (Prof G T Feyissa MPH), 
Department of Environmental Health Sciences and Technology 
(Prof S Mereta PhD), Jimma University, Jimma, Ethiopia; Department of 
Pharmacology and Clinical Pharmacy (S M Abay PhD), School of Public 
Health (K Deribe PhD, Y J Yasin MPH), College of Health Sciences 
(B Gebremichael MSc), School of Allied Health Sciences 
(Prof E Yisma MPH), Addis Ababa University, Addis Ababa, Ethiopia 
(G T Demoz MSc); Department of Law Philosophy and Economic 
Studies, La Sapienza University, Rome, Italy (Prof C Abbafati PhD); 
Non-communicable Diseases Research Center (N Abbasi MD, 
F Farzadfar MD, S N Irvani MD, M Shams-Beyranvand MSc, 
H Ebrahimi MD, F Pishgar MD), Department of Health 
(H Abbastabar PhD), Department of Urology (E Amini MD), 
Department of Health Management and Economics 
(M Anjomshoa PhD, S Mousavi PhD), Liver and Pancreaticobilliary 
Disease Research Center (H Ebrahimi MD), Multiple Sclerosis Research 
Center (I Abdollahpour PhD, S Eskandarieh PhD, P Heydarpour MD, 
Prof M Sahraian MD), Endocrinology and Metabolism Research Center 
(Prof A Esteghamati MD), School of Medicine (N Hafezi-Nejad MD), 
Department of Pharmacology (A Haj-Mirzaian MD), Department of 
Epidemiology and Biostatistics (Prof S Hosseini PhD, 
M Mansournia PhD, Prof M Yaseri PhD), Hematologic Malignancies 
Research Center (A Kasaeian PhD), Knowledge Utilization Research 
Center (Prof R Majdzadeh PhD), Digestive Diseases Research Institute 
(Prof R Malekzadeh MD, Prof A Pourshams MD, H Poustchi PhD, 
G Roshandel PhD, S G Sepanlou MD), Cancer Research Center 
(Prof A Nahvijou PhD), Uro-oncology Research Center 
(M Nowroozi MD, F Pishgar MD), Iranian National Center for Addiction 
Studies (INCAS) (Prof A Rahimi-Movaghar MD), Sina Trauma and 
Surgery Research Center (M Safdarian MD, Prof P Salamati MD, 
M Sharif-Alhoseini PhD), Center of Expertise in Microbiology 
(Prof S Seyedmousavi PhD), Cancer Biology Research Center 
(Prof R Shirkoohi PhD), Department of Anatomy (S Sobhani MD), 
Hematology-Oncology and Stem Cell Transplantation Research Center 
(A Kasaeian PhD), Community-Based Participatory Research Center 
(Prof R Majdzadeh PhD), Cancer Research Institute 
(Prof R Shirkoohi PhD), Tehran University of Medical Sciences, Tehran, 
Iran; Montreal Neuroimaging Center (N Abbasi MD), Montreal 
Neurological Institute (S Fereshtehnejad PhD), McGill University, 
Montreal, QC, Canada; Department of Neurology (Prof F Abd-Allah MD, 
Prof A Abdelalim MD, Prof M I Hegazy PhD), Department of Medical 
Parasitology (M M Khater MD), Cairo University, Cairo, Egypt; 
Department of Epidemiology, Arak University of Medical Sciences, Arak, 
Iran (I Abdollahpour PhD); Department of Statistics, Manonmaniam 
Sundaranar University, Tirunelveli, India (R S Abdulkader MD); College 
of Health Sciences (H T Abebe PhD), School of Public Health 
(Prof S F Abera MSc, B M Adhena MPH, A B Belachew MSc), Clinical 
Pharmacy Unit (H N Abraha MSc, T D Kassa MSc, Y L Nirayo MSc, 
(A K Gebre MSc, T G Gebremichael MSc, A G Tsadik MSc, 
E Yimer MSc), Department of Biostatistics (K Gezae MSc), Anatomy 
Unit (T B Hagos MSc), Biomedical Sciences Division 
(Prof G B Hailu MSc), School of Medicine (D T Mengistu MSc), 
Department of Microbiology and Immunology (S Muthupandian PhD), 
Department of Environmental Health Science (A A Werkneh MSc), 
Department of Midwifery (Prof Z M Zenebe MSc), Mekelle University, 
Mekelle, Ethiopia (E Belay MSc, Prof B D Demtsu MSc, 
S G Tassew MSc); Department of Clinical Chemistry (M Abebe MSc, 
B Biadgo BSc), Human Nutrition Department (Z Abebe MSc), Institute 
of Public Health (Prof K A Alene MPH, B Bekele MPH, 
Prof A F Dadi MPH, M A Limenih MSc, Prof M Melku MSc, 
Prof K Muchie MSc, G A Tessema MPH, B Tilahun PhD, 
Prof M M Wassie MSc), Department of Medical Microbiology 
(B Tessema PhD), Department of Medical Parasitology 
(Prof A J Zeleke MSc), University of Gondar, Gondar, Ethiopia 
(H W Baynes MSc); Department of Nursing (A Alebel MSc, 
G A Dessie MSc, D H Kassa MSc, F W S Wagnew MSc), Department of 
Public Health (Y A Belay MPH, G D Kibret MPH, C T Leshargie MPH), 
College of Health Sciences (G M Kassa MSc), Debre Markos University, 
Debre Markos, Ethiopia (A N Abejie MPH); Institute of Biological 
Chemistry and Nutrition, University of Hohenheim, Stuttgart, Germany 
(Prof S F Abera MSc); Department of Medical Laboratory Sciences 
(O Abil MSc), Department of Health Sciences (Prof E Duken MSc), 
Wollega University, Nekemte, Ethiopia; School of Public Health, 
University of Medical Science, Ondo, Ondo, Nigeria (O Abil MSc); 
Department of Healthcare Policy and Research, Weill Cornell Medical 
College in Qatar, Doha, Qatar (Prof L J Abu-Raddad PhD); Epidemiology 
(M M K Accrombessi PhD), Bénin Clinical Research Institute (IRCB), 
Cotonou, Benin (E F A Avokpaho MD); Department of Preventive 
Medicine, Dongguk University, Gyeongju, South Korea 
(Prof D Acharya MPH); Department of Community Medicine, 
Kathmandu University, Devdaha, Nepal (Prof D Acharya MPH); 
Department of Global Health (A A Adamu MSc, O O Adetokunboh MSc, 
Prof C S Wiysonge MD), Faculty of Medicine & Health Sciences 
(Prof P S Nyasulu PhD), Department of Psychiatry 
(Prof C D H Parry PhD), Stellenbosch University, Cape Town, 
South Africa; Cochrane South Africa (A A Adamu MSc, 
O O Adetokunboh MSc), Burden of Disease Research Unit 
(R Matzopoulos PhD), Unit for Hypertension and Cardiovascular 
Disease (Prof A E Schutte PhD), South African Medical Research 
Global Health Metrics
1778 www.thelancet.com   Vol 392   November 10, 2018
Council, Cape Town, South Africa (Prof D J Stein MD); Medicine, 
University College Hospital, Ibadan, Ibadan, Nigeria 
(O M Adebayo MD); Department of Medical Rehabilitation, Obafemi 
Awolowo University, Ile-Ife, Nigeria (Prof R A Adedoyin PhD); School of 
Medicine, Cardiff University, Cardiff, UK (V Adekanmbi PhD); 
Emergency Department, Saint Mark Hospital, Alexandria, Egypt 
(M G Adib MD); School of Public Health, Wolaita Sodo University, Addis 
Ababa, Ethiopia (A Admasie MPH); Department of Family Medicine, 
McMaster University, Hamilton, ON, Canada (G Agarwal MD); Research 
Area for Informatics and Big Data, Csir Institute of Genomics and 
Integrative Biology, Delhi, India (Prof A Agrawal PhD); Department of 
Internal Medicine (Prof A Agrawal PhD), National School of Tropical 
Medicine (Prof P J Hotez PhD), Baylor College of Medicine, Houston, 
TX, USA; Health Promotion Division (M Arora PhD), Department of 
Social and Behavioral Sciences (S Goenka PhD), Non Communicable 
Diseases (Prof M R Mathur PhD), Indian Institute of Public Health 
(Prof S Zodpey PhD), Public Health Foundation of India, India 
(S Agrawal PhD, A Awasthi PhD, Prof L Dandona MD, 
Prof R Dandona PhD, G Kumar PhD, D K Lal MD, K Reddy DM); Vital 
Strategies, Gurugram, India (S Agrawal PhD); Department of 
Anesthesiology (Prof A Ahmadi PhD), Department of Traditional and 
Complementary Medicine (Prof M Farzaei PhD), Sleep Disorders 
Research Center (M Ghadami MD), Faculty of Nutrition and Food 
Sciences (F Heydarpour PhD), Faculty of Public Health 
(Prof B Karami Matin PhD, A Kazemi Karyani PhD), Department of 
Epidemiology & Biostatistics (Prof F Najafi PhD, Prof Y Salimi PhD), 
Environmental Determinants of Health Research Center 
(Prof S Rezaei PhD, M Soofi PhD), Department of Food Technology & 
Quality Control (Prof E Sadeghi PhD), Sports Medicine & Rehabilitation 
(M Shamsi PhD), Imam Ali Cardiovascular Research Center 
(Prof S Siabani PhD), Pharmaceutical Sciences Research Center 
(Prof M Farzaei PhD), Kermanshah University of Medical Sciences, 
Kermanshah, Iran (Prof S Heydarpour PhD, Prof M Pirsaheb PhD, 
Prof S Rezaeian PhD, Prof K Sharafi PhD); Environmental Technologies 
Research Center (Prof M Ahmadi PhD), Department of Public Health 
(Prof M A Khafaie PhD), Thalassemia and Hemoglobinopathy Research 
Center (Prof F Rahim PhD), Deapartment of Neurosurgery 
(Prof H Safari MD), Education Development Center 
(Prof M Sayyah PsyD), Medical Physics Department 
(Prof A Yadollahpour PhD), Ahvaz Jundishapur University of Medical 
Sciences, Ahvaz, Iran; Health Systems and Population Studies Division 
(S Ahmed MSc), Initiative for Non Communicable Diseases 
(A Naheed PhD), Health Economics and Financing Research Group 
(A R Sarker MSc), Maternal and Child Health Division (S Zaman MPH), 
International Centre for Diarrhoeal Disease Research, Bangladesh, 
Dhaka, Bangladesh; Department of Learning, Informatics, Management, 
and Ethics (S Ahmed MSc), Department of Public Health Sciences 
(Prof P Allebeck MD, Z El-Khatib PhD), Department of Neurobiology 
(Prof J Ärnlöv PhD), Department of Medical Epidemiology and 
Biostatistics (Prof J J Carrero PhD, Prof E Weiderpass PhD), Department 
of Neurobiology, Care Sciences and Society  (S Fereshtehnejad PhD), 
Karolinska Institutet, Stockholm, Sweden; University Ferhat Abbas of 
Setif, Algeria (A Aichour B Med Sc, I Aichour B Pharm); Higher 
National School of Veterinary Medicine, Algiers, Algeria 
(M Aichour MA); Cancer Research Center (Prof M Akbari MD), 
Research Institute for Endocrine Sciences (A Haj-Mirzaian MD, 
S N Irvani MD), Safety Promotion and Injury Prevention Research 
Center (Prof N Jahanmehr PhD), Department of Biostatistics 
(A Khajavi MSc), Department of Epidemiology (S Riahi PhD), 
Ophthalmic Research Center (S Safi MSc, Prof M Yaseri PhD), School of 
Public Health (Prof N Jahanmehr PhD), Ophthalmic Epidemiology 
Research Center (S Safi MSc), Shahid Beheshti University of Medical 
Sciences, Tehran, Iran; Institute for Advanced Medical Research and 
Training, University of Ibadan, Ibadan, Nigeria (R O Akinyemi PhD, 
Prof M O Owolabi DrM); Centre for Global Child Health, The Hospital 
for Sick Children (N Akseer PhD), Department of Nutritional Sciences 
(A Badawi PhD), The Centre for Global Child Health, Hospital for Sick 
Children (Prof Z A Bhutta PhD), University of Toronto, Toronto, ON, 
Canada; Internal Medicine Department, Washington University in 
St Louis, St Louis, MO, USA (Z Al-Aly MD); Clinical Epidemiology 
Center, VA St Louis Health Care System, Department of Veterans 
Affairs, St Louis, MO, USA (Z Al-Aly MD); Pediatric Intensive Care Unit 
(A Al-Eyadhy MD), Department of Pediatrics (Prof B H Sobaih MD, 
Prof M Temsah MRCPCH, MD), King Saud University, Riyadh, Saudi 
Arabia (K Altirkawi MD); Department of Family and Community 
Medicine, King Abdulaziz University, Jeddah, Saudi Arabia 
(Prof R M Al-Raddadi PhD); Evidence Based Practice Center, Mayo 
Clinic Foundation for Medical Education and Research, Rochester, MN, 
USA (Prof F Alahdab MD); Research Committee, Syrian American 
Medical Society, Washington, DC, USA (Prof F Alahdab MD); School of 
Population and Global Health (K Alam PhD), School of Medicine 
(Prof G J Hankey MD), University of Western Australia, Perth, WA, 
Australia; Research School of Population Health (Prof K A Alene MPH), 
National Centre for Epidemiology and Population Health 
(M Bin Sayeed MSPS, A Parisi MD), Australian National University, 
Canberra, ACT, Australia; Department of Public Health 
(Prof A H Pakpour PhD), Qazvin University of Medical Sciences, 
Qazvin, Iran (M Alijanzadeh PhD); Gastrointestinal Cancer Research 
Center (R Alizadeh-Navaei PhD), Department of Medical Mycology 
(Prof H Badali PhD), Toxoplasmosis Research Center 
(Prof A Daryani PhD, Prof S Sarvi PhD), Department of Physiology and 
Pharmacology (Prof M Mohammadi PhD), Molecular and Cell Biology 
Research Center (Prof A Rafiei PhD), Department of Pediatrics 
(Prof M Rezai MD), Department of Medical Mycology and Parasitology 
(A Vaezi PhD), Department of Immunology (Prof A Rafiei PhD), 
Mazandaran University of Medical Sciences, Sari, Iran 
(Prof M Fakhar PhD, Prof A Hedayatizadeh-Omran PhD, 
M Nourollahpour Shiadeh PhD, Prof Z Zare PhD); Department of 
Health Policy and Management, Kuwait University, Safat, Kuwait 
(Prof S M Aljunid PhD); International Centre for Casemix and Clinical 
Coding, National University of Malaysia, Bandar Tun Razak, Malaysia 
(Prof S M Aljunid PhD); Department of Population Health, Luxembourg 
Institute of Health, Strassen, Luxembourg (A Alkerwi PhD); Isped, 
University of Bordeaux, Bordeaux, France (Prof F Alla PhD); Swedish 
Research Council for Health, Working Life, and Welfare, Stockholm, 
Sweden (Prof P Allebeck MD); Research Program in Epidemiology & 
Public Health, Hospital Del Mar Medical Research Institute, Barcelona, 
Spain (Prof J Alonso MD); Department of Experimental and Health 
Sciences, Pompeu Fabra University , Barcelona, Spain 
(Prof J Alonso MD); Research Group on Health Economics 
(Prof N Alvis-Guzman PhD), Epiunit, Instituto de Saúde Pública 
(Prof C Castro PhD), University of Cartagena, Cartagena, Colombia; 
Research Group in Hospital Management and Health Policies, 
University of the Coast, Barranquilla, Colombia 
(Prof N Alvis-Guzman PhD); Sansom Institute (A Amare PhD), 
Wardliparingga Aboriginal Research Unit (P S Azzopardi PhD), South 
Australian Health and Medical Research Institute, Adelaide, SA, 
Australia; Department of Public Health Nutrition (N Fentahun PhD), 
Bahir Dar University, Bahir Dar, Ethiopia (A Amare PhD); School of 
Public Health (L N Aminde MD, F J Charlson PhD, H E Erskine PhD, 
A J Ferrari PhD, D F Santomauro PhD, Prof J G Scott PhD), School of 
Dentistry (Prof R Lalloo PhD), Institute for Social Science Research 
(J C Maravilla PhD), Queensland Brain Institute (Prof J J McGrath MD), 
The University of Queensland, Brisbane, QLD, Australia 
(Prof H A Whiteford PhD); Department of the Health Industrial 
Complex and Innovation in Health (Prof D A Silveira MSc), Federal 
Ministry of Health, Beirut, Lebanon (Prof W Ammar PhD); Faculty of 
Health Sciences, American University of Beirut, Beirut, Lebanon 
(Prof W Ammar PhD); Department of Internal Medicine, Komfo Anokye 
Teaching Hospital, Kumasi, Ghana (Y A Amoako MD); Faculty of 
Medicine (N H Anber PhD), Department of Clinical Pathology 
(Prof M El Sayed Zaki PhD), Mansoura University, Mansoura, Egypt 
(N H Anber PhD); Emergency Hospital of Bucharest 
(Prof M Beuran PhD, Prof I Negoi PhD), Department of General 
Surgery (Prof D V Davitoiu PhD, Prof M Hostiuc PhD), Department of 
Legal Medicine and Bioethics (Prof S Hostiuc PhD), Anatomy and 
Embryology Department (Prof R I Negoi PhD), Carol Davila University 
of Medicine and Pharmacy, Bucharest, Romania (C Andrei PhD); 
Department of Medicine, University of Thessaly, Volos, Greece 
(Prof S Androudi PhD); Department of Public Health 
(Y C D Geramo MSc, M Y Teshale MPH), Medical Laboratory Science 
(Prof M Hussen MA), Arba Minch University, Arba Minch, Ethiopia 
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1779
(M D Animut MPH); Social Determinants of Health Research Center 
(M Anjomshoa PhD), Rafsanjan University of Medical Sciences, 
Rafsanjan, Iran; Zahedan University of Medical Sciences, Iran 
(Prof H Ansari PhD); Department of Public Health (M G Ansha MPH, 
Prof T Kolola MPH), Department of Midwifery (M T Dinberu MA), 
Debre Berhan University, Debre Berhan, Ethiopia; Department of 
Health Policy and Administration (C T Antonio MD), Development and 
Communication Studies (E K Macarayan PhD), University of the 
Philippines Manila, Manila, Philippines; Research Unit 
(R Ofori-Asenso MSc), Independent Consultant, Kabul, Afghanistan 
(P Anwari MSc); School of Health Sciences, Birmingham City 
University, Birmingham, England (O Aremu PhD); School of Health and 
Social Studies, Dalarna University, Falun, Sweden (Prof J Ärnlöv PhD); 
School of Science and Health (A Arora PhD), School of Social Sciences 
and Psychology (Prof A M N Renzaho PhD), Western Sydney University, 
Sydney, NSW, Australia (F A Ogbo PhD); Oral Health Services, Sydney 
Local Health District, Sydney, NSW, Australia (A Arora PhD); Health 
Related Information Dissemination Amongst Youth, New Delhi, India 
(M Arora PhD); Department of Community Health Sciences, University 
of Manitoba, Winnipeg, MB, Canada (A Artaman PhD); DfID Nepal 
Health Sector Programme 3, Monitoring Evaluation and Operational 
Research Project, Abt Associates Nepal, Lalitpur, Nepal (K K Aryal PhD); 
Qom University of Medical Sciences, Qom, Iran (H Asayesh MSc); 
University Institute of Public Health, The University of Lahore, Lahore, 
Pakistan (S Atique PhD); Public Health Department (S Atique PhD), 
Department of Family and Community Medicine (Prof I A Ginawi MD), 
University of Hail, Hail, Saudi Arabia; Center for Clinical Global Health 
Education (S R Atre PhD), Department of Radiology 
(N Hafezi-Nejad MD, A Haj-Mirzaian MD), Department of 
Epidemiology (S Hutfless PhD, Prof J B Nachega PhD), Department of 
Health Policy and Management (Prof A T Khoja MD), School of 
Medicine (S Hutfless PhD), Johns Hopkins University, Baltimore, MD, 
USA; Dr D Y Patil Medical College (S R Atre PhD), Dr D Y Patil 
Vidyapeeth, Pune, India (A R Sawant MD); School of Business 
(Prof M Ausloos PhD), Department of Health Sciences 
(Prof T Brugha MD), University of Leicester, Leicester, UK; Conrol of 
Infectious Diseases, Laboratory of Studies and Research-Action in 
Health, Porto Novo, Benin (E F A Avokpaho MD); Indian Institute of 
Public Health, Gandhinagar, India (A Awasthi PhD); The Judith Lumley 
Centre (B Ayala Quintanilla PhD), School of Nursing and Midwifery 
(Prof D Edvardsson PhD), Austin Clinical School of Nursing 
(M Rahman PhD), La Trobe University, Melbourne, VIC, Australia; 
General Office for Research and Technological Transfer, Peruvian 
National Institute of Health, Lima, Peru (B Ayala Quintanilla PhD); 
Department of Community and Global Health (R Ayer MSc), 
Department of Global Health Policy (Prof S Nomura MSc), University of 
Tokyo, Tokyo, Japan; Global Adolescent Health Group, Burnet Institute, 
Melbourne, VIC, Australia (P S Azzopardi PhD); Department of 
Infectious Diseases, Center for Infectious Diseases Research, Babol, Iran 
(A Babazadeh MD, Prof S Ebrahimpour PhD); School of Health Sciences 
(U Bacha M Phil), School of Food and Agricultural Sciences 
(N Khalid PhD), University of Management and Technology, Lahore, 
Pakistan; Public Health Risk Sciences Division (A Badawi PhD), Applied 
Research Division (H M Orpana PhD), Public Health Agency of Canada, 
Toronto, ON, Canada; Department of Hypertension, Medical University 
of Lodz, Lodz, Poland (Prof M Banach PhD); Polish Mothers’ Memorial 
Hospital Research Institute, Lodz, Poland (Prof M Banach PhD); 
Department of Mathematical Demography & Statistics 
(K Banerjee MSc), Department of Public Health & Mortality Studies 
(M H U Rahman M Phil, Prof U Ram PhD), International Institute for 
Population Sciences, Mumbai, India (S Goli PhD, P Kumar PhD, 
M H U Rahman M Phil); Faculty of Medicine, Alexandria University, 
Alexandria, Egypt (J A M Banoub MD); Department of Transplant 
Services, University Hospital Foundation Santa Fe de Bogotá, Bogotá, 
Colombia (J A M Banoub MD); Department of Neurosciences, Rafael A 
Calderón Guardia Hospital (Prof M A Barboza MSc), Area de Estadística, 
Dirección Actuarial (Prof J Castillo Rivas MSc), Costa Rican Department 
of Social Security, San Jose, Costa Rica; School of Medicine 
(Prof M A Barboza MSc), School of Dentistry (Prof J Castillo Rivas MSc), 
University of Costa Rica, San Pedro, Costa Rica; School of Psychology 
(Prof S L Barker-Collo PhD), Molecular Medicine and Pathology 
(K B Tran MD), University of Auckland, Auckland, New Zealand; 
Institute of Public Health (Prof T W Bärnighausen MD, 
Prof J De Neve MD, B Moazen MSc, S Mohammed PhD), Department 
of Ophthalmology (Prof J B Jonas MD), Medical Clinic V 
(Prof W März MD), Augenpraxis Jonas (S Panda-Jonas MD), Heidelberg 
University, Heidelberg, Germany; Department of Global Health and 
Population (Prof T W Bärnighausen MD, A B Feigl PhD, 
Prof O F Norheim PhD), Department of Nutrition (E L Ding DSc, 
M S Farvid PhD), T H Chan School of Public Health (P C Gupta DSc), 
Ariadne Labs (E K Macarayan PhD), Department of Genetics 
(A Pereira PhD), Division of General Internal Medicine and Primary 
Care (Prof A Sheikh MSc), Heart and Vascular Center 
(M Vaduganathan MD), Department of Environmental Health 
(G R Wagner MD), Harvard University, Boston, MA, USA (N Islam PhD, 
M G Shrime MD, B Yakob PhD); Center for Nutrition and Health 
Research (E Denova-Gutiérrez DSc), Center for Health Systems 
Research (H Gómez-Dantés MSc, M Rios-Blancas MPH, 
Prof E Serván-Mori DSc), Center for Population Health Research 
(C Razo-García MSc), National Institute of Public Health, Cuernavaca, 
Mexico (S Barquera PhD, I R Campos-Nonato PhD, 
J Campuzano Rincon PhD, Prof R Lozano PhD); Department of 
Industrial Engineering, Pontifical Javeriana University, Bogota, 
Colombia (Prof L H Barrero DSc); Barcelona Institute for Global Health 
(Prof Q Bassat MD), Tuberculosis Department 
(A L Garcia-Basteiro MSc), Barcelona Institute for Global Health, 
Barcelona, Spain (Prof J V Lazarus PhD); Tuberculosis 
(A L Garcia-Basteiro MSc), Manhiça Health Research Center, Manhiça, 
Mozambique (Prof Q Bassat MD); Department of Medicine, Stanford 
University, Palo Alto, CA, USA (Prof S Basu PhD); Melbourne Medical 
School, Melbourne, VIC, Australia (Prof B T Baune PhD); Department 
of Psychiatry, Charles R Drew University of Medicine and Science, 
Los Angeles, CA, USA (Prof S Bazargan-Hejazi BEP); Department of 
Psychiatry and Biobehavioral Sciences, University of California 
Los Angeles, Los Angeles, CA, USA (Prof S Bazargan-Hejazi BEP); 
Department of Community Medicine, Gandhi Medical College Bhopal, 
Bhopal, India (Prof N Bedi MD); Jazan University, Jazan, Saudi Arabia 
(Prof N Bedi MD); Department of Neuroscience (E Beghi MD, 
G Giussani PhD), Department of Renal Medicine (B Bikbov MD, 
N Perico MD), Department of Oncology (C Bosetti PhD, 
M Cortinovis PhD), Department of Environmental Health Science 
(S Gallus DSc), Mario Negri Institute for Pharmacological Research, 
Milan, Italy (Prof G Remuzzi MD); Health Management and Economics 
Research Center (M Behzadifar PhD), Department of Ophthalmology 
(K Ghasemi Falavarjani MD), Air Pollution Research Center 
(B Heibati PhD), Preventive Medicine and Public Health Research 
Center (M Moradi-Lakeh MD, Prof A Tehrani-Banihashemi PhD), 
Department of Neuroscience (M Safdarian MD), Department of Health 
Policy (H Shabaninejad PhD), Department of Community Medicine 
(Prof A Tehrani-Banihashemi PhD), Physiology Research Center 
(M Yousefifard PhD), Iran University of Medical Sciences, Tehran, Iran 
(T Beyranvand PhD, F Farhadi MD); Social Determinants of Health 
Research Center (M Behzadifar PhD), Lorestan University of Medical 
Sciences, Khorramabad, Iran (M Behzadifar MS); Department of 
Neurology, University Hospital of Dijon, Dijon, France 
(Prof Y Béjot PhD); Dijon Stroke Registry - Ufr Sciences Santé, 
University of Burgundy, Dijon, France (Prof Y Béjot PhD); Public Health 
Department (B Bekele MPH, H Y Hassen MPH), Pharmacy Department 
(A T Kefale MSc), Mizan-tepi University, Teppi, Ethiopia 
(Prof A Henok MPH); School of Forestry and Environmental Studies 
(Prof M L Bell PhD), Department of Ophthalmology and Visual Science 
(Prof J J Huang MD), Yale University, New Haven, CT, USA; Department 
of Medicine, University of Alberta, Edmonton, AB, Canada 
(Prof A K Bello PhD); Nuffield Department of Population Health 
(D A Bennett PhD), Nuffield Department of Medicine 
(Prof P W Gething PhD), Department of Psychiatry 
(Prof C R J Newton MD), Nuffield Department of Women’s and 
Reproductive Health (Prof K Rahimi MD), University of Oxford, Oxford, 
UK (Prof V Jha MD); Department of Internal Medicine 
(I M Bensenor PhD, Prof I S Santos PhD), Ribeirão Preto Medical 
School, Division of Ophthalmology (Prof J M Furtado MD), University 
Hospital, Internal Medicine Department (A C Goulart PhD), 
Global Health Metrics
1780 www.thelancet.com   Vol 392   November 10, 2018
Department of Medicine (Prof P A Lotufo DrPH), Department of 
Biomechanics (L G Mandarano-Filho PhD), Laboratory of Genetics and 
Molecular Cardiology (A Pereira PhD), Department of Pathology and 
Legal Medicine (M R Tovani-Palone MSc), Department of Psychiatry 
(Y Wang PhD), Center for Clinical and Epidemiological Research 
(A C Goulart PhD), University of São Paulo, São Paulo, Brazil; Division 
of Cardiology, Medical College of Georgia at Augusta University, 
Augusta, GA, USA (Prof A E Berman MD); Department of Health Policy 
(Prof A E Berman MD), Personal Social Services Research Unit 
(R Kadel MPH), London School of Economics and Political Science, 
London, UK; Dental Institute (E Bernabe PhD), Faculty of Life Sciences 
and Medicine (Prof P I Dargan MB, M Molokhia PhD), St John’s 
Institute of Dermatology (Prof R J Hay MD), Division of Patient and 
Population (Prof W Marcenes PhD), School of Population Health & 
Environmental Sciences (Prof C D A Wolfe MD), King’s College London, 
London, UK; Hubert Department of Global Health (R S Bernstein MD), 
Rollins School of Public Health (Prof Y Liu PhD), Emory University, 
Atlanta, GA, USA; Department of Global Health, University of South 
Florida, Tampa, FL, USA (R S Bernstein MD); Department of Internal 
Medicine (Prof A Bhalla MD, D P Lad DM), Department of Pediatrics 
(S D Lad MD), Post Graduate Institute of Medical Education and 
Research, Chandigarh, India; Department of Infectious Disease 
Epidemiology (O J Brady PhD, Prof H J Larson PhD), Department of 
Disease Control (Prof J Cano PhD), Department of Health Services 
Research and Policy (Prof M McKee DSc), London School of Hygiene & 
Tropical Medicine, London, UK (S Bhattarai MSc); Nepal Academy of 
Science & Technology, Patan, Nepal (S Bhattarai MSc); George Institute 
(Prof V Jha MD), Research (Prof P K Maulik PhD), The George Institute 
for Global Health, New Delhi, India (S Bhaumik MBBS); Center of 
Excellence in Women and Child Health, Aga Khan University, Karachi, 
Pakistan (Prof Z A Bhutta PhD); Social Determinant of Health Research 
Center (A Bijani PhD), Health Research Institute (Prof R Ghadimi PhD, 
M Ghasemi-Kasman PhD), Fatemeh Zahra Infertility and Reproductive 
Health Center (Prof P Mirabi PhD), Department of Clinical 
Biochemistry (N Neamati MSc, Prof H Parsian PhD), Cellular and 
Molecular Biology Research Center (H Nouri PhD), Infectious Diseases 
and Tropical Medicine Research Center (A Rostami PhD), 
Immunoregulation Research Center (Prof S Seyedmousavi PhD), 
Department of Microbiology and Immunology (Prof M Shahbazi PhD), 
Student Research Committee (M Zamani MD), Babol University of 
Medical Sciences, Babol, Iran (Prof M Faramarzi PhD, S Mouodi MD); 
Department of Epidemiology and Biostatistics (V Bilano PhD, 
F B Piel PhD), Department of Primary Care and Public Health 
(M Car PhD, Prof A Majeed MD, Prof S Rawaf PhD), Department of 
Surgery and Cancer (Prof A C Davis PhD), Department of Infectious 
Disease Epidemiology (Prof C A Donnelly DSc), WHO Collaborating 
Centre for Public Health Education and Training (D L Rawaf MD), 
School of Public Health (Prof S Saxena MD), Imperial College London, 
London, UK; Woldia University, Woldia, Ethiopia (N Bililign B Hlth Sci); 
Department of Clinical Pharmacy and Pharmacology, University of 
Dhaka, Ramna, Bangladesh (M Bin Sayeed MSPS); Global Health 
Division, Research Triangle Institute International, Research Triangle 
Park, NC, USA (D Bisanzio PhD); School of Medicine, University of 
Nottingham, Nottingham, UK (D Bisanzio PhD, F Shokraneh MSc); 
Department of Health Sciences (I Filip MD), A T Still University, 
Brisbane, QLD, Australia (T Biswas MPH, A Radfar MD); General 
Directorate of Health Information Systems (B Bora Basara PhD), 
Department of Public Health (A Chitheer FETP), Epidemiology & 
Disease Control (Prof S Ma PhD), Research Department, Prince 
Mohammed Bin Abdulaziz Hospital (Prof Z A Memish MD), NCD 
Prevention & Control Unit (S S Ong MBBS, FAMS), Health and 
Disability Intelligence Group (I Salz MD), Department of Health 
Statistics (G K Yentür MSc), Ministry of Health, Ankara, Turkey 
(M Car PhD, B Er MSc); Centre for Adolescent Health 
(R Borschmann PhD), Population Health Group (Prof G C Patton MD), 
Murdoch Children’s Research Institute, Melbourne, VIC, Australia 
(Prof R G Weintraub MB); School of Population and Global Health 
(R Borschmann PhD), Department of Medicine (Prof B C Cowie PhD), 
Department of Paediatrics (Prof M T Mackay PhD, Prof G C Patton MD), 
School of Health Sciences (Prof A Meretoja MD, Prof C E I Szoeke PhD), 
University of Melbourne, Carlton, Melbourne, VIC, Australia 
(Prof A D Lopez PhD); Department of General Practice and Health 
Services Research, Heidelberg University Hospital, Germany 
(K Bozorgmehr MSc); School of Medicine and Clinical Hospital 
(Prof L C Brant PhD), Department of Maternal and Child Nursing and 
Public Health (Prof D C Malta PhD), Hospital of the Federal University 
of Minas Gerais (Prof B R Nascimento PhD, Prof A P Ribeiro MD), 
Post-graduate Program in Infectious Diseases and Tropical Medicine 
(B P Sao Jose PhD), Federal University of Minas Gerais, Belo Horizonte, 
Brazil; Department of Public Health and Primary Care 
(Prof C Brayne MD, Prof R Chowdhury PhD), MRC Epidemiology Unit 
(N Islam PhD), University of Cambridge, Cambridge, UK; Institute of 
Epidemiology, Comenius University, Bratislava, Slovakia 
(Prof A Brazinova MD); Department of Psychology 
(Prof N J K Breitborde PhD), College of Public Health 
(Prof M Yotebieng PhD), Psychiatry and Behavioral Health Department 
(Prof N J K Breitborde PhD), The Ohio State University, Columbus, OH, 
USA; Division of Clinical Epidemiology and Aging Research, German 
Cancer Research Center, Heidelberg, Germany (Prof H Brenner MD, 
B Schöttker PhD); Department of Neuroscience, Institute for Scientific 
Research and High Technology Services, City Of Knowledge, Panama 
(G Britton PhD); Department of Research and Health Technology 
Assessment (F Castro MD) Gorgas Memorial Institute for Health 
Studies, Panama, Panama (G Britton PhD, I Moreno Velásquez PhD, 
H Quintana PhD); Institute of Public Health (Prof R Busse PhD, 
Prof E Schaeffner MD), Department of Neurology (Prof M Endres MD), 
Department of Operative and Preventive Dentistry 
(Prof F Schwendicke MPH), Charité University Medical Center Berlin, 
Berlin, Germany; School of Population and Public Health 
(Z A Butt PhD, Prof N Sarrafzadegan MD), University of British 
Columbia, Vancouver, BC, Canada (J A Kopec PhD); Al Shifa School of 
Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan 
(Z A Butt PhD); School of Medicine, University of the Valley of 
Cuernavaca, Cuernavaca, Mexico (J Campuzano Rincon PhD); 
Department of Population and Health, Metropolitan Autonomous 
University, Mexico City, Mexico (Prof R Cárdenas DSc); Institute for 
Cancer Research, Prevention and Clinical Network, Florence, Italy 
(G Carreras PhD); Institute of Public Health (Prof F Carvalho PhD), 
Institute of Biomedical Engineering (J Das Neves PhD), REQUIMTE/
LAQV (Prof E Fernandes PhD, Prof D M Pereira PhD), Department of 
Community Medicine, Information and Health Decision Sciences, 
Cintesis, Faculty of Medicine (J V Santos MD), Ucibio (J P Silva PhD), 
Applied Molecular Biosciences Unit (Prof F Carvalho PhD), Institute for 
Research and Innovation in Health (I3S) (J Das Neves PhD), University 
of Porto, Porto, Portugal; Colombian National Health Observatory, 
National Institute of Health, Bogota, Colombia 
(C A Castañeda-Orjuela MSc); Epidemiology and Public Health 
Evaluation Group (C A Castañeda-Orjuela MSc), Department of Public 
Health (Prof F P De La Hoz PhD), National University of Colombia, 
Bogota, Colombia; Department of Epidemiology, Portuguese Oncology 
Institute of Porto, Porto, Portugal (Prof C Castro PhD); Department of 
Health Planning and Economics, Institute of Health Carlos III, Madrid, 
Spain (F Catalá-López PhD); Mary Mackillop Institute for Health 
Research (Prof E Cerin PhD), Institute for Positive Psychology and 
Education (Prof C Lonsdale PhD), The Brain Institute 
(Prof C E I Szoeke PhD), Australian Catholic University, Melbourne, 
VIC, Australia; School of Public Health (Prof E Cerin PhD), Centre for 
Suicide Research and Prevention (Prof P Yip PhD), University of Hong 
Kong, Hong Kong, China (Prof P Yip PhD); College of Medicine, Alfaisal 
University, Riyadh, Saudi Arabia (Y Chaiah, Prof Z A Memish MD, 
Prof M Temsah MRCPCH, MD, O Temsah); College of Medicine 
(Prof J Chang PhD), Institute of Epidemiology and Preventive Medicine 
(Y Wu MSc), National Taiwan University, Taipei, Taiwan; Surgical 
Oncology, Tata Memorial Hospital, Mumbai, India 
(Prof P Chaturvedi MD); Clinical Governance, Gold Coast Health, Gold 
Coast, QLD, Australia (P P Chiang PhD); Institute of Industrial 
Ecological Science, University of Occupational and Environmental 
Health, Kitakyushu, Japan (O Chimed-Ochir PhD); Department of 
Population Studies, University of Zambia, Lusaka, Zambia 
(V H Chisumpa PhD, C Mapoma PhD); Demography and Population 
Studies, University of the Witwatersrand, Johannesburg, South Africa 
(V H Chisumpa PhD); Institute of Clinical Medicine and Bispebjerg 
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1781
Hospital (Prof H Christensen DMSci), Department of Neurology 
(T C Truelsen PhD), University of Copenhagen, Copenhagen, Denmark; 
Department of Pulmonary Medicine (Prof D J Christopher MD), 
Department of Neurology (Prof J D Pandian MD), Department of 
Endocrinology (Prof N Thomas PhD), Christian Medical College and 
Hospital (CMC), Vellore, India; Department of Health Informatics 
(S Chung PhD), Ear Institute (Prof A C Davis PhD), Department of 
Epidemiology and Public Health (Prof M Kivimäki PhD, 
Prof M R Mathur PhD), Department of Psychology (M Kumar PhD), 
University College London, London, UK; Health Data Research UK, 
London, UK (S Chung PhD); School of Public Health and Preventive 
Medicine (Prof F M Cicuttini PhD, Prof Y Guo PhD, S Li PhD, 
S Si PhD), Centre of Cardiovascular Research and Education in 
Therapeutics (R Ofori-Asenso MSc), Monash University, Melbourne, 
VIC, Australia (Prof A G Thrift PhD); Adelaide Medical School 
(L G Ciobanu PhD, T K Gill PhD), School of Public Health 
(G A Tessema MPH), University of Adelaide, Adelaide, SA, Australia 
(A T Olagunju MD); Scuola Medica Salernitana, University of Salerno, 
Baronissi, Italy (Prof M Cirillo MD); Health Effects Institute, Boston, 
MA, USA (A J Cohen DSc); Department of Cardiovascular Medicine, 
Mayo Clinic, Jacksonville, FL, USA (L T Cooper MD); Malaria Vaccines 
(C Karema MPH), Epidemiology and Public Health (T Fürst PhD), Swiss 
Tropical and Public Health Institute, Basel, Switzerland; Quality and 
Equity Health Care, Kigali, Rwanda (C Corine MPH); School of 
Medicine and Surgery, University of Milan Bicocca, Monza, Italy 
(P A Cortesi PhD, C Fornari PhD, A Lafranconi MD, F Madotto PhD); 
Postgraduate Program in Epidemiology, Federal University of Rio 
Grande do Sul, Porto Alegre, Brazil (E Cousin MSc, B B Duncan MD, 
Prof M I Schmidt PhD); WHO Collaborating Centre for Viral Hepatitis 
(Prof B C Cowie PhD), Victorian Infectious Diseases Service (VIDS) 
(K B Gibney PhD), Epidemiology Discipline (J H MacLachlan MSc), 
The Peter Doherty Institute for Infection and Immunity, Melbourne, 
VIC, Australia; Department of Family Medicine and Public Health, 
University of California San Diego, La Jolla, CA, USA 
(Prof M H Criqui MD); Centre for International Health, University of 
Otago, Dunedin, New Zealand (Prof J A Crump MD); Division of 
Infectious Diseases and International Health (Prof J A Crump MD), 
Duke University School of Medicine (P P Doshi MS), Duke Global 
Health Institute (Prof L L Yan PhD), Duke University, Durham, NC, 
USA; College of Medicine and Health Sciences (A K Daba MSc), 
Department of Reproductive Health (D T Hibstu MPH), Hawassa 
University, Hawassa, Ethiopia; Discipline of Public Health, Flinders 
University, Adelaide, SA, Australia (Prof A F Dadi MPH); Institute for 
Global Health Innovations, Duy Tan University, Hanoi, Vietnam 
(A K Dang MD, L H Nguyen MPH, T H Nguyen BMedSc, 
N T Truong B Hlth Sci); Clinical Toxicology Service 
(Prof P I Dargan MB), Biomedical Research Council 
(Prof C D A Wolfe MD), Guy’s and St Thomas’ NHS Foundation Trust, 
London, UK; Department of Rheumatology, K G Medical University, 
Lucknow, India (Prof S K S Das MD); James P Grant School of Public 
Health (R Das Gupta MPH, M Hasan MPH, I Sutradhar MPH), 
Research and Evaluation Division (M Rahman PhD), BRAC University, 
Dhaka, Bangladesh; Central University of Tamil Nadu, Thiruvarur, India 
(Prof A P Dash DSc); Department of Surgery, Clinical Emergency 
Hospital St. Pantelimon, Bucharest, Romania (Prof D V Davitoiu PhD); 
Kazakh National Medical University, Almaty, Kazakhstan 
(Prof K Davletov PhD); National Drug and Alcohol Research Centre 
(Prof L Degenhardt PhD), South Western Sydney Clinical School 
(Prof G B Marks PhD), School of Medicine (Prof P K Maulik PhD, 
Prof B Neal PhD), School of Psychiatry (Prof P S Sachdev MD), 
University of New South Wales, Sydney, NSW, Australia; Population 
Dynamics and Reproductive Health Unit, African Population Health 
Research Centre, Nairobi, Kenya (T T Degfie PhD); Department of 
Clinical Pharmacy, Aksum University, Aksum, Ethiopia 
(G T Demoz MSc); Department of Global Health and Infection, 
Brighton and Sussex Medical School, Brighton, UK (K Deribe PhD); 
National Health Service Scotland, Edinburgh, UK (N Dervenis MD, 
G M A Wyper MSc); Aristotle University of Thessaloniki, Thessaloniki, 
Greece (N Dervenis MD); Department of Psychiatry 
(Prof D C Des Jarlais PhD), Department of Medicine 
(Prof J R Masci MD), Icahn School of Medicine at Mount Sinai, 
New York, NY, USA; Disha Foundation, Gurgaon, India (S Dey PhD); 
Department of Community Medicine, University of Peradeniya, 
Peradeniya, Sri Lanka (S D Dharmaratne MD); Swedish Family Medicine 
- First Hill, Seattle, WA, USA (M A Dirac MD); Deputy of Research and 
Technology (Prof S Djalalinia PhD), Center of Communicable Disease 
Control (B Eshrati PhD), Department of Human Resources 
(Z Kazemi MSc), Ministry of Health and Medical Education, Tehran, 
Iran (Z Kazemi MSc, Prof A Khosravi PhD); Department of Social 
Medicine and Health Care Organisation, Medical University of Varna, 
Varna, Bulgaria (Prof K Dokova PhD); Department of Population and 
Health, University of Cape Coast, Cape Coast, Ghana (D T Doku PhD); 
Faculty of Social Sciences, Health Sciences (D T Doku PhD), Faculty of 
Health Sciences, Health Sciences (S Neupane PhD), University of 
Tampere, Tampere, Finland; University of Rochester, Rochester, NY, 
USA (E Dorsey MD); School of Health and Biomedical Sciences 
(Prof K E Doyle PhD, Prof A L Zhang PhD), Department of Psychology 
(Prof S R Robinson PhD), Royal Melbourne Institute of Technology 
University, Bundoora, VIC, Australia; Sydney School of Public Health 
(Prof T R Driscoll PhD), Sydney Medical School (S Islam PhD), Asbestos 
Diseases Research Institute (J Leigh MD), Woolcock Institute of Medical 
Research (Prof G B Marks PhD), University of Sydney, Sydney, NSW, 
Australia (D G Hoy PhD, M A Mohammed PhD, Prof K Takahashi PhD); 
United Nations World Food Programme, New Delhi, India 
(M Dubey PhD); Faculty of Medicine (E Dubljanin PhD), Institute of 
Social Medicine, Centre School of Public Health and Health 
Management (Prof M M Santric Milicevic PhD), University of Belgrade, 
Belgrade, Serbia; School of Medicine, Federal University of Bahia, 
Salvador, Brazil (Prof A R Duraes PhD); Diretoria Médica, Roberto 
Santos General Hospital, Salvador, Brazil (Prof A R Duraes PhD); 
Department of Nursing, Umeå University, Umea, Sweden 
(Prof D Edvardsson PhD); Department of Community Medicine, 
University of Tromsø, Tromsø, Norway (Prof A E Eggen PhD); 
Department of Community Medicine, Tripoli University, Tripoli, Libya 
(H Elkout PhD); Health Information (H Elkout PhD), Tuberculosis 
Health Topic (K W Rade MD), World Health Organization (WHO), 
Tripoli, Libya; Department of Pathology, Stavanger University Hospital, 
Stavanger, Norway (C L Ellingsen MD); Centre for Disease Burden 
(A S Knudsen PhD), Division of Mental and Physical Health 
(Prof S Øverland PhD), Norwegian Institute of Public Health, Oslo, 
Norway (C L Ellingsen MD); Public Health Department, Saint Paul’s 
Hospital Millennium Medical College, Addis Ababa, Ethiopia 
(A Y Endries MPH); Policy and Epidemiology Group 
(D F Santomauro PhD), Child and Youth Mental Health 
(Prof J G Scott PhD), Queensland Centre for Mental Health Research, 
Brisbane, QLD, Australia (H E Erskine PhD, A J Ferrari PhD); 
Department of Public Health (Prof R Esmaeili PhD), Gonabad 
University of Medical Sciences, Gonabad, Iran; Department of Medical 
Parasitology and Mycology, Urmia University of Medical Science, Urmia, 
Iran (Prof H Fakhim PhD); College of Medicine (M Fareed PhD), 
Department of Public Health (Prof A T Khoja MD), Imam Muhammad 
Ibn Saud Islamic University, Riyadh, Saudi Arabia; National Statistical 
Office, Lisbon, Portugal (C S E Farinha MSc); Department of Psychology, 
Federal University of Sergipe, Sao Cristovao, Brazil (Prof A Faro PhD); 
National Institute for Stroke and Applied Neurosciences, Auckland 
University of Technology, Auckland, New Zealand (Prof V L Feigin PhD); 
Health Division, Organisation for Economic Co-operation and 
Development, Paris, France (A B Feigl PhD); Center for Biotechnology 
and Fine Chemistry - Associate Laboratory, Faculty of Biotechnology, 
Catholic University of Portugal, Porto, Portugal (J C Fernandes PhD); 
Department of Psychiatry (I Filip MD), Division of Research 
(J O Lam PhD), Kaiser Permanente, Fontana, CA, USA; Department of 
Public Health Medicine, Bielefeld University, Bielefeld, Germany 
(F Fischer PhD); Institute of Gerontology, National Academy of Medical 
Sciences of Ukraine, Kyiv, Ukraine (N A Foigt PhD); Gene Expression & 
Regulation Program, Cancer Institute, Philadelphia, PA, USA 
(T Fukumoto PhD); Department of Dermatology, Kobe University, Kobe, 
Japan (T Fukumoto PhD); University of Basel, Basel, Switzerland 
(T Fürst PhD); Faculty of Business and Management 
(M A Garcia-Gordillo PhD), Institute of Physical Activity and Health 
(Prof P R Olivares PhD), Autonomous University of Chile, Talca, Chile; 
School of Public Health, Curtin University, Perth, WA, Australia 
Global Health Metrics
1782 www.thelancet.com   Vol 392   November 10, 2018
(A T Gebremedhin MPH, D Hendrie PhD, T R Miller PhD); Division of 
Human Nutrition and Health, Wageningen University & Research, 
Wageningen, Netherlands (Prof J M Geleijnse PhD); Directorate General 
for Public Health, Regional Health Council, Madrid, Spain 
(R Genova-Maleras MSc); Department of Health Care Policy and 
Management, University of Tsukuba, Tsukuba, Japan (M Ghimire MA); 
The Royal Melbourne Hospital, Melbourne, VIC, Australia 
(K B Gibney PhD); Unit of Academic Primary Care (Prof P S Gill DM), 
Division of Health Sciences (Prof O A Uthman PhD), University of 
Warwick, Coventry, UK; Department of Community and Family 
Medicine (R R F Gillum MD), Division of General Internal Medicine 
(R R F Gillum MD), Howard University, Washington, DC, USA; 
Department of Neurology (Prof M Giroud PhD), Department of Vital 
and Health Statistics (H L Harb MPH), Department of Disease, 
Epidemics, and Pandemics Control (J Nansseu MD), Ministry of Public 
Health, Dijon, France; Faculty of Medicine, Postgraduate Medical 
Institute, Dijon, France (Prof M Giroud PhD); Physical Activity and 
Obesity Prevention (S Goenka PhD), Centre for Chronic Disease 
Control, New Delhi, India (Prof S Liu PhD); Center for the Study of 
Regional Development, Jawahar Lal Nehru University, New Delhi, India 
(S Goli PhD); Nursing and Health Sciences Department, University of 
Massachusetts Boston, Boston, MA, USA (Prof P N Gona PhD); 
Department of Biostatistics and Epidemiology, University of Oklahoma, 
Oklahoma City, OK, USA (S V Gopalani MPH); Department of Health 
and Social Affairs, Government of the Federated States of Micronesia, 
Palikir, Federated States of Micronesia (S V Gopalani MPH); Metabolic 
Epidemiology Section, National Cancer Center, Chuo-ku, Japan 
(A Goto MD); School of Medicine, Boston University, Boston, MA, USA 
(A Grada MD); Registro Tumori Integrato, Vittorio Emanuele University 
Hospital Polyclinic, Catania, Italy (G Grosso PhD); Department of 
Epidemiology (Prof H C Gugnani PhD), Department of Microbiology 
(Prof H C Gugnani PhD), Saint James School of Medicine, The Valley, 
Anguilla; School of Dentistry, State University of Montes Claros, Montes 
Claros, Brazil (Prof A L S Guimaraes PhD); Department of 
Epidemiology, Healis Sekhsaria Institute for Public Health, Mumbai, 
India (P C Gupta DSc, D N Sinha PhD); Commissioner of Public Health, 
West Virginia Bureau for Public Health, Charleston, WV, USA 
(Prof R Gupta MD); Department of Health Policy, Management & 
Leadership, West Virginia University School of Public Health, 
Morgantown, WV, USA (Prof R Gupta MD); Academics and Research, 
Rajasthan University of Health Sciences, Jaipur, India 
(Prof R Gupta MD); Department of Preventive Cardiology, Eternal Heart 
Care Centre & Research Institute, Jaipur, India (Prof R Gupta MD); 
Department of Cardiology, Montefiore Medical Center, Bronx, NY, USA 
(T Gupta MD); Department of Epidemiology and Population Health 
(H Hosgood PhD), Albert Einstein College of Medicine, Bronx, NY, USA 
(T Gupta MD); Department of Epidemiology and Psychosocial Research, 
Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico City, 
Mexico (R A Gutiérrez PhD); Department of Public Health 
(B Gyawali MPH), National Centre for Register-based Research 
(Prof J J McGrath MD), Aarhus University, Aarhus, Denmark; Nepal 
Development Society, Pokhara, Nepal (B Gyawali MPH); Department of 
Public Health, Erasmus University Medical Center, Rotterdam, 
Netherlands (J A Haagsma PhD, S Kochhar MD, S Polinder MA); 
Department of Family and Community Medicine, Arabian Gulf 
University, Manama, Bahrain (Prof R R Hamadeh DPhil); School of 
Health and Environmental Studies, Hamdan Bin Mohammed Smart 
University, Dubai, United Arab Emirates (Prof S Hamidi DrPH); 
Population Health Department, University of New Mexico, Albuquerque, 
NM, USA (A J Handal PhD); Neurology Department, Sir Charles 
Gairdner Hospital, Perth, WA, Australia (Prof G J Hankey MD); 
Cardiology Department (Prof S Harikrishnan MD), Achutha Menon 
Centre for Health Science Studies (Prof P Jeemon PhD, G Mini PhD, 
Prof K R Thankappan MD), Neurology Department (Prof P Sylaja), Sree 
Chitra Tirunal Institute for Medical Sciences and Technology, 
Trivandrum, India; Research and Development Unit, San Juan de Dios 
Sanitary Park, Sant Boi De Llobregat, Spain (Prof J M Haro MD, 
S Tyrovolas PhD); Department of Medicine (Prof J M Haro MD), 
University of Barcelona, Barcelona, Spain (S Tyrovolas PhD); Public 
Health Department (L Jahangiry PhD), Tabriz University of Medical 
Sciences, Tabriz, Iran (H Hassankhani PhD); Independent Consultant, 
Tabriz, Iran (H Hassankhani PhD); Unit of Epidemiology and Social 
Medicine, University Hospital Antwerp, Wilrijk, Belgium 
(H Y Hassen MPH); Clinical Sciences Department, Karolinska 
University Hospital, Stockholm, Sweden (R Havmoeller PhD); 
International Foundation for Dermatology, London, UK 
(Prof R J Hay MD); Department of Environmental Health Engineering, 
Hormozgan University of Medical Sciences, Bandar Abbas, Iran 
(Prof M Heidari PhD); Department of Statistics and Econometrics, 
Bucharest University of Economic Studies, Bucharest, Romania 
(Prof C Herteliu PhD, Prof A Mirica PhD, A Pana MD); Department of 
Psychiatry, University Medical Center Groningen, Groningen, 
Netherlands (Prof H W Hoek MD); Department of Epidemiology 
(Prof H W Hoek MD), Department of Health and Behavior Studies 
(Prof I D Sigfusdottir PhD), Columbia University, New York, NY, USA; 
University of Texas - Austin, Austin, TX, USA (M K Hole MD); School of 
Health (Prof E Homaie Rad PhD), Guilan Road Trauma Research Center 
(Prof E Homaie Rad PhD), Guilan University of Medical Sciences, Rasht, 
Iran; Transdisciplinary Centre for Qualitative Methods, Manipal 
University, Manipal, India (A Pujar PhD, P Hoogar PhD); Department of 
Computer Science, University of Human Development, Sulaimaniyah, 
Iraq (M Hosseinzadeh PhD); Department of Internal Medicine, 
Bucharest Emergency Hospital, Bucharest, Romania 
(Prof M Hostiuc PhD); Clinical Legal Medicine, National Institute of 
Legal Medicine Mina Minovici, Bucharest, Romania 
(Prof S Hostiuc PhD); Department of Epidemiology and Health 
Statistics, Central South University, Changsha, China (Prof G Hu PhD); 
Institute of Community and Public Health, Birzeit University, Birzeit, 
Palestine (Prof A Husseini PhD); Health Sciences Department, Qatar 
University, Doha, Qatar (Prof A Husseini PhD); Infectious Diseases 
Department, Bashkir State Medical University, Ufa, Russia 
(B Idrisov MD); Department of Public Health and Community Medicine, 
University of Liberia, Monrovia, Liberia (O S Ilesanmi PhD); Global 
Health and Development Department (Prof U Iqbal PhD), Graduate 
Institute of Biomedical Informatics (D N A Ningrum MPH), Taipei 
Medical University, Taipei City, Taiwan; Institute for Physical Activity 
and Nutrition (S Islam PhD), School of Medicine (M Rahman PhD), 
Department of Psychology (Prof M A Stokes PhD), Deakin University, 
Burwood, VIC, Australia; Surveillance and Health Services Research, 
American Cancer Society, Atlanta, GA, USA (F Islami PhD); Department 
of Global and Community Health, George Mason University, Fairfax, 
VA, USA (K H Jacobsen PhD); Public Health Department, Tabriz 
University of Medical Sciences, Tabriz, Iran (L Jahangiry PhD); 
Department of Parasitic Diseases, National Centre for Disease Control 
Delhi, Delhi, India (S K Jain MD); Medical Sciences Department, 
University of Kragujevac, Kragujevac, Serbia (Prof M Jakovljevic PhD); 
Newcastle University, Tyne, UK (M Javanbakht PhD); Faculty of 
Graduate Studies (A U Jayatilleke PhD), Institute of Medicine 
(A U Jayatilleke PhD), University of Colombo, Colombo, Sri Lanka; 
Center for Applied Pediatric Quality Analytics, Boston Children’s 
Hospital, Boston, MA, USA (K J Jenkins MD); Department of 
Community Medicine, Banaras Hindu University, Varanasi, India 
(R P Jha MSc); Beijing Institute of Ophthalmology, Beijing Tongren 
Hospital, Beijing, China (Prof J B Jonas MD); Centre for Community 
Medicine (Prof A Joshi MD, Prof A P Pakhare MD), Department of 
Paediatrics (Prof R Lodha MD), Department of Cardiology 
(Prof A Roy MD), Department of Psychiatry (Prof R Sagar MD), 
Department of Endocrinology, Metabolism, & Diabetes 
(Prof N Tandon PhD), All India Institute of Medical Sciences, 
New Delhi, India; Institution of Health and Nutrition Sciences, 
Czestochowa University of Technology, Czestochowa, Poland 
(Prof J J Jozwiak PhD); Faculty of Medicine and Health Sciences, 
University of Opole, Opole, Poland (Prof J J Jozwiak PhD); School of 
Health Sciences, Savitribai Phule Pune University, Pune, India 
(S B Jungari MA); Institute of Family Medicine and Public Health, 
University of Tartu, Tartu, Estonia (M Jürisson PhD); School of Public 
Health, University College Cork, Cork, Ireland (Z Kabir PhD); 
Department of Epidemiology (M Karami PhD), Department of 
Environmental Health Engineering (M Leili PhD), Chronic Diseases 
(Home Care) Research Center, Hamadan University of Medical Sciences, 
Hamadan, Iran (M Shamsizadeh MSc), Hamadan University of Medical 
Sciences, Hamadan, Iran; Department for Epidemiology, Helmholtz 
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1783
Centre for Infection Research, Braunschweig, Germany (A Karch MD); 
Baqiyatallah Research Center for Gastroenterology and Liver Diseases 
(H Karimi-Sari MD), Student Research Committee (M Khosravi MD), 
Baqiyatallah University of Medical Sciences, Tehran, Iran; Department 
of Young Investigators, Middle East Liver Disease Center, Tehran, Iran 
(H Karimi-Sari MD); Department of Anesthesiology & Pain Medicine, 
Seattle Children’s Hospital, Seattle, WA, USA (N J Kassebaum MD); 
MRC/CSO Social and Public Health Sciences Unit, University of 
Glasgow, Glasgow, UK (S V Katikireddi PhD); School of Health Care 
Administration, Oklahoma State University, Tulsa, OK, USA 
(Prof A Kaul MD); Health Care Delivery Sciences, University of Tulsa, 
Tulsa, OK, USA (Prof A Kaul MD); Department of Epidemiology and 
Biostatistics (D S Kazi MD, Prof K M Mehta DSc), Department of 
Medicine (D S Kazi MD), University of California San Francisco, 
San Francisco, CA, USA; ODeL Campus (Prof P N Keiyoro PhD), School 
of Medicine (Prof G Yonga MD), University of Nairobi, Nairobi, Kenya 
(M Kumar PhD); Department of Linguistics and Germanic, Slavic, 
Asian, and African Languages, Michigan State University, East Lansing, 
MI, USA (G R Kemp BA); Non-communicable Diseases Research Unit 
(Prof A P Kengne PhD), Alcohol, Tobacco, & Other Drug Use Research 
Unit (Prof C D H Parry PhD), Cochrane South Africa (E Z Sambala PhD, 
Prof C S Wiysonge MD), Medical Research Council South Africa, Cape 
Town, South Africa; Department of Medicine (Prof A P Kengne PhD, 
G A Mensah MD, J Noubiap MD, Prof K Sliwa MD, 
Prof L J Zuhlke PhD), School of Public Health and Family Medicine 
(R Matzopoulos PhD), Department of Psychiatry and Mental Health 
(Prof D J Stein MD), Department of Paediatrics and Child Health 
(Prof L J Zuhlke PhD), University of Cape Town, Cape Town, South 
Africa; Institute of Cardiology, Assuta Hospital, Tel Aviv Yaffo, Israel 
(Prof A Keren MD); Heart Failure and Cardiomyopathies Center, 
Hadassah Hebrew University Hospital, Jerusalem, Israel 
(Prof A Keren MD); CSIR-Indian Institute of Toxicology Research, 
Council of Scientific & Industrial Research, Lucknow, India 
(C Kesavachandran PhD); Department of Public Health and Community 
Medicine, Jordan University of Science and Technology, Ramtha, Jordan 
(Prof Y S Khader PhD); Department of Statistics, Azad University, 
Omidiyeh Branch, Iran (B Khafaei PhD); Epidemiology and Biostatistics 
Department, Health Services Academy, Islamabad, Pakistan 
(Prof E A Khan MPH); Department of Internal Medicine, 
John H. Stroger Jr Hospital of Cook County, Chicago, IL, USA 
(M S Khan MD); Department of Internal Medicine (M S Khan MD, 
T J Siddiqi MB, M S Usman MB), Dow University of Health Sciences, 
Karachi, Pakistan; Department of Epidemiology (G Naik MPH, 
J A Singh MD), Department of Medicine (P Ranjan PhD, J A Singh MD), 
Department of Psychology (D C Schwebel PhD), University of Alabama 
at Birmingham, Birmingham, AL, USA (M Khan MD, A R Sawant MD); 
University of Tennessee, Knoxville, TN, USA (M Khan MD); Institute of 
Health Policy and Management (Prof Y Khang MD), Department of 
Health Policy and Management (Prof Y Khang MD), Seoul National 
University, Seoul, South Korea; International Otorhinolaryngology 
Research Association, Tehran, Iran (M Khosravi MD); Department of 
Nutrition and Health Science, Ball State University, Muncie, IN, USA 
(Prof J Khubchandani PhD); Clinical Epidemiology Unit 
(A A Kiadaliri PhD), Department of Clinical Sciences 
(Prof B Norrving PhD), Lund University, Lund, Sweden; Kenya Revenue 
Authority, Nairobi, Kenya (D N Kiirithio MSc); Research and Data 
Solutions, Synotech Consultant, Nairobi, Kenya (D N Kiirithio MSc); 
Department of Health Sciences, Northeastern University, Boston, MA, 
USA (Prof D Kim DrPH); Department of Preventive Medicine, Korea 
University, Seoul, South Korea (Y Kim PhD, Prof S Yoon PhD); School of 
Medicine, Xiamen University Malaysia, Sepang, Malaysia 
(Prof Y Kim PhD); Department of Nutrition, Simmons College, Boston, 
MA, USA (R W Kimokoti MD); Faculty of Health, University of 
Canberra, Canberra, ACT, Australia (Y Kinfu PhD); Department of 
Health Management and Health Economics (Prof A Kisa PhD), Institute 
of Health and Society (A S Winkler PhD), University of Oslo, Oslo, 
Norway; Department of Global Community Health and Behavioral 
Sciences, Tulane University, New Orleans, LA, USA (Prof A Kisa PhD); 
Department of Health Economics and Social Security 
(K Kissimova-Skarbek PhD), Institute of Public Health 
(R Topor-Madry PhD), Jagiellonian University Medical College, Krakow, 
Poland; Department of Public Health (Prof M Kivimäki PhD, 
T Lallukka PhD), University of Helsinki, Helsinki, Finland 
(T J Meretoja MD); Department of Psychosocial Science 
(A S Knudsen PhD, Prof S Øverland PhD), Department of Global Public 
Health and Primary Care (Prof O F Norheim PhD), University of 
Bergen, Bergen, Norway; Public Health Sciences Division, Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA 
(J M Kocarnik PhD); Department of Preventive Cardiology, National 
Cerebral and Cardiovascular Center, Suita, Japan (Prof Y Kokubo PhD); 
Arthritis Research Canada, Richmond, BC, Canada (J A Kopec PhD); 
Department of Internal and Pulmonary Medicine, Sheri Kashmir 
Institute of Medical Sciences, Srinagar, India (Prof P A Koul MD); 
Research Center of Neurology, Moscow, Russia (E V Gnedovskaya PhD, 
M A Kravchenko PhD); Department of Anthropology, Panjab University, 
Chandigarh, India (Prof K Krishan PhD); Department of Social and 
Preventive Medicine (Prof B Kuate Defo PhD), Department of 
Demography (Prof B Kuate Defo PhD), University of Montreal, 
Montreal, QC, Canada; Department of Public Health, Yuksek Ihtisas 
University, Ankara, Turkey (Prof B Kucuk Bicer BEP); Department of 
Public Health, Hacettepe University, Ankara, Turkey 
(Prof B Kucuk Bicer BEP); Population and Work Ability Program 
(T Lallukka PhD), Finnish Institute of Occupational Health, Helsinki, 
Finland (R Shiri PhD); Department of Community and Family Medicine 
(Prof F H Lami PhD), Assistant Professor of Epidemiology 
(Prof M Moradinazar PhD), Academy of Medical Science, Baghdad, Iraq; 
HelpMeSee, New York, NY, USA (Prof V C Lansingh PhD); Belo 
Horizonte City Hall, Municipal Health Department of Belo Horizonte, 
Belo Horizonte, Brazil (Prof S Lansky PhD); Relaciones Internacionales, 
Mexican Institute of Ophthalmology, Queretaro, Mexico 
(Prof V C Lansingh PhD); Department of Public Health (A Latifi PhD), 
Managerial Epidemiology Research Center (S Safiri PhD), Maragheh 
University of Medical Sciences, Maragheh, Iran; Department of 
Information and Internet Technologies, I M Sechenov First Moscow 
State Medical University, Moscow, Russia (Prof G Lebedev PhD, 
S K Vladimirov PhD); Central Research Institute of Cytology and 
Genetics (E Varavikova PhD) Federal Research Institute for Health 
Organization and Informatics of the Ministry of Health (FRIHOI), 
Moscow, Russia (Prof G Lebedev PhD, Prof V I Starodubov DSc, 
S K Vladimirov PhD); School of Nursing, Hong Kong Polytechnic 
University, Hong Kong, China (P H Lee PhD); Department of Clinical 
Research and Epidemiology, Shenzhen Sun Yat-sen Cardiovascular 
Hospital, Shenzhen, China (Prof Y Li PhD); National Office for Maternal 
and Child Health Surveillance, Chengdu, China (Prof J Liang MD, 
Prof Y Wang MD); National Center of Birth Defects Monitoring of 
China, Chengdu, China (Prof J Liang MD, Prof Y Wang MD); 
Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia 
(L Lim MD); Department of Medicine and Therapeutics, The Chinese 
University of Hong Kong, Shatin, China (L Lim MD); School of Public 
Health, University of Haifa, Haifa, Israel (Prof S Linn DrPH); Institute 
of Nutrition, Friedrich Schiller University Jena, Jena, Germany 
(Prof S Lorkowski PhD); Competence Cluster for Nutrition and 
Cardiovascular Health (NUTRICARD), Jena, Germany 
(Prof S Lorkowski PhD); General Surgery Department, Aintree 
University Hospital National Health Service  Foundation Trust (NHS), 
Liverpool, UK (R Lunevicius PhD); Surgery Department, University of 
Liverpool, Liverpool, UK (R Lunevicius PhD); Saw Swee Hock School of 
Public Health (Prof S Ma PhD), Yong Loo Lin School of Medicine 
(Prof N Venketasubramanian MBBS), National University of Singapore, 
Singapore; Neurology Department (Prof M T Mackay PhD), Cardiology 
Department (Prof R G Weintraub MB), Royal Children’s Hospital, 
Melbourne, VIC, Australia; Cardiology, Damietta University, Damietta, 
Egypt (H Magdy Abd El Razek MD); Ophthalmology Department, Aswan 
Faculty of Medicine, Aswan, Egypt (M Magdy Abd El Razek MB); 
Department of Internal Medicine, Grant Medical College & Sir J J Group 
of Hospitals, Mumbai, India (D P Maghavani MBBS); Department of 
Public Health, Trnava University, Trnava, Slovakia (Prof M Majdan PhD); 
Non-communicable Diseases Research Center, Shiraz University of 
Medical Sciences, Shiraz, Iran (Prof R Malekzadeh MD, 
S G Sepanlou MD); Surgery Department, Emergency University 
Hospital Bucharest, Bucharest, Romania (A Manda MD); Department of 
Economics, Autonomous Technology Institute of Mexico, Mexico City, 
Global Health Metrics
1784 www.thelancet.com   Vol 392   November 10, 2018
Mexico (Prof G Martinez PhD); Campus Caucaia, Federal Institute of 
Education, Science and Technology of Ceará, Caucaia, Brazil 
(F R Martins-Melo PhD); Clinical Institute of Medical and Chemical 
Laboratory Diagnostics, Medical University of Graz, Graz, Austria 
(Prof W März MD); Graduate School, University of the East Ramon 
Magsaysay Memorial Medical Center, Quezon City, Philippines 
(M B Marzan MSc); National Centre for Disease Informatics and 
Research (P Mathur PhD), Regional Medical Research Centre 
(S Pati MD), Indian Council of Medical Research, Bengaluru, India; 
Department of Biology and Biological Engineering, Chalmers University 
of Technology, Gothenburg, Sweden (M Mazidi PhD); Department of 
Ophthalmology, Hywel Dda University Health Board, Carmarthen, UK 
(C McAlinden PhD); Liver Disease and Hepatitis Program, Alaska Native 
Medical Center, Anchorage, AK, USA (B J McMahon MD); Research, 
Monitoring and Evaluation, Ipas Nepal, Kathmandu, Nepal 
(S Mehata PhD); Neurology Department, Janakpuri Super Specialty 
Hospital Society, New Delhi, India (Prof M Mehndiratta MD); Preventive 
Oncology, National Institute of Cancer Prevention and Research, Noida, 
India (Prof R Mehrotra PhD); Department of Internal Medicine, 
Sevenhills Hospital, Mumbai, India (V Mehta MD); Department of 
Public Health (T C Mekonnen MPH), Department of Pharmacy 
(G Mengistu MSc), Wollo University, Dessie, Ethiopia; College of Health 
Sciences, Debre Tabor University, Debre Tabor, Ethiopia (A Melese MSc); 
Department of Public Health, University of West Florida, Pensacola, FL, 
USA (Prof P T N Memiah DrPH); Peru Country Office, United Nations 
Population Fund (UNFPA), Lima, Peru (W Mendoza MD); Center for 
Translation Research and Implementation Science, National Institutes of 
Health, Bethesda, MD, USA (G A Mensah MD); Neurocenter 
(Prof A Meretoja MD), Breast Surgery Unit (T J Meretoja MD), Helsinki 
University Hospital, Helsinki, Finland; Clinical Microbiology and 
Parasitology Unit, Zagreb, Croatia (Prof T Mestrovic PhD); University 
Centre Varazdin, University North, Varazdin, Croatia 
(Prof T Mestrovic PhD); Department of Pharmacy, Ethiopian Academy 
of Medical Science, Mekelle, Ethiopia (Prof H B Mezgebe MSc); 
Department of Hypertension (Prof T Miazgowski MD), Zdroje Hospital 
(J Widecka PhD), Emergency Department (B Miazgowski MD), 
Pomeranian Medical University, Szczecin, Poland (B Miazgowski MD); 
Pacific Institute for Research & Evaluation, Calverton, MD, USA 
(T R Miller PhD); Nevada Division of Public and Behavioral Health, 
Carson City, NV, USA (M Mirarefin MPH); President’s Office, National 
Institute of Statistics, Bucharest, Romania (Prof A Mirica PhD); Faculty 
of General Medicine, Kyrgyz State Medical Academy, Bishkek, 
Kyrgyzstan (Prof E M Mirrakhimov MD); Department of Atherosclerosis 
and Coronary Heart Disease, National Center of Cardiology and Internal 
Disease, Bishkek, Kyrgyzstan (Prof E M Mirrakhimov MD); Institute of 
Addiction Research (ISFF), Frankfurt University of Applied Sciences, 
Frankfurt, Germany (B Moazen MSc); Department of Biology, 
Salahaddin University, Erbil, Iraq (K A Mohammad PhD); Erbil, Ishik 
University, Erbil, Iraq (K A Mohammad PhD); Cardiovascular Research 
Institute, Isfahan University of Medical Sciences, Isfahan, Iran 
(N Mohammadifard PhD, Prof N Sarrafzadegan MD); Department of 
Public Health, Jigjiga University, Jigjiga, Ethiopia 
(M A Mohammed PhD); Health Systems and Policy Research Unit 
(S Mohammed PhD), Department of Community Medicine 
(M B Sufiyan MD), Ahmadu Bello University, Zaria, Nigeria; 
Department of Diabetology, Madras Diabetes Research Foundation, 
Chennai, India (V Mohan DSc); Clinical Epidemiology and Public 
Health Research Unit, Burlo Garofolo Institute for Maternal and Child 
Health, Trieste, Italy (L Monasta DSc, L Ronfani PhD); Department of 
Epidemiology and Biostatistics (Prof G Moradi PhD), Social 
Determinants of Health Research Center (Prof G Moradi PhD), 
Kurdistan University of Medical Sciences, Sanandaj, Iran; Lancaster 
University, Lancaster, UK (P Moraga PhD); International Laboratory for 
Air Quality and Health (Prof L Morawska PhD), Australian Centre for 
Health Services Innovation (R Pacella PhD), School of Exercise and 
Nutrition Sciences (Q G To PhD), Queensland University of Technology, 
Brisbane, QLD, Australia; Santo Antonio Hospital, Hospital Center of 
Porto, Porto, Portugal (J Morgado-Da-Costa MSc); 1st Department of 
Ophthalmology, General Hospital of Athens, University of Athens, 
Athens, Greece (Prof M M Moschos PhD); Biomedical Research 
Foundation, Academy of Athens, Athens, Greece 
(Prof M M Moschos PhD); Demographic Change and Ageing Research 
Area (A Werdecker PhD), Competence Center Mortality-follow-up 
(R Westerman PhD), Federal Institute for Population Research, 
Wiesbaden, Germany (Prof U O Mueller MD); Center for Population and 
Health, Wiesbaden, Germany (Prof U O Mueller MD); Department of 
Endocrinology & Metabolism, Institute of Post Graduate Medical 
Education & Research, Kolkata, India (Prof S Mukhopadhyay MD); 
Department of Obstetrics and Gynecology, University of Jos, Jos, Nigeria 
(J Musa MD); Center for Global Health (J Musa MD), Department of 
Preventative Medicine (Prof Y Yano MD), Northwestern University, 
Chicago, IL, USA; School of Medical Sciences, Science University of 
Malaysia, Kubang Kerian, Malaysia (Prof K Musa PhD); Pediatrics 
Department, Nishtar Medical University, Multan, Pakistan 
(Prof G Mustafa MD); Pediatrics & Pediatric Pulmonology, Institute of 
Mother & Child Care, Multan, Pakistan (Prof G Mustafa MD); 
Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 
USA (Prof J B Nachega PhD); Institute of Epidemiology and Medical 
Biometry, Ulm University, Ulm, Germany (Prof G Nagel PhD, 
Prof D Rothenbacher MD); Department of Pulmonary Medicine, 
Government Medical College Trivandrum, Trivandrum, India 
(Prof S Nair MD); Health Action by People, Trivandrum, India 
(Prof S Nair MD); Department of Dermatology, San Bortolo Hospital, 
Vicenza, Italy (Prof L Naldi MD); Direction, GISED Study Center, 
Bergamo, Italy (Prof L Naldi MD); Department of Preventive Medicine 
and Public Health, Chungnam National University School of Medicine, 
Daejeon, South Korea (Prof H Nam PhD); Daejeon Regional Cancer 
Center, Chungnam National University Hospital, Daejeon, South Korea 
(Prof H Nam PhD); Ophthalmology, Suraj Eye Institute, Nagpur, India 
(V Nangia MD); Department of Public Heath (J Nansseu MD), 
Department of Internal Medicine and Specialties (Prof E Sobngwi PhD), 
University of Yaoundé I, Yaoundé, Cameroon; Department of 
Nephrology, Madras Medical College, Chennai, India 
(Prof G Natarajan BEP); Department of Cardiology, Cardio-aid, 
Bucharest, Romania (Prof R I Negoi PhD); Department of 
Neurosciences, Kenya Medical Research Institute/Wellcome Trust 
Research Programme, Kilifi, Kenya (Prof C R J Newton MD); Ministry of 
Health, Community Development, Gender, Elderly and Children, Dar Es 
Salaam, Tanzania (F N Ngalesoni PhD); Department of Biological 
Sciences, University of Embu, Embu, Kenya (J W Ngunjiri DrPH); 
Hanoi School of Public Health, Hanoi, Vietnam (A Q Nguyen PhD, 
H T Nguyen MSc, Prof H T Nguyen PhD); Public Health Science 
Department, State University of Semarang, Kota Semarang, Indonesia 
(D N A Ningrum MPH); National Department of Health, South African 
Embassy, Pretoria, South Africa (N Nolutshungu MD); Institute for 
Global Health Policy Research, National Center for Global Health and 
Medicine, Shinjuku-ku, Japan (Prof S Nomura MSc); University of 
Social Welfare and Rehabilitation Sciences, Iran (Prof M Noroozi PhD); 
Department of Preventive Medicine, Kyung Hee University, 
Dongdaemun-gu, South Korea (Prof I Oh PhD); Department of 
HIV/AIDS, STIs & TB, Human Sciences Research Council, Durban, 
South Africa (O Oladimeji MD); School of Public Health, University of 
Namibia, Oshakati Campus, Namibia (O Oladimeji MD); Department of 
Psychiatry, University of Lagos, Lagos, Nigeria (A T Olagunju MD); 
Centre for Healthy Start Initiative, Ikoyi, Nigeria (B O Olusanya PhD, 
J O Olusanya MBA); Institute of Health Science, University of Brunei 
Darussalam, Gadong, Brunei (S S Ong MBBS, FAMS); Graduate School 
of Public Health, San Diego State University, San Diego, CA, USA 
(Prof E Oren PhD); School of Psychology, University of Ottawa, Ottawa, 
ON, Canada (H M Orpana PhD); School of Medicine (Prof A Ortiz MD), 
Pneumology Service (Prof J B Soriano MD), Autonomous University of 
Madrid, Madrid, Spain; Nephrology and Hypertension Department, 
The Institute for Health Research Foundation Jiménez Díaz University 
Hospital, Madrid, Spain (Prof A Ortiz MD); Center for Vaccine 
Development (Prof J R Ortiz MD), School of Medicine 
(Prof M T Wallin MD), University of Maryland, Baltimore, MD, USA; 
The Center for Healthcare Quality Assessment and Control, Ministry of 
Health of the Russian Federation, Moscow, Russia (S S Otstavnov PhD); 
Moscow Institute of Physics and Technology, Moscow State University, 
Dolgoprudny, Russia (S S Otstavnov PhD); Occupational Health and 
Safety Department, Karabuk University, Karabük, Turkey 
(Prof R Özdemir PhD); Department of TB & Respiratory Medicine, 
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1785
Jagadguru Sri Shivarathreeswara University, Mysore, India 
(Prof M P A DNB); University of Chichester, Chichester, UK 
(R Pacella PhD); Department of Medicine, University of Ottowa, Ottawa, 
ON, Canada (S Pakhale MD); Center for Health Outcomes & Evaluation, 
Bucharest, Romania (A Pana MD); Department of Medical Humanities 
and Social Medicine, Kosin University, Busan, South Korea 
(Prof E Park PhD); Department of Medicine, Maimonides Medical 
Center, Brooklyn, NY, USA (S Patel MD); Clinical Research Department, 
Diabetes Research Society, Hyderabad, India (Prof V R Paturi MD); 
Clinical Research Department, Diabetomics, Portland, OR, USA 
(Prof V R Paturi MD); Cartagena University, Cartagena, Colombia 
(Prof D M Pereira PhD); Independent Consultant, Glenelg, SA, Australia 
(Prof K Pesudovs PhD); Institute of Medicine, University of Gothenburg, 
Gothenburg, Sweden (Prof M Petzold PhD); School of Public Health, 
University of Witwatersrand, Johannesburg, South Africa 
(Prof M Petzold PhD); Shanghai Mental Health Center, Shanghai Jiao 
Tong University, Shanghai, China (Prof M R Phillips MD); Basic Medical 
Sciences Department, Durban University of Technology, Durban, South 
Africa (Prof J D Pillay PhD); University Medical Center Groningen, 
University of Groningen, Groningen, Netherlands 
(Prof M J Postma PhD); Department of Nephrology, Sanjay Gandhi 
Postgraduate Institute of Medical Sciences, Lucknow, India 
(S Prakash PhD, Prof N Prasad MD); Non-communicable Diseases 
Research Center, Alborz University of Medical Sciences, Karaj, Iran 
(M Qorbani PhD); Department of Environmental & Occupational 
Health, Drexel University, Philadelphia, PA, USA 
(Prof D Quistberg PhD); Medichem, Barcelona, Spain (A Radfar MD); 
Epidemiology & Biostatistics, Contech School of Public Health, Lahore, 
Pakistan (A Rafay MS); Society for Health and Demographic 
Surveillance, Suri, India (R Rai MPH); Department of Economics, 
University of Göttingen, Göttingen, Germany (R Rai MPH); Medical 
University Innsbruck, Innsbruck, Austria (S Rajsic MD); Institute for 
Poverty Alleviation and International Development, Yonsei University, 
Nepal (C L Ranabhat PhD); University College London Hospitals, 
London, UK (D L Rawaf MD); Public Health England, London, UK 
(Prof S Rawaf PhD); Brien Holden Vision Institute, Sydney, NSW, 
Australia (Prof S Resnikoff MD); Organization for the Prevention of 
Blindness, Paris, France (Prof S Resnikoff MD); Department of 
Epidemiology, Birjand University of Medical Sciences, Iran 
(S Riahi PhD); Department of Clinical Research, Federal University of 
Uberlândia, Uberlândia, Brazil (L Roever PhD); Golestan Research 
Center of Gastroenterology and Hepatology, Golestan University of 
Medical Sciences, Gorgan, Iran (G Roshandel PhD); Biotechnology, 
Ikiam Amazon Regional University, Ciudad De Tena, Ecuador 
(E Rubagotti PhD); Department of Ocean Science and Engineering, 
Southern University of Science and Technology, Shenzhen, China 
(E Rubagotti PhD); Neuropsychiatric Institute, Prince of Wales Hospital, 
Randwick, NSW, Australia (Prof P S Sachdev MD); Medical Department, 
University of Sharjah, Sharjah, United Arab Emirates 
(Prof B Saddik PhD); Department of Medical Biotechnology, Mashhad 
University of Medical Sciences, Mashhad, Iran (Prof A Sahebkar PhD); 
College of Medicine, Al-Imam Mohammad Ibn Saud Islamic University, 
Riyadh, Saudi Arabia (N Salam PhD); School of Health and Policy 
Management, Faculty of Health, York University, Toronto, ON, Canada 
(Prof P Salamati MD); Institute of Scientific and Technological 
Communication and Information in Health, Oswaldo Cruz Foundation, 
Rio De Janeiro, Brazil (R D Saldanha MPH); Punjab University College 
of Pharmacy, Anarkali, Pakistan (Z Saleem PharmD); Clinical Research 
Division, Chest Research Foundation, Pune, India (Prof S S Salvi MD); 
Department of Entomology, Ain Shams University, Cairo, Egypt 
(A M Samy PhD); Department of Surgery, Marshall University, 
Huntington, WV, USA (Prof J Sanabria MD); Department of Nutrition 
and Preventive Medicine, Case Western Reserve University, Cleveland, 
OH, USA (Prof J Sanabria MD); Nephrology Group, Jimenez Diaz 
Foundation University Hospital Institute for Health Research, Madrid, 
Spain (M Sanchez-Niño PhD); Department of Public Health, Regional 
Health Administration Do Norte I P, Vila Nova De Gaia, Portugal 
(J V Santos MD); Department of Health and Society, Faculty of Medicine, 
University of Applied and Environmental Sciences, Bogotá, Colombia 
(Prof R Sarmiento-Suárez MPH); Department of Public Health 
Medicine, University of Kwazulu-natal, Durban, South Africa 
(Prof B Sartorius PhD); Surgery Department, Hamad Medical 
Corporation, Doha, Qatar (B Sathian PhD); Faculty of Health & Social 
Sciences, Bournemouth University, Bournemouth, UK (B Sathian PhD); 
UGC Centre of Advanced Study in Psychology, Utkal University, 
Bhubaneswar, India (Prof M Satpathy PhD); Udyam-Global Association 
for Sustainable Development, Bhubaneswar, India 
(Prof M Satpathy PhD); Department of Public Health Sciences, 
University of North Carolina at Charlotte, Charlotte, NC, USA 
(M Sawhney PhD); School of Health Sciences, Federal University of 
Santa Catarina, Ararangua, Brazil (Prof I J C Schneider PhD, 
Prof D A S Silva PhD); Hypertension in Africa Research Team (HART), 
North-West University, Potchefstroom, South Africa 
(Prof A E Schutte PhD); Department of Medical Statistics, Epidemiology 
and Medical Informatics, University of Zagreb, Zagreb, Croatia 
(M Sekerija PhD); Division of Epidemiology and Prevention of Chronic 
Noncommunicable Diseases, Croatian Institute of Public Health, 
Zagreb, Croatia (M Sekerija PhD); Langone Medical Center 
(A Shafieesabet MD), Institute of Environmental Medicine 
(Prof G D Thurston DSc), New York University, New York, NY, USA; 
Public Health Division, An-Najah National University, Nablus, Palestine 
(A A Shaheen PhD); Department of Laboratory Sciences 
(Prof M Sharif PhD), Department of Basic Sciences (Prof M Sharif PhD), 
Islamic Azad University, Sari, Iran; University School of Management 
and Entrepreneurship, Delhi Technological University, New Delhi, India 
(Prof R Sharma PhD); Independent Consultant, Karachi, Pakistan 
(M A Shaikh MD); Department of Pulmonary Medicine, Fudan 
University, Shanghai, China (J She MD); Usher Institute of Population 
Health Sciences and Informatics, University of Edinburgh, Edinburgh, 
UK (Prof A Sheikh MSc, I N Soyiri PhD); Friedman School of Nutrition 
Science and Policy, Tufts University, Boston, MA, USA (P Shi PhD); 
National Institute of Infectious Diseases, Tokyo, Japan 
(M Shigematsu PhD); Institute of Medical Epidemiology, Martin Luther 
University Halle-Wittenberg, Halle, Germany (I Shiue PhD); School of 
Health, University of Technology Sydney, Sydney, NSW, Australia 
(Prof S Siabani PhD); Department of Psychology, Reykjavik University, 
Reykjavik, Iceland (Prof I D Sigfusdottir PhD, R Sigurvinsdottir PhD); 
Department of Neurology, University of Pennsylvania, Philadelphia, PA, 
USA (D H Silberberg MD); Portuguese Institute of Sport and Youth, 
Lisbon, Portugal (N T D Silva MPsych); Brasília University, Brasília, 
Brazil (Prof D A Silveira MSc); Max Hospital, Ghaziabad, India 
(Prof N P Singh MD); Department of Policy Studies, The Energy and 
Resources Institute School of Advanced Studies (TERI), New Delhi, 
India (P K Singh PhD); Department of Pulmonary Medicine, Asthma 
Bhawan, Jaipur, India (Prof V Singh MD); Epidemiology, School of 
Preventive Oncology, Patna, India (D N Sinha PhD); Pediatric 
Department, King Khalid University Hospital, Riyadh, Saudi Arabia 
(Prof B H Sobaih MD); Department of Endocrinology and Diabetes, 
Yaoundé Central Hospital, Yaounde, Cameroon (Prof E Sobngwi PhD); 
The Dartmouth Institute for Health Policy, Dartmouth College, Lebanon, 
NH, USA (Prof S S Soneji PhD); Service of Pulmonology, Health 
Research Institute of the University Hospital “de la Princesa”, Madrid, 
Spain (Prof J B Soriano MD); Clinical Neurological Sciences, The 
University of Western Ontario, London, ON, Canada (L A Sposato MD); 
Division of Community Medicine, International Medical University, 
Kuala Lumpur, Malaysia (Prof C T Sreeramareddy MD); Department of 
Occupational Therapy, Athens University of Applied Sciences, Athens, 
Greece (V Stathopoulou PhD); Department of Nursing, Muhammadiyah 
University of Surakarta, Kartasura, Indonesia (Prof A Sudaryanto MPH); 
School of Medicine, University of California Riverside, Riverside, CA, 
USA (P J Sur MPH); Department of Criminology, Law and Society, 
University of California Irvine, Irvine, CA, USA (Prof B L Sykes PhD); 
Department of Medicine (Prof R Tabarés-Seisdedos PhD), Department 
of Pediatrics, Obstetrics and Gynecology (Prof M Tortajada-Girbés PhD), 
University of Valencia, Valencia, Spain; Carlos III Health Institute, 
Biomedical Research Networking Center for Mental Health Network 
(CIBERSAM), Madrid, Spain (Prof R Tabarés-Seisdedos PhD); Cancer 
Control Center, Osaka International Cancer Institute, Osaka, Japan 
(T Tabuchi MD); Menzies Health Institute Queensland, Griffith 
University, Gold Coast, QLD, Australia (S K Tadakamadla PhD); 
Asbestos Diseases Research Institute, Sydney, NSW, Australia 
(Prof K Takahashi PhD); University Institute “Egas Moniz”, Monte Da 
Global Health Metrics
1786 www.thelancet.com   Vol 392   November 10, 2018
Caparica, Portugal (Prof N Taveira PhD); Research Institute for 
Medicines, Faculty of Pharmacy of Lisbon, University of Lisbon, Lisbon, 
Portugal (Prof N Taveira PhD); Anesthesiology Department, University 
of Virginia, Charlottesville, VA, USA (A S Terkawi MD); Syrian 
Expatriate Medical Association (SEMA), Charlottesville, VA, USA 
(A S Terkawi MD); Lee Kong Chian School of Medicine 
(Prof L Tudor Car PhD), Nanyang Technological University, Singapore, 
Singapore (S Thirunavukkarasu PhD); Department of Health Policy, 
National Center for Child Health and Development, Setagaya, Japan 
(Prof R Tobe-Gai PhD); Department Of Medicine, University of Calgary, 
Calgary, AB, Canada (Prof M Tonelli MD); Agency for Health Technology 
Assessment and Tariff System, Warszawa, Poland (R Topor-Madry PhD); 
Pediatric Department, University Hospital Doctor Peset, Valencia, Spain 
(Prof M Tortajada-Girbés PhD); Nutritional Epidemiology Research 
Team, National Institute of Health and Medical Research, Paris, France 
(M Touvier PhD); Department of Health Economics, Hanoi Medical 
University, Hanoi, Vietnam (Prof B X Tran PhD); Clinical Hematology 
and Toxicology, Military Medical University, Hanoi, Vietnam 
(K B Tran MD); King George’s Medical University, Lucknow, India 
(S Tripathi MD); CV Medicine, Cleveland Clinic, Cleveland, OH, USA 
(Prof E Tuzcu MD); Cleveland Clinic Abu Dhabi, Abu Dhabi, United 
Arab Emirates (Prof E Tuzcu MD); Department of Internal Medicine, 
Federal Teaching Hospital, Abakaliki, Nigeria (K N Ukwaja MSc); Gomal 
Center of Biochemistry and Biotechnology, Gomal University, Dera 
Ismail Khan, Pakistan (I Ullah PhD); TB Culture Laboratory, Mufti 
Mehmood Memorial Teaching Hospital, Dera Ismail Khan, Pakistan 
(I Ullah PhD); School of Government, Pontifical Catholic University of 
Chile, Santiago, Chile (E A Undurraga PhD); Schneider Institutes for 
Health Policy, Brandeis University, Waltham, MA, USA 
(E A Undurraga PhD); Ankara University, Ankara, Turkey 
(S B Uzun MSc); Division of Cardiovascular Medicine, University of 
Louisville, Louisville, KY, USA (G Vaidya MD); President, Argentine 
Society of Medicine, Buenos Aires, Argentina (Prof P R Valdez MEd); 
Intensive Care Unit Staff, Velez Sarsfield Hospital, Buenos Aires, 
Argentina (Prof P R Valdez M Ed); UKK Institute, Tampere, Finland 
(Prof T J Vasankari MD); Raffles Neuroscience Centre, Raffles Hospital, 
Singapore (Prof N Venketasubramanian MBBS); Sport Science 
Department, University of Extremadura, Cáceres, Spain 
(S Villafaina MSc); Department of Medical and Surgical Sciences, 
University of Bologna, Bologna, Italy (Prof F S Violante MPH); 
Occupational Health Unit, Sant’orsola Malpighi Hospital, Bologna, Italy 
(Prof F S Violante MPH); Department of Health Care Management and 
Economics, National Research University Higher School of Economics, 
Moscow, Russia (Prof V Vlassov MD); Foundation University Medical 
College, Foundation University, Rawalpindi, Pakistan 
(Prof Y Waheed PhD); Department of Neurology, George Washington 
University, Washington, DC, USA (Prof M T Wallin MD); Independent 
Consultant, Staufenberg, Germany (A Werdecker PhD); Department of 
Research, Cancer Registry of Norway, Oslo, Norway 
(Prof E Weiderpass PhD); Department of Neurology, Technical 
University of Munich, Munich, Germany (A S Winkler PhD); Kailuan 
General Hospital, Kailuan General Hospital, Tangshan, China 
(Prof S Wu PhD); University of Strathclyde, Glasgow, UK 
(G M A Wyper MSc); Department of Pharmacology, St John’s National 
Academy of Health Sciences, Bangalore, India (Prof D Xavier MD); 
School of Medicine, Nanjing University, Nanjing, China 
(Prof G Xu MD); Clinical Cancer Research Center, Milad General 
Hospital, Tehran, Iran (S Yahyazadeh Jabbari MD); Global Health 
Research Center, Duke Kunshan University, Kunshan, China 
(Prof L L Yan PhD); Department of Earth Science, King Fahd University 
of Petroleum and Minerals, Dhahran, Saudi Arabia (Y J Yasin MPH); 
Wolkite University, Wolkite, Ethiopia (A Yeshaneh BHlthSci); University 
of South Australia, Adelaide, NSW, Australia (B D Yirsaw PhD); 
Department of Biostatistics, Kyoto University, Kyoto, Japan 
(Prof N Yonemoto MPH); School of Public Health, University of 
Kinshasa, Kinshasa, Democratic Republic of the Congo 
(Prof M Yotebieng PhD); Department of Health Policy and Management, 
Jackson State University, Jackson, MS, USA (Prof M Z Younis DrPH); 
Tsinghua University, Tsinghua University, Beijing, China 
(Prof M Z Younis DrPH); Global Health Institute (Prof C Yu PhD), 
Department of Epidemiology and Biostatistics (Prof C Yu), Wuhan 
University, Wuhan, China; Epidemiology and Cancer Registry Sector, 
Institute of Oncology Ljubljana, Ljubljana, Slovenia 
(Prof V Zadnik PhD); Department of Epidemiology, University Hospital 
of Setif, Setif, Algeria (Prof Z Zaidi PhD); Department of Epidemiology, 
Human Genetics and Environmental Sciences, University of Texas, 
Houston, TX, USA (K Zhang PhD); Noncommunicable Disease Control 
and Prevention Center, Chinese Center for Disease Control and 
Prevention, Beijing, China (M Zhou PhD).
Contributors
Please see appendix 1 for more detailed information about individual 
authors’ contributions to the research, divided into the following 
categories: managing the estimation process; writing the first draft of the 
manuscript; providing data or critical feedback on data sources; 
developing methods or computational machinery; applying analytical 
methods to produce estimates; providing critical feedback on methods or 
results; drafting the work or revising it critically for important intellectual 
content; extracting, cleaning, or cataloguing data; designing or coding 
figures and tables; and managing the overall research enterprise.
Declaration of interests
Ettore Beghi reports personal fees from MA-Provider and grants from the 
Italian Ministry of Health, UCB-PHARMA, American ALS Association, 
EISAI, and Shire. Yannick Bejot reports grants and personal fees from 
AstraZeneca and Boehringer Ingelheim and personal fees from Daiichi-
Sankyo, Bristol-Myers Squibb (BMS), Pfizer, Medtronic, Bayer, Novex 
pharma, and Merck Sharpe & Dohme (MSD). Adam Berman reports 
personal fees from Philips. Louisa Degenhardt reports grants from 
Indivior, Mundipharma, and Seqirus. Panniyammakal Jeemon reports a 
Clinical and Public Health Intermediate Fellowship from the Wellcome 
Trust–DBT India Alliance (2015–20). Jacek Jóźwiak reports a grant from 
Valeant, personal fees from Valeant, ALAB Laboratoria and Amgen, and 
non-financial support from Microlife and Servier. Nicholas Kassebaum 
reports personal fees and other support from Vifor Pharmaceuticals. 
Srinivasa Vittal Katikireddi reports grants from NHS Research Scotland, 
the Medical Research Council, and the Scottish Government Chief 
Scientist Office. Jeffrey Lazarus reports personal fees from Janssen and 
CEPHEID and grants and personal fees from AbbVie, Gilead Sciences, 
and MSD. Stefan Lorkowski reports personal fees from Amgen, 
Berlin-Chemie, MSD, Novo Nordisk, Sanofi-Aventis, Synlab, Unilever, 
and non-financial support from Preventicus. Winfried März reports 
grants and personal fees from Siemens Diagnostics, Aegerion 
Pharmaceuticals, Amgen, AstraZeneca, Danone Research, Pfizer, BASF, 
Numares, and Berline-Chemie; personal fees from Hoffmann LaRoche, 
MSD, Sanofi, and Synageva; grants from Abbott Diagnostics; and other 
support from Synlab. Walter Mendoza is currently a Program Analyst for 
Population and Development at the Peru Country Office of the United 
Nations Population Fund. Ted Miller reports an evaluation contract from 
AB InBev Foundation. Frédéric Piel reports personal fees from Novartis. 
Postma Maarten reports grants from Mundipharma, Bayer, BMS, 
AstraZeneca, ARTEG, and AscA; grants and personal fees from Sigma 
Tau, MSD, GlaxoSmithKline, Pfizer, Boehringer-Ingelheim, Novavax, 
Ingress Health, AbbVie, and Sanofi; personal fees from Quintiles, 
Astellas, Mapi, OptumInsight, Novartis, Swedish Orphan, Innoval, 
Jansen, Intercept, and Pharmerit, and stock ownership in Ingress Health 
and Pharmacoeconomics Advice Groningen. Kazem Rahimi reports 
grants from the National Insitute for Health Research Biomedical 
Research Centre, Economic and Social Research Council, and Oxford 
Martin School. Mark Shrime reports grants from Mercy Ships and 
Damon Runyon Cancer Research Foundation. Jasvinder Singh reports 
consulting for Horizon, Fidia, UBM, Medscape, WebMD, the National 
Institutes of Health, and the American College of Rheumatology; they 
serve as the principal investigator for an investigator-initiated study 
funded by Horizon pharmaceuticals through a grant to DINORA, a 501c3 
entity; they are on the steering committee of OMERACT, an international 
organization that develops measures for clinical trials and receives 
arms-length funding from 36 pharmaceutical companies. Jeffrey Stanaway 
reports a grant from Merck & Co. Cassandra Szoeke reports a grant from 
the National Medical Health Research Council, Lundbeck, Alzheimer’s 
Association, and the Royal Australasian College of Practicioners; she holds 
patent PCT/AU2008/001556. Amanda Thrift reports grants from National 
Health and Medical Research Council, Australia. Muthiah Vaduganathan 
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1787
receives research support from the NIH/National Heart, Lung, and Blood 
Institute and serves as a consultant for Bayer and Baxter Healthcare. 
Marcel Yotebieng reports grants from the US National Institutes of 
Health. All other authors declare no competing interests.
Data sharing
To download the data used in these analyses, please visit the Global 
Health Data Exchange at http://ghdx.healthdata.org/gbd−2017.
Acknowledgments
Research reported in this publication was supported by the Bill & Melinda 
Gates Foundation, the University of Melbourne, Public Health England, 
the Norwegian Institute of Public Health, St Jude Children's Research 
Hospital, the National Institute on Ageing of the National Institutes of 
Health (award P30AG047845), and the National Institute of Mental Health 
of the National Institutes of Health (award R01MH110163). The content is 
solely the responsibility of the authors and does not necessarily represent 
the official views of the funders. Data for this research was provided by 
MEASURE Evaluation, funded by the United States Agency for 
International Development (USAID). Views expressed do not necessarily 
reflect those of USAID, the US Government, or MEASURE Evaluation. 
Collection of these data was made possible by USAID under the terms of 
cooperative agreement GPO-A-00-08-000_D3-00. The opinions expressed 
are those of the authors and do not necessarily reflect the views of USAID 
or the US Government. The data reported here have been supplied by the 
US Renal Data System. The interpretation and reporting of these data are 
the responsibility of the authors and in no way should be seen as an 
official policy or interpretation of the US Government. 
References
1 Alter GC, Carmichael AG. Classifying the dead: toward a history of 
the registration of causes of death. J Hist Med Allied Sci 1999; 
54: 114–32.
2 WHO. Family of international classifications. June 18, 2018. 
http://www.who.int/classifications/icd/en/ (accessed June 30, 2018). 
3 AbouZahr C, De Savigny D, Mikkelsen L, et al. Civil registration 
and vital statistics: progress in the data revolution for counting and 
accountability. Lancet 2015; 386: 1373–85.
4 Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, et al. Trends and 
patterns of geographic variation in mortality from substance use 
disorders and intentional injuries among US counties, 1980–2014. 
JAMA 2018; 319: 1013–23.
5 Shkolnikov V, McKee M, Leon DA. Changes in life expectancy in 
Russia in the mid-1990s. Lancet 2001; 357: 917–21.
6 Mokdad AH. Intentional injuries in the Eastern Mediterranean 
Region, 1990–2015: findings from the Global Burden of Disease 
2015 study. Int J Public Health 2017; 63: 1–8.
7 Lefeuvre D, Pavillon G, Aouba A, et al. Quality comparison of 
electronic versus paper death certificates in France, 2010. 
Popul Health Metr 2014; 12: 3.
8 Bancroft EA, Lee S. Use of electronic death certificates for influenza 
death surveillance. Emerg Infect Dis 2014; 20: 78.
9 WHO. SDG 3: ensure healthy lives and promote wellbeing for all at 
all ages. http://www.who.int/sdg/targets/en/ 
(accessed March 31, 2018).
10 WHO. Moscow Declaration to end TB. November, 2017. 
http://www.who.int/tb/features_archive/Online_Consultation_
MinisterialConferenceDeclaration/en/ (accessed March 31, 2018).
11 WHO. WHO’s First Global Conference on Air Pollution and 
Health, 30 October – 1 November 2018. http://www.who.int/
airpollution/events/conference/en/ (accessed March 31, 2018).
12 WHO. Noncommunicable diseases and their risk factors. Third UN 
high-level meeting on NCDs (2018). http://www.who.int/ncds/
governance/third-un-meeting/about/en/ (accessed June 30, 2018).
13 WHO. UN General Assembly high-level meeting on ending TB. 
Tuberculosis. http://www.who.int/tb/features_archive/UNGA_
HLM_ending_TB/en/ (accessed June 30, 2018).
14 GBD 2017 Population and Fertility Collaborators. Population and 
fertility by age and sex for 195 countries, 1950–2017: a systematic 
analysis for the Global Burden of Disease Study 2017. Lancet 2018; 
392: 1995–2051.
15 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and 
Transparent Health Estimates Reporting: the GATHER statement. 
Lancet 2016; 388: e19–23.
16 Naghavi M, Makela S, Foreman K, O’Brien J, Pourmalek F, 
Lozano R. Algorithms for enhancing public health utility of national 
causes-of-death data. Popul Health Metr 2010; 8: 9.
17 Janssen F, Kunst AE. ICD coding changes and discontinuities in 
trends in cause-specific mortality in six European countries, 1950–99. 
Bull World Health Organ 2004; 82: 904–13.
18 GBD 2016 Causes of Death Collaborators. Global, regional, and 
national age-sex specific mortality for 264 causes of death, 1980–2016: 
a systematic analysis for the Global Burden of Disease Study. 
Lancet 2017; 390: 1151–210.
19 Kotloff KL, Blackwelder WC, Nasrin D, et al. The Global Enteric 
Multicenter Study (GEMS) of diarrheal disease in infants and young 
children in developing countries: epidemiologic and clinical methods 
of the case/control study. Clin Infect Dis 2012; 55: S232–45.
20 Das Gupta P. Standardization and decomposition of rates: a user’s 
manual. 1993. https://www.census.gov/content/dam/Census/
library/publications/1993/demo/p23-186.pdf (accessed Sept 13, 2018). 
21 Flaxman AD, Vos T, Murray CJ. An integrative metaregression 
framework for descriptive epidemiology. Seattle: University of 
Washington Press, 2015.
22 GBD 2017 Mortality Collaborators. Global, regional, and national 
age-sex-specific mortality and life expectancy, 1950–2017: 
a systematic analysis for the Global Burden of Disease Study 2017. 
Lancet 2018; 392: 1684–735.
23 GBD 2017 Risk Factor Collaborators. Global, regional, and national 
comparative risk assessment of 84 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks for 195 
countries and territories, 1990–2017: a systematic analysis for the 
Global Burden of Disease Study 2017. Lancet 2018; 392: 1923–94.
24 GBD 2015 Obesity Collaborators. Health effects of overweight and 
obesity in 195 countries over 25 years. N Engl J Med 2017; 377: 13–27.
25 Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD 
and NASH: trends, predictions, risk factors and prevention. 
Nat Rev Gastroenterol Hepatol 2018; 15: 11.
26 Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: 
shaped by global drivers and local environments. Lancet 2011; 
378: 804–14.
27 Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, 
Murray CJ. Estimates of global and regional premature 
cardiovascular mortality in 2025. Circulation 2015; 132: 1270–82.
28 Roberto CA, Swinburn B, Hawkes C, et al. Patchy progress on 
obesity prevention: emerging examples, entrenched barriers, 
and new thinking. Lancet 2015; 385: 2400–09.
29 WHO. Global nutrition policy review: what does it take to scale up 
nutrition action? Geneva: World Health Organization, 2013.
30 Fleming DM, Elliot AJ. Lessons from 40 years’ surveillance of 
influenza in England and Wales. Epidemiol Infect 2008; 
136: 866–875.
31 Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile 
infection in the United States. N Engl J Med 2015; 372: 825–34.
32 Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic 
consumption 2000 to 2010: an analysis of national pharmaceutical 
sales data. Lancet Infect Dis 2014; 14: 742–50.
33 Hay SI, Rao PC, Dolecek C, et al. Measuring and mapping the 
global burden of antimicrobial resistance. BMC Med 2018; 16: 78. 
34 Fujita K, Shinomoto S, Rocha LE. Correlations and forecast of death 
tolls in the Syrian conflict. Sci Rep 2017; 7: 15737.
35 Murray CJ, King G, Lopez AD, Tomijima N, Krug EG. Armed conflict 
as a public health problem. BMJ 2002; 324: 346–49.
36 Nkengasong JN, Maiyegun O, Moeti M. Establishing the Africa 
Centres for Disease Control and Prevention: responding to Africa’s 
health threats. Lancet Glob Health 2017; 5: e246–47.
37 Blencowe H, Kancherla V, Moorthie S, Darlison MW, Modell B. 
Estimates of global and regional prevalence of neural tube defects 
for 2015: a systematic analysis. Ann NY Acad Sci 2018; 1414: 31–46.
38 WHO. Global action plan for the prevention and control of NCDs 
2013–2020. Geneva: World Health Organization, 2013.
39 Tian M, Ajay V, Dunzhu D, et al. A cluster-randomized controlled 
trial of a simplified multifaceted management program for 
individuals at high cardiovascular risk (SimCard Trial) in rural 
Tibet, China, and Haryana, India. Circulation 2015; 132: 815–24.
40 Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for 
universal health coverage. Lancet 2017; 389: 403–76.
Global Health Metrics
1788 www.thelancet.com   Vol 392   November 10, 2018
41 Wong JQ, Uy J, Haw NJL, et al. Priority setting for health service 
coverage decisions supported by public spending: experience from 
the Philippines. Health Syst Reform 2018; 4: 19–29.
42 British Columbia Coroner’s Service. Fentanyl-detected illicit drug 
overdose deaths January 1, 2012 to March 31, 2018. Burnaby, British 
Columbia: Office of the Chief Coroner, Ministry of Public Safety 
and Solicitor, 2018.
43 Mounteney J, Giraudon I, Denissov G, Griffiths P. Fentanyls: are we 
missing the signs? Highly potent and on the rise in Europe. 
Int J Drug Policy 2015; 26: 626–31.
44 Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access 
to opioid analgesics: a worldwide, regional, and national study. 
Lancet 2016; 387: 1644–56.
45 Prekupec MP, Mansky PA, Baumann MH. Misuse of novel 
synthetic opioids: a deadly new trend. J Addict Med 2017; 11: 256.
46 Kickbusch I. Global health governance challenges 2016—are we 
ready? Int J Health Policy Manag 2016; 5: 349–53.
47 Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, 
Finfer S. Recognizing sepsis as a global health priority—a WHO 
resolution. N Engl J Med 2017; 377: 414–17.
48 Goldberg DS, McGee SJ. Pain as a global public health priority. 
BMC Public Health 2011; 11: 770.
49 Taylor AL. Addressing the global tragedy of needless pain: 
rethinking the United Nations single convention on narcotic drugs. 
J Law Med Ethics 2007; 35: 556–70, 511.
50 Chaudhary NK, Connolly J, Tison J, Solomon M, Elliott KR. 
Evaluation of NHTSA distracted driving high-visibility enforcement 
demonstration projects in California and Delaware. Washington, 
DC: National Highway Traffic Safety Administration, 2015.
51 Wang SY, Li YH, Chi GB, et al. Injury-related fatalities in China: 
an under-recognised public-health problem. Lancet 2008; 
372: 1765–73.
52 Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. 
Global burden of cancers attributable to infections in 2012: 
a synthetic analysis. Lancet Glob Health 2016; 4: e609–16.
53 Foreman K, Marquez N, Dolgert A, et al. Forecasting life expectancy, 
years of life lost, and all-cause and cause-specific mortality for 250 
causes of death: reference and alternative scenarios for 2016–40 for 
195 countries and territories Lancet 2018; 392: 2052–90.
54 Goff DA, Kullar R, Goldstein EJC, et al. A global call from 
five countries to collaborate in antibiotic stewardship: united we 
succeed, divided we might fail. Lancet Infect Dis 2017; 17: e56–63.
55 Martyn CN, Pippard EC. Usefulness of mortality data in 
determining the geography and time trends of dementia. 
J Epidemiol Community Health 1988; 42: 134–37.
56 GBD 2015 Disease and Injury Incidence and Prevalence 
Collaborators. Global, regional, and national incidence, prevalence, 
and years lived with disability for 310 diseases and injuries, 
1990–2015: a systematic analysis for the Global Burden of Disease 
Study 2015. Lancet 2016; 388: 1545–602.
57 Langa KM. Is the risk of Alzheimer’s disease and dementia 
declining? Alzheimers Res Ther 2015; 7: 34.
58 Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the 
prevalence of Alzheimer’s disease in the United States. 
Alzheimers Dement 2011; 7: 61–73.
59 Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison 
of prevalence of dementia in individuals aged 65 years and older 
from three geographical areas of England: results of the Cognitive 
Function and Ageing Study I and II. Lancet 2013; 382: 1405–12.
60 Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence 
and prevalence of Alzheimer’s disease, dementia, and cognitive 
impairment in the United States. Alzheimers Dement 2011; 7: 80–93.
61 Adewemimo A, Kalter HD, Perin J, Koffi AK, Quinley J, Black RE. 
Direct estimates of cause-specific mortality fractions and rates of 
under-five deaths in the northern and southern regions of Nigeria 
by verbal autopsy interview. PLoS One 2017; 12: e0178129.
62 Bray F, Colombet M, Mery L, et al, eds. Cancer incidence in five 
continents. Lyon: International Agency for Research on Cancer, 2017.
63 Mahy M, Penazzato M, Ciaranello A, et al. Improving estimates of 
children living with HIV from the Spectrum AIDS Impact Model. 
AIDS 2017; 31: S13–22.
64 WHO. World malaria report 2017. WHO Global Malaria 
Programme. Geneva: World Health Organization, 2018.
65 WHO. Global hepatitis report, 2017. http://www.who.int/hepatitis/
publications/global-hepatitis-report2017/en/ (accessed June 30, 2018). 
66 WHO. MCEE-WHO methods and data sources for child causes of 
death 2000–2015. Department of Evidence, Information and 
Research (WHO, Geneva) and Maternal Child Epidemiology 
Estimation (MCEE). February, 2018. http://www.who.int/healthinfo/
global_burden_disease/childcod_methods_2000_2016.pdf 
(accessed June 30, 2018).
67 Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global 
seasonal influenza-associated respiratory mortality: a modelling 
study. Lancet 2018; 391: 1285–300.
68 WHO. Trends in maternal mortality: 1990–2015: estimates from 
WHO, UNICEF, UNFPA, World Bank Group and the United Nations 
Population Division. Geneva: World Health Organization, 2015.
69 Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0: 
Estimated cancer incidence, mortality and prevalence worldwide in 
2012. Lyon: International Agency for Research on Cancer, 2017. 
70 Manthey J, Probst C, Rylett M, Rehm J. National, regional and global 
mortality due to alcoholic cardiomyopathy in 2015. Heart 2018; 
published online March 13. DOI:10.1136/heartjnl-2017-312384.
71 WHO. Road safety: estimated number of road traffic deaths, 2013. 
http://gamapserver.who.int/gho/interactive_charts/road_safety/
road_traffic_deaths/atlas.html (accessed April 2, 2018).
72 WHO. Falls. Jan 16, 2018. http://www.who.int/mediacentre/
factsheets/fs344/en/ (accessed March 31, 2018).
73 WHO. Suicide data. http://www.who.int/mental_health/prevention/ 
suicide/suicideprevent/en/ (accessed March 31, 2018).
74 Riley WJ, Beitsch LM, Parsons HM, Moran JW. 
Quality improvement in public health: where are we now? 
J Public Health Manag Pract 2010; 16: 1–2.
